<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        71-68-97
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MOBIC 7.5MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MELOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        7.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROTTENDORF PHARMA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROTTENDORF PHARMA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MOBIC tablets contains the active substance meloxicam. Meloxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) which are used to reduce inflammation and pain in joints and muscles.</p><p>MOBIC tablets are indicated in adults and children aged 16 years and older.</p><p>MOBIC tablets is used for the:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; short-term treatment of flare-ups of osteoarthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term treatment of</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatoid arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankylosing spondylitis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take MOBIC: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to meloxicam or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during the last three months of pregnancy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children and adolescents below 16 years of age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any of the following signs after taking aspirin or other NSAIDs:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing, chest tightness, breathlessness (asthma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nasal blockage due to swellings in the lining in your nose (nasal polyps)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes/nettle rash (urticaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden skin or mucosal swelling, such as swelling around the eyes, face, lips, mouth or throat, possibly making breathing difficult (angio-oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after previous therapy with NSAIDs and history of</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in your stomach or intestines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; holes (perforations) in your stomach or intestines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcers or a bleeding in your stomach or intestines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recent or history of stomach or peptic ulcers or bleeding (ulceration or bleeding occurring at least twice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely impaired liver function&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non dialysed severe kidney failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recent bleeding in the brain (cerebrovascular bleeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any kind of bleeding disorders&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intolerance to some sugars as this product contains lactose (see also &ldquo;MOBIC contains milk sugar (lactose) and sodium&rdquo;)</p><p>If you are unsure whether any of the above applies to you, please contact your doctor.</p><p><strong>Warnings and precautions &nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking MOBIC.</p><p>&nbsp;</p><p>Warnings</p><p>Medicines such as MOBIC may be associated with a small increased risk of heart attack (myocardial infarction) or stroke (apoplexy). Any risk is more likely with high doses and prolonged treatment. Do not take more than the recommended dose. Do not take MOBIC for longer than it is prescribed for you (see section 3 &ldquo;How to take MOBIC&rdquo;).</p><p>If you have heart problems, previous stroke or think that you might be at risk of these conditions, you should discuss your treatment with your doctor or pharmacist. For example if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high levels of sugar in the blood (diabetes mellitus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high levels of cholesterol in the blood (hypercholesterolemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are a smoker</p><p>&nbsp;</p><p>Stop your treatment with MOBIC immediately as soon as you notice bleeding (causing tar-coloured stools) or ulceration of your digestive tract (causing abdominal pain).</p><p>Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of MOBIC, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of MOBIC, you must not be re-started on MOBIC at any time.</p><p>Talk to your doctor or pharmacist before taking MOBIC if you have ever developed fixed drug eruption (round or oval patches of redness and swelling of the skin that usually recurs at the same site(s), blistering, hives and itching) after taking meloxicam or other oxicams (e.g. piroxicam).</p><p>&nbsp;</p><p>If you develop a rash or these skin symptoms, stop taking MOBIC, seek urgent advice from a doctor and tell him that you are taking this medicine.</p><p>&nbsp;</p><p>MOBIC is not appropriate, if you require immediate relief from acute pain.</p><p>&nbsp;</p><p>MOBIC may hide the symptoms of infection (e.g. fever). If you think you may have an infection you should see your doctor.</p><p>Precautions for use</p><p>As it will be necessary to adjust the treatment, it is important to ask your doctor&rsquo;s advice before you take MOBIC in case of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; history of inflammation of the gullet (oesophagitis), inflammation of the stomach (gastritis) or a history of any other disease of the digestive tract, e.g. Crohn&rsquo;s Disease or Ulcerative Colitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; older age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart, liver or kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of sugar in the blood (diabetes mellitus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced blood volume (hypovolaemia) which may occur if you have a serious blood loss or burn, surgery or low fluid intake</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intolerance to some sugars diagnosed by your doctor as this product contains lactose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high potassium levels in the blood previously diagnosed by your doctor</p><p>&nbsp;</p><p>Your doctor will need to monitor your progress whilst on treatment.</p><p>Other medicines and MOBIC</p><p>As MOBIC may affect or be affected by other medicines, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular please tell your doctor or pharmacist if you are taking/have taken, or are using any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other NSAIDs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium salts &ndash; used to prevent or to treat low blood levels of potassium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus &ndash; used after organ transplants</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trimethoprim &ndash; used in the treatment of urinary tract infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which prevent blood clotting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which break down blood clots (thrombolytics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heart and kidney diseases</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids (e.g. used against inflammation or allergic reactions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporin &ndash; used after organ transplants, or for severe skin conditions, rheumatoid arthritis or nephrotic syndrome</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deferasirox &ndash; used to treat chronic iron overload due to frequent blood transfusions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any diuretic medicine (&ldquo;water tablets&rdquo;)</p><p>Your doctor may monitor your kidney function if you are taking diuretics.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine to treat high blood pressure (e.g. Beta-blockers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium &ndash; used to treat mood disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; selective Serotonin re-uptake inhibitors (SSRIs) &ndash; used in the treatment of depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate &ndash; used to treat tumours or severe uncontrolled skin conditions and active rheumatoid arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pemetrexed &ndash; used in the treatment of cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestyramine &ndash; used to lower cholesterol levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral antidiabetics (sulphonylureas, nateglinide) &ndash; used in the treatment of diabetics. Your doctor should carefully monitor your level of blood sugar for hypoglycemia.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong><em>Pregnancy</em></strong></p><p>Do not take MOBIC if you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery. It can cause kidney and heart problems in your unborn baby. It may affect your and your baby&rsquo;s tendency to bleed and cause labour to be later or longer than expected.</p><p>You should not take MOBIC during the first 6 months of pregnancy unless absolutely necessary and advised by your doctor. If you need treatment during this period or while you are trying to get pregnant, the lowest dose for the shortest time possible should be used. If taken for more than a few days from 20 weeks of pregnancy onward, MOBIC can cause kidney problems in your unborn baby that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the heart of the baby. If you need treatment for longer than a few days, your doctor may recommend additional monitoring.</p><p>If you have taken this medicine while you were pregnant, you must immediately talk to your doctor/midwife so that adequate monitoring can be considered.</p><p><strong><em>Breast-feeding</em></strong></p><p>This product is not recommended during breast feeding.</p><p><strong><em>Fertility</em></strong></p><p>This product may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Visual disturbances, including blurred vision, dizziness, drowsiness, vertigo or other central nervous system disturbances may occur with this product. If affected do not drive or operate machinery.</p><p>&nbsp;</p><p>MOBIC contains milk sugar (lactose) and sodium</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The recommended dose for MOBIC 7.5 mg is:</strong></p><p><strong>Flare-ups of osteoarthritis:</strong></p><p>7.5 mg (one tablet) once a day. This may be increased to 15 mg (two tablets) once a day.</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis:</strong></p><p>15 mg (two tablets) once a day. This may be reduced to 7.5 mg (one tablet) once a day.</p><p>&nbsp;</p><p><strong>Ankylosing spondylitis:</strong></p><p>15 mg (two tablets) once a day. This may be reduced to 7.5 mg (one tablet) once a day.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose for MOBIC 15 mg is:</strong></p><p><strong>Flare-ups of osteoarthritis:</strong></p><p>7.5 mg (half a tablet) once a day. This may be increased to 15 mg (one tablet) once a day.</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis:</strong></p><p>15 mg (one tablet) once a day. This may be reduced to 7.5 mg (half a tablet) once a day.</p><p>&nbsp;</p><p><strong>Ankylosing spondylitis:</strong></p><p>15 mg (one tablet) once a day. This may be reduced to 7.5 mg (half a tablet) once a day.</p><p>&nbsp;</p><p><strong>Do not exceed the recommended maximum dose of 15 mg a day.</strong></p><p>&nbsp;</p><p>If any of the statements listed under the heading &quot;<strong>Warnings and precautions</strong>&quot; apply to you, your doctor may restrict your dose to 7.5 mg (one tablet) once a day.</p><p>&nbsp;</p><p><strong><em>Elderly&nbsp; </em></strong></p><p>If you are of an older age the recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis is 7.5 mg (one tablet of MOBIC 7.5 mg or half a tablet of MOBIC 15 mg) per day.</p><p>&nbsp;</p><p><strong><em>Patients with increased risks for adverse reaction </em></strong></p><p>If you are a patient with an increased risk for adverse reactions, your doctor will start the treatment at a dose of 7.5 mg (one tablet of MOBIC 7.5 mg or half a tablet of MOBIC 15 mg) per day.</p><p>&nbsp;</p><p><strong><em>Renal impairment </em></strong></p><p>If you are a dialysis patient with severe renal impairment, your dose should not exceed 7.5 mg (one tablet of MOBIC 7.5 mg or half a tablet of MOBIC 15 mg) per day. No dose reduction is required in patients with mild to moderate renal impairment.</p><p>&nbsp;</p><p><strong><em>Hepatic impairment </em></strong></p><p>No dose reduction is required in patients with mild to moderate hepatic impairment.</p><p>&nbsp;</p><p><strong><em>Use in children and adolescents</em></strong><strong><em> </em></strong></p><p>MOBIC tablets should not be given to children and adolescents below 16 years of age.</p><p>&nbsp;</p><p>If you feel that the effect of MOBIC tablets is too strong or too weak, or if after several days you do not feel any improvement in your condition, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>Method of administration</p><p>Oral use.</p><p>The tablets should be swallowed with water, or another drink, during a meal.</p><p>&nbsp;</p><p>The score line of MOBIC 7.5 mg tablet is only there to help you break the tablet if you have difficulty swallowing it whole.</p><p>MOBIC 15 mg tablet can be divided into equal doses. The tablet should be divided by hand and not by a sharp object (e.g. a knife).</p><p>&nbsp;</p><p><strong>If you take more MOBIC tablets than you should</strong></p><p><strong>Whether you have taken too many tablets or suspect an overdose, contact your doctor or go to your nearest hospital immediately.</strong></p><p>&nbsp;</p><p><strong>Symptoms following acute NSAID overdose are usually limited to:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of energy (lethargy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) and being sick (vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the area of the stomach (epigastric pain)</p><p>These symptoms generally get better when you stop taking MOBIC tablets. You may suffer from bleeding of the stomach or intestines (gastrointestinal bleeding).</p><p>&nbsp;</p><p><strong>Severe poisoning may result in serious drug reaction (see section 4.):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute kidney (renal) failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver (hepatic) dysfunction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction/flattening or standstill of breathing (respiratory depression)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness (coma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (convulsions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse of the blood circulation (cardiovascular collapse)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; standstill of the heart (cardiac arrest)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immediate allergic (hypersensitivity) reactions, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take MOBIC tablets</strong></p><p>Do <u>not</u> take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Stop taking MOBIC and consult a doctor or your nearest hospital immediately if you notice:</p><p>&nbsp;</p><p>Any allergic (hypersensitivity) reactions, which may appear in the form of:</p><p>-&nbsp;&nbsp; skin reactions, such as itching (pruritus), blistering or peeling of the skin, which can be potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis), lesions of soft tissues (mucosal lesions) or erythema multiforme (see section 2).</p><p>Erythema multiforme is a serious allergic skin reaction causing spots, red welts or purple or blistered areas. It can also affect the mouth, eyes and other moist body surfaces.&nbsp;</p><p>-&nbsp;&nbsp; swelling of skin or mucosa, such as swelling around the eyes, face and lips, mouth or throat, possibly making breathing difficult, swollen ankles or legs (oedema of the lower limbs)</p><p>-&nbsp;&nbsp; shortness of breath or asthma attack</p><p>-&nbsp;&nbsp; inflammation of the liver (hepatitis). This can cause symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin or the eyeballs (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite &nbsp;</p><p>&nbsp;</p><p>Any side effects of the digestive tract, especially:</p><p>-&nbsp;&nbsp; bleeding (causing tar-coloured stools)</p><p>-&nbsp;&nbsp; ulceration of your digestive tract (causing abdominal pain) &nbsp;</p><p>&nbsp;</p><p>Bleeding of the digestive tract (gastrointestinal bleeding), formation of ulcers or formation of a hole in the digestive tract (perforation) may sometimes be severe and potentially fatal, especially in elderly.</p><p>If you have previously suffered from any symptoms of the digestive tract due to long term use of NSAIDs, seek medical advice immediately, especially if you are elderly. Your doctor may monitor your progress whilst on treatment.&nbsp;</p><p>If affected by visual disturbances do not drive or operate machinery.</p><p>General side effects of non-steroidal anti-inflammatory medicines (NSAIDs)</p><p>The use of some non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with a small increased risk of occlusion of arterial vessels (arterial thrombotic events), e.g. heart attack (myocardial infarction) or stroke (apoplexy), particularly at high doses and in long term treatment.</p><p>Fluid retention (oedema), high blood pressure (hypertension) and heart failure (cardiac failure) have been reported in association with NSAID treatment.<strong> </strong></p><p>The most commonly-observed side effects affect the digestive tract (gastrointestinal events):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcers of the stomach and upper part of the small bowels (peptic /gastroduodenal ulcers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hole in the wall of the bowels (perforation) or bleeding of the digestive tract (sometimes fatal, particularly in the elderly)</p><p>&nbsp;</p><p>The following side effects have been reported after NSAID administration:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) and being sick (vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loose stools (diarrhoea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flatulence</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (dyspepsia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tar-coloured stool due to bleeding in the digestive tract (melaena)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting of blood (haematemesis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation with building of ulcers in the mouth (ulcerative stomatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of inflammation of the digestive tract (e.g. exacerbation of colitis or Crohn&#39;s disease)</p><p>&nbsp;</p><p>Less frequently, inflammation of the stomach (gastritis) has been observed.</p><p>&nbsp;</p><p>Side effects of meloxicam &ndash; the active substance of MOBIC</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>- gastrointestinal adverse events such as indigestion (dyspepsia), feeling sick (nausea) and being sick (vomiting), abdominal pain, constipation, flatulence, loose stools (diarrhoea)&nbsp;</p><p><strong>Co</strong><strong>mmon: may affect up to 1 in 10 people&nbsp; </strong></p><p><strong>- </strong>headache<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness (light-headedness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of dizziness or spinning (vertigo)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; somnolence (drowsiness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia (reduction of the concentration of the red blood pigment haemoglobin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing (temporary redness of the face and neck)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium and water retention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased potassium levels (hyperkalaemia). This can lead to symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to your heartbeat (arrythmias)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (when you feel your heartbeat more than usual)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eructation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach (gastritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding of the digestive tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth (stomatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immediate allergic (hypersensitivity) reactions&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid retention (oedema), including swollen ankles/legs (oedema of the lower limbs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden skin or mucosal swelling, such as swelling around the eyes, face, lips, mouth or throat, possibly making breathing difficult (angio-oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; momentary disturbance of liver function tests (e.g. raised liver enzymes like transaminases or an increase of the bile pigment bilirubin). Your doctor can detect these using a blood test.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbance of laboratory tests investigating kidney (renal) function (e.g. raised creatinine or urea)</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood count, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal differential blood count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells (leucocytopenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of blood platelets (thrombocytopenia)</p><p>These side effects may lead to increased risk of infection and symptoms such as bruising or nosebleeds.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ear (tinnitus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling your heartbeat (palpitations)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcers of the stomach or upper part of the small bowels (peptic /gastroduodenal ulcers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the gullet (oesophagitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset of asthma attacks (seen in people who are allergic to aspirin or other NSAIDs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe blistering of the skin or peeling (Stevens-Johnson Syndrome and toxic epidermal necrolysis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nettle rash (urticaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conjunctivitis (inflammation of the eyeball or eyelids)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the large bowel (colitis) &nbsp;</p><p>&nbsp;</p><p><strong>Very rare: may affect up to 1 in 10,000 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering reactions of the skin (bullous reactions) and erythema multiforme.</p><p>Erythema multiforme is a serious allergic skin reaction causing spots, red welts or purple or blistered areas. It can also affect the mouth, eyes and other moist body surfaces.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis). This can cause symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin or the eyeballs (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain of the abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute failure of the kidneys (renal failure) in particular in patients with risk factors such as heart disease, diabetes or kidney disease.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hole in the wall of the bowels (perforation)</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorientation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath and skin reactions (anaphylactic/anaphylactoid reactions) rashes caused by exposure to sunlight (photosensitivity reactions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure (cardiac failure) has been reported in association with NSAID treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complete loss of specific types of white blood cells (agranulocytosis), especially in patients who take MOBIC together with other drugs that are potentially inhibitory, depressant or destructive to a component of the bone marrow (myelotoxic drugs). This can cause:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (pancreatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility in women, ovulation delay</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a distinctive cutaneous allergic reaction known as fixed drug eruption, that usually recurs at the same site(s) on re-exposure to the medication and may look like round or oval patches of redness and swelling of the skin, blistering (hives), itching.</p><p>&nbsp;</p><p>Side effects caused by non-steroidal anti-inflammatory medicines (NSAIDs), but not yet seen after taking MOBIC</p><p>Changes to the kidney structure resulting in acute kidney failure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very rare cases of kidney inflammation (interstitial nephritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; death of some of the cells within the kidney (acute tubular or papillary necrosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protein in the urine (nephrotic syndrome with proteinuria)</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in a safe place below 30&deg;C</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister strip and outer carton. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meloxicam</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one tablet of MOBIC 7.5 mg tablets contains 7.5&nbsp;mg meloxicam.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one tablet of MOBIC 15 mg tablets contains 15&nbsp;mg meloxicam.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium citrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactose monohydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; povidone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anhydrous colloidal silica</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crospovidone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                MOBIC 7.5 mg tablets is a light yellow, round tablet with the company logo on one side and 59D/59D on the other side. Each MOBIC 7.5 mg tablet has a score line. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
MOBIC 15 mg tablets is a light yellow, round tablet with the company logo on one side and 77C/77C on the other side. Each MOBIC 15 mg tablet has a score line and can be divided into two equal halves.
MOBIC tablets are available in Aluminium/Aluminium blister packs.
Pack sizes:
Mobic 7.5 mg Packs of 1, 2, 7, 10, 14, 15, 20, 28, 30, 50, 60, 100, 140, 280, 300, 500 tablets.
Mobic 15 mg Packs of 1, 2, 7, 10, 14, 15, 20, 28, 30, 50, 60, 100, 140, 280, 300, 500, 1000 tablets.
Not all pack sizes may be marketed.

Other strengths of MOBIC and other ways to take meloxicam
In some countries meloxicam is also available as:
-	meloxicam 7.5 mg suppositories
-	meloxicam 15 mg suppositories
-	meloxicam 15 mg per 1.5 mL solution for injection. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Boehringer Ingelheim International GmbH</p><p>Binger Strasse &nbsp;173</p><p>D-55216 Ingelheim am Rhein</p><p>Germany</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Rottendorf Pharma GmbH</p><p>Ostenfelder Stra&szlig;e 51 - 61</p><p>59320 Ennigerloh</p><p>GERMANY</p><p>&nbsp;</p><p dir="LTR"><strong>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder</strong>:</p><p dir="LTR">&nbsp;</p><p dir="LTR">Kingdom of Saudi Arabia (Scientific Office) Riyadh.</p><p dir="LTR">Tel: +966-11-5116504</p><p dir="LTR">Fax: +966-11-5116545</p><p dir="LTR">&nbsp;</p><p dir="LTR"><strong>This leaflet was last revised in June 2023.</strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="LTR"><strong>To report any side effect(s):</strong></p><p dir="LTR">&bull;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="LTR">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p dir="LTR">&middot; Fax: +966-11-205-7662</p><p dir="LTR">&middot; SFDA Call Center: 19999</p><p dir="LTR">&middot; E-mail: npc.drug@sfda.gov.sa</p><p dir="LTR">&middot; Website: https://ade.sfda.gov.sa</p><p dir="LTR">&nbsp;</p><p dir="LTR">&bull;&nbsp;&nbsp; <strong>Other countries:</strong></p><p dir="LTR">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="LTR">&nbsp;</p><p dir="LTR"><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:61.25pt;
  margin-top:14.75pt;width:479.05pt;height:156.85pt;z-index:-251657216;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center dir=LTR style='margin-top:0cm;margin-right:
     183.35pt;margin-bottom:8.0pt;margin-left:183.5pt;text-align:center;
     line-height:13.05pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:
     normal'><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>This
     is a Medicament<o:p></o:p></span></b></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:20.2pt;
     margin-bottom:0cm;margin-left:32.15pt;text-indent:0cm;line-height:95%;
     mso-pagination:none;mso-list:l2 level1 lfo1;tab-stops:42.15pt;text-autospace:
     none'><![if !supportLists]><span lang=EN-US style='font-size:12.0pt;
     line-height:95%;font-family:"Times New Roman",serif;mso-fareast-font-family:
     "Times New Roman"'><span style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:95%'>Medicament
     is a product which affects your health and its consumption contrary to an
     instruction is dangerous for<span style='letter-spacing:-.1pt'> </span>you.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:20.05pt;
     margin-bottom:0cm;margin-left:32.15pt;text-indent:0cm;line-height:93%;
     mso-pagination:none;mso-list:l2 level1 lfo1;tab-stops:42.4pt;text-autospace:
     none'><![if !supportLists]><span lang=EN-US style='font-size:12.0pt;
     line-height:93%;font-family:"Times New Roman",serif;mso-fareast-font-family:
     "Times New Roman"'><span style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:93%'>Follow
     strictly the doctor’s prescription, the method of use and the instructions
     of the Pharmacist who sold the<span style='letter-spacing:-.1pt'> </span>medicament.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:0cm;
     margin-bottom:0cm;margin-left:41.85pt;text-indent:-9.75pt;line-height:
     12.8pt;mso-line-height-rule:exactly;mso-pagination:none;mso-list:l2 level1 lfo1;
     tab-stops:41.9pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
     mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>−<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
     11.0pt'>The doctor and the pharmacist are the experts in medicines, their
     benefits and<span style='letter-spacing:-.55pt'> </span>risks.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:0cm;
     margin-bottom:0cm;margin-left:41.85pt;text-indent:-9.75pt;line-height:
     12.95pt;mso-line-height-rule:exactly;mso-pagination:none;mso-list:l2 level1 lfo1;
     tab-stops:41.9pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
     mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>−<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
     11.0pt'>Do not by yourself interrupt the period of treatment prescribed
     for<span style='letter-spacing:-.35pt'> </span>you.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:0cm;
     margin-bottom:0cm;margin-left:41.85pt;text-indent:-9.75pt;line-height:
     13.0pt;mso-line-height-rule:exactly;mso-pagination:none;mso-list:l2 level1 lfo1;
     tab-stops:41.9pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
     mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>−<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
     11.0pt'>Do not repeat the same prescription without consulting your<span
     style='letter-spacing:-.15pt'> </span>doctor.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:0cm;
     margin-bottom:0cm;margin-left:41.85pt;text-indent:-9.75pt;line-height:
     13.45pt;mso-line-height-rule:exactly;mso-pagination:none;mso-list:l2 level1 lfo1;
     tab-stops:41.9pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
     mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>−<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
     11.0pt'>Keep all medicaments out of reach of children.<o:p></o:p></span></p>
     <p class=MsoNormal dir=LTR style='margin-top:0cm;margin-right:0cm;
     margin-bottom:0cm;margin-left:32.1pt;line-height:13.45pt;mso-line-height-rule:
     exactly;mso-pagination:none;tab-stops:41.9pt;text-autospace:none'><span
     lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="643" height="213" alt="Text Box: This is a Medicament
−	Medicament is a product which affects your health and its consumption contrary to an instruction is dangerous for you.
−	Follow strictly the doctor’s prescription, the method of use and the instructions of the Pharmacist who sold the medicament.
−	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
−	Do not by yourself interrupt the period of treatment prescribed for you.
−	Do not repeat the same prescription without consulting your doctor.
−	Keep all medicaments out of reach of children.

" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">Council of Arab Health Ministers Union of Arab Pharmacists</p><p dir="LTR">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار موبيك على المادة الفعّالة ميلوكسيكام. ينتمي ميلوكسيكام إلى مجموعة من مضادات الالتهاب غير الستيرويدية التي تستخدم للحد من الالتهاب وألم المفاصل والعضلات.</p><p dir="RTL">تُستَخدَم أقراص عقار موبيك في البالغين والأطفال بعُمْر 16 عامًا فأكثر.</p><p dir="RTL">تُستَخدَم أقراص عقار موبيك للأغراض الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج حالات احتدام التهاب المفاصل على المدى القصير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الآتي على المدى الطويل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الروماتويدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>التهاب الفقار اللاصق</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أقراص عقار موبيك في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه فينتانيل أو أي مكونات أخرى بهذا الدَّواء (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال آخر 3 أشهر من فترة الحمل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأطفال والمراهقون </strong><strong>(</strong><strong>تحت سن </strong><strong>16 </strong><strong>عاماً</strong><strong>)</strong></p><p dir="RTL"><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>إذا عانيت من أيٍّ من العلامات التَّالية بعد تناوُل الأسبرين أو غيره من مضادات الالتهاب غير الستيرويدية:</p><p dir="RTL"><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>أزيز بالصدر، ضيق بالصدر، ضيق التنفس (الربو).</p><p dir="RTL"><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>انسداد الأنف بسبب تورم بطانة الأنف (السَّلَائِلُ الأَنْفِيَّة).</p><p dir="RTL"><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>طفح جلدي/ شرى القراص (أرتكاريا).</p><p dir="RTL"><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s><strong>-</strong>تورم مفاجئ للجلد أو الأغشية المخاطية مثل: التورم حول العينين والوجه والشفاه والفم أو الحلق، مما قد يجعل التَّنفس صعبًا (وذمة وعائية عصبية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعد علاج سابق بمضادات الالتهاب غير الستيرويدية وتاريخ مرضي سابق من</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المعدة أو الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فتحات (ثقوب) في المعدة أو الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح أو نزيف في المعدة أو الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاريخ مرضي سابق أو حديث بالإصابة بالقرح المعدية أو القرح الهضمية أو النزيف (حدوث تقرح أو نزيف على الأقل مرتين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور شديد بوظائف الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي الشديد دون الغسيل الكلوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف حديث بالمخ (نزيف دماغي وعائي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي نوع من اضطرابات النزيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب الشديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم تحمل لبعض السكريات؛ إذ قد يحتوي هذا المنتج على اللاكتوز (انظر أيضًا:&quot;يحتوي عقار موبيك على سكر اللبن (اللاكتوز) والصوديوم&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فيُرجى الاتصال بالطبيب الخاص بك.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار ريميرون.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التَّحذيرات</strong></p><p dir="RTL">قد ترتبط أدوية مثل عقار موبيك بزيادة ضئيلة في خطر الإصابة بالنوبة القلبية (احتشاء عضلة القلب) أو السكتة الدِّماغية. تَحدُث أي من هذه المخاطر بشكل أكبر مع الجرعات المرتفعة والعلاج المطول. لا تتناول أكثر من الجرعة الموصى بها لحالتك. لا تستخدم عقار موبيك لفترات أطول مما تم وصفه لك (انظر قسم 3: &quot;كيف تستخدم عقار موبيك؟&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مشاكل بالقلب، أو سكتة دماغية سابقة، أو كنت تعتقد أنك قد تكون معرضًا لخطر الإصابة بهذه الحالات، يجب مناقشة العلاج الخاص بك مع الطبيب أو الصيدلي الخاص بك. على سبيل المثال، إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ارتفاع ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ارتفاع مستويات السُّكَّرِ في الدم (مرض السكري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ارتفاع مستويات الكوليسترول في الدم (فرط كوليسترول الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; كنت مدخنا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أوقف العلاج بعقار موبيك على الفور بمجرد ملاحظتك لحدوث نزيف (مما يسبب برازًا بلون القطران) أو تقرح الجهاز الهضمي (ما يسبب آلام في البطن).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث طفح جلدي قد يهدد الحياة (متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسَمُّمِيّ) عند استخدام عقار موبيك، يظهر في البداية على شكل بقع حمراء شبيهة بالهدف أو بقع دائرية غالبًا مع ظهور بثور مركزية على الجذع. تشمل العلامات الإضافية التي يمكنك البحث عنها: القرح بالفم والحلق والأنف والأعضاء التَّناسلية والتهاب الملتحمة (احمرار وتورم بالعينين). هذا الطَّفح الجلدي الذي قد يهدد الحياة غالبًا يكون مصحوبًا بأعراض شبيهة بأعراض الأنفلونزا. قد يتطور الطفح الجلدي إلى ظهور بثور على نطاق واسع أو تقشر الجلد.</p><p dir="RTL">تكون أكثر مخاطر تفاعلات الجلد الخطيرة حدوثًا خلال الأسابيع الأولى من العلاج. إذا كنت قد أصبت بمتلازمة ستيفنز جونسون أو انحلال البشرة النخري التَّسَمُّمِيّ مع استخدام عقار موبيك، فيجب عليك عدم استئناف العلاج بعقار موبيك في أي وقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي قبل تناوُل عقار موبيك إذا كنت قد أصبت من قبل بطفح دوائي ثابت (بقع احمرار مستديرة أو بيضاوية وتورم في الجلد يتكرران عادة في الموضع نفسه (المواضع نفسها)، وبثور، وشرى (أرتكاريا)، وحكة) بعد تناوُل ميلوكسيكام أو عقاقير أخرى من فئة أوكسيكام (مثل بيروكسيكام).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بطفح جلدي أو أعراض الجلد هذه، فتوقف عن تناول عقار موبيك، واطلب المشورة العاجلة من الطبيب وأخبره بأنك تتناول هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار موبيك غير مناسب للاستخدام في حالة الحاجة إلى تخفيف فوري للألم الحاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يخفي عقار موبيك أعراض العدوى (على سبيل المثال: الحمى). يجب عليك زيارة طبيبك على الفور إذا كنت تعتقد بأنك مصاب بعدوى.</p><p dir="RTL"><strong>احتياطات الاستخدام</strong></p><p dir="RTL">بما أنه سيكون من الضروري ضبط العلاج، فمن المهم أن تستشير الطبيب قبل تلقي عقار موبيك في حالة وجود:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تاريخ مرضي سابق بالإصابة بالتهاب المريء، أو التهاب المعدة أو تاريخ سابق لأي مرض آخر في الجهاز الهضمي، مثل مرض كرون أو التهاب القولون التقرُّحي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; السن المتقدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أمراض بالقلب، أو الكبد أو الكلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السُّكَّرِ في الدم (مرض السكري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حجم الدم (نقص حجم الدم) الذي قد يحدث إذا كنت تعاني من فقدان الدم الخطير أو حرق، والجراحة أو انخفاض في شرب السوائل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; في حال شخصك طبيبك بعدم تحمل بعض أنواع السكريات؛ إذ يحتوي هذا المنتج على اللاكتوز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع بوتاسيوم الدم سبق تشخيصه من قبل الطبيب</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحتاج طبيبك أن يراقب تقدم حالتك أثناء العلاج.</p><p dir="RTL"><strong>استخدام أدوية أخرى مع عقار موبيك</strong></p><p dir="RTL">نظرًا لأن عقار موبيك يمكن أن يُؤثر أو يتأثر بالأدوية الأخرى، فيُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تتناول/ قد تناولت، أو تستخدم أيًّا مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية الأخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:group
 id="Group_x0020_8586" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:-8.85pt;margin-top:-12.4pt;width:23.05pt;height:52.1pt;
 z-index:-251658752' coordsize="2926,6614" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_12863" o:spid="_x0000_s1027" style='position:absolute;
  left:1127;top:1478;width:1799;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="179845,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l179845,r,9144l,9144,,e" fillcolor="red" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;1799,0;1799,91;0,91;0,0"
   o:connectangles="0,0,0,0,0" textboxrect="0,0,179845,9144"/>
 </v:shape><v:shape id="Shape_x0020_12864" o:spid="_x0000_s1028" style='position:absolute;
  width:91;height:1661;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,166129" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCqU9K7wwAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disIw
FITvhX2HcBb2TtMV/KEaiwgLLohoFa+PzbEtbU5qE7W+vVlY8HKYmW+YedKZWtypdaVlBd+DCARx
ZnXJuYLj4ac/BeE8ssbaMil4koNk8dGbY6ztg/d0T30uAoRdjAoK75tYSpcVZNANbEMcvIttDfog
21zqFh8Bbmo5jKKxNFhyWCiwoVVBWZXejIJr+nvdbVbpc3Q4V9sIzXJ0Wu+U+vrsljMQnjr/Dv+3
11rBBP6uhBsgFy8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAqlPSu8MAAADaAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l9144,r,166129l,166129,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;91,0;91,1661;0,1661;0,0"
   o:connectangles="0,0,0,0,0" textboxrect="0,0,9144,166129"/>
 </v:shape><v:shape id="Shape_x0020_12865" o:spid="_x0000_s1029" style='position:absolute;
  top:1661;width:91;height:1646;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,164592" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,164592l,164592,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;91,0;91,1646;0,1646;0,0"
   o:connectangles="0,0,0,0,0" textboxrect="0,0,9144,164592"/>
 </v:shape><v:shape id="Shape_x0020_12866" o:spid="_x0000_s1030" style='position:absolute;
  top:3307;width:91;height:1646;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,164592" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,164592l,164592,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;91,0;91,1646;0,1646;0,0"
   o:connectangles="0,0,0,0,0" textboxrect="0,0,9144,164592"/>
 </v:shape><v:shape id="Shape_x0020_12867" o:spid="_x0000_s1031" style='position:absolute;
  top:4953;width:91;height:1661;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,166116" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,166116l,166116,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;91,0;91,1661;0,1661;0,0"
   o:connectangles="0,0,0,0,0" textboxrect="0,0,9144,166116"/>
 </v:shape></v:group><![endif]--><img width="31" height="70" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />أملاح البوتاسيوم &ndash; تُستخدم لمنع انخفاض مستويات البوتاسيوم بالدم أو لعلاجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس &ndash; يُستَخدَم بعد الخضوع لعملية زرع أعضاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايميثوبريم &ndash; يُستَخدَم في علاج عدوى المسالك البولية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تمنع تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تقوم بتكسير الجلطات الدموية (الأدوية المذيبة للجلطات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لعلاج أمراض القلب والكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات (مثل تلك المستخدمة لعلاج الالتهابات وتفاعلات الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين - يستخدم بعد زرع الأعضاء، أو في الحالات الجلدية الشديدة، والتهاب المفاصل الروماتويدي أو المتلازمة الكلائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيراسيروكس &ndash; يُستخدم لعلاج التحميل المفرط بالحديد المزمن الناجم عن عمليات نقل الدم المتكررة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مدرات البول، فسيقوم طبيبك بمراقبة وظائف الكُلى لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لعلاج ارتفاع ضغط الدم (مثل حاصرات بيتا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم - يستخدم في علاج بعض الاضطرابات المزاجية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين الانتقائية (SSRIs) - تُستخدَم في علاج الاكتئاب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات- تستخدم لعلاج الأورام أو الحالات الجلدية الشديدة غير المتحكم فيها والتهاب المفاصل الروماتويدي الناشط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -ريتونافير (يُستَخدَم في علاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولستيرامين- يُستخدَم لخفض مستويات الكوليسترول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لمرض السُّكَّري التي يتم تناوُلها عن طريق الفم (سلفونيل يوريا، ناتيجلينيد) &ndash; تُستَخدم في علاج مرض السُّكَّرِي. ينبغي أن يراقب طبيبك مستويات السُّكَّر بالدَّم لديك بعناية تحسبًا لانخفاض السكر بالدم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناوُل هذا الدَّواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">لا تتناولي موبيك إذا كنت في آخر 3 أشهر من الحمل لأنه قد يضر طفلك الذي لم يولد بعد أو يسبب مشاكل عند الولادة. ويمكن أن يسبب مشاكل في الكلى والقلب في طفلك الذي لم يولد بعد. وقد يؤثر ذلك على ميلك وميل طفلك إلى النزيف ويتسبب في تأخر المخاض أو أن يكون أطول من المتوقع.</p><p dir="RTL">يجب ألا تتناولي موبيك خلال أول 6 أشهر من الحمل ما لم يكن ذلك ضروريا للغاية وينصح به طبيبك. إذا كنت بحاجة إلى علاج خلال هذه الفترة أو أثناء محاولتك الحمل ، فيجب استخدام أقل جرعة لأقصر وقت ممكن. إذا تم تناوله لأكثر من بضعة أيام من 20 أسبوعا من الحمل فصاعدا ،يمكن أن يسبب MOBIC مشاكل في الكلى في طفلك الذي لم يولد بعد والتي قد تؤدي إلى انخفاض مستويات السائل السلوي الذي يحيط بالطفل (قلة السائل السلوي) أو تضيق الأوعية الدموية (القناة الشريانية) في قلب الطفل. إذا كنت بحاجة إلى علاج لمدة تزيد عن بضعة أيام ، فقد يوصي طبيبك بمراقبة إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولتِ هذا الدَّواء بينما كنتِ حاملًا، يجب عليكِ التحدث إلى طبيبكِ/القابلة الخاصة بك على الفور حتى يتم الأخذ بعين الاعتبار مراقبة حالتك كما ينبغي.</p><p dir="RTL"><strong>الرَّضاعة الطبيعية</strong></p><p dir="RTL">لا يُوصى باستخدام هذا المُنتَج أثناء الرضاعة الطبيعية.</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">قد يجعل عقار موبيك حدوث الحمل أكثر صعوبة. يجب عليكِ إخبار طبيبك إذا كنتِ تخططين للحمل أو إذا كان لديكِ مشاكل في أن تصبحي حاملًا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تحدث اضطرابات بصرية، بما في ذلك عدم وضوح الرؤية أو الدوخة أو النُّعاس أو الدوار أو اضطرابات الجهاز العصبي المركزي الأخرى مع هذا المُنتَج. إذا أُصِبت بذلك، فتجنب القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>تحتوي أقراص عقار موبيك على سكر اللبن </strong><strong>(</strong><strong>اللاكتوز</strong><strong>) والصوديوم.</strong></p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) لكل قرص ، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المُوصى بها من عقار موبيك </strong><strong>7.5 </strong><strong>مجم هي</strong><strong>:</strong></p><p dir="RTL"><strong>حالات احتدام التهاب المفاصل</strong><strong>:</strong></p><p dir="RTL">7.5 مجم (قرص واحد) مرة واحدة يوميًّا. قد تتم زيادة هذه الجرعة لتبلغ 15 مجم (قرصين) مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التهاب المفاصل الروماتويدي</em></p><p dir="RTL">15 مجم (قرصين) مرة واحدة يوميًّا. قد يتم خفض هذه الجرعة لتبلغ 7.5 مجم (قرص واحد) مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التهاب الفقار اللاصق</em></p><p dir="RTL">15 مجم (قرصين) مرة واحدة يوميًّا. قد يتم خفض هذه الجرعة لتبلغ 7.5 مجم (قرص واحد) مرة واحدة يوميًّا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة المُوصى بها من عقار موبيك </strong><strong>15 </strong><strong>مجم هي</strong><strong>:</strong></p><p dir="RTL"><strong>حالات احتدام التهاب المفاصل</strong><strong>:</strong></p><p dir="RTL">7.5 مجم (نصف قرص) مرة واحدة يوميًّا. قد تتم زيادة هذه الجرعة لتبلغ 15 مجم (قرص واحد) مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التهاب المفاصل الروماتويدي</em></p><p dir="RTL">15 مجم (قرص واحد) مرة واحدة يوميًّا. قد يتم خفض هذه الجرعة لتبلغ 7.5 مجم (نصف قرص) مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التهاب الفقار اللاصق</em></p><p dir="RTL">15 مجم (قرص واحد) مرة واحدة يوميًّا. قد يتم خفض هذه الجرعة لتبلغ 7.5 مجم (نصف قرص) مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتجاوز الجرعة القصوى الموصى بها البالغة </strong><strong>15&nbsp;</strong><strong>مجم في اليوم</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أيٌّ مما هو مدرج تحت العنوان: &quot;<strong>تحذيرات واحتياطات</strong>&quot;، فقد يقوم طبيبك بتقليل جرعتك إلى 7.5 مجم مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى من كبار السن</strong><strong><em>&nbsp; </em></strong></p><p dir="RTL">إذا كنت من كبار السن، تبلغ الجرعة المُوصى بها فيما يخص علاج التهاب المفاصل الروماتويدي والتهاب الفقار اللاصق طويل الأمد 7.5 مجم (قرص واحد من عقار موبيك 7.5 مجم أو نصف قرص من عقار موبيك 15 مجم) في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>المرضى ممن لديهم مخاطر متزايدة للتعرض لتفاعلات عكسية </em></strong></p><p dir="RTL">إذا كنت أحد المرضى ممن لديهم مخاطر متزايدة للتعرض لتفاعلات عكسية، سيبدأ طبيبك العلاج بجرعة قدرها 7.5 مجم (قرص واحد من عقار موبيك 7.5 مجم أو نصف قرص من عقار موبيك 15 مجم) في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>قصور وظائف الكُلى </em></strong></p><p dir="RTL">إذا كنت أحد مرضى الغسيل الكلوى ممن يعانون من قصور شديد بوظائف الكُلى، ينبغي ألا تتجاوز جرعتك 7.5 مجم (قرص واحد من عقار موبيك 7.5 مجم أو نصف قرص من عقار موبيك 15 مجم) في اليوم. لا يلزم ضبط الجرعة للمرضى المصابين بقصور خفيف إلى معتدل في وظائف الكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>قصور وظائف الكبد </em></strong></p><p dir="RTL">لا يلزم تعديل الجرعة في المرضى المصابين بقصور كبدي خفيف إلى معتدل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال في الأطفال والمراهقين</strong><strong><em> </em></strong></p><p dir="RTL">لا يجب إعطاء عقار موبيك للأطفال والمراهقين الأقل من 16 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا شعرت أن تأثير عقار موبيك أقوى من اللازم أو أقل من اللازم، أو إذا لم تشعر بعد عدة أيام بأي تحسُّن في حالتك، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">طريقة التَّناوُل</p><p dir="RTL">يتم استخدامه عن طريق الفم.</p><p dir="RTL">ينبغي ابتلاع الأقراص مع&nbsp; الماء أو غيره من المشروبات، أثناء تناوُل إحدى الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوجد خط التحزيز فقط لمساعدتك على كسر القرص إذا كنت تواجه صعوبة في ابتلاعه كاملًا.</p><p dir="RTL">يمكن تقسيم قرص عقار موبيك 15 مجم إلى جرعات متساوية. ينبغي تقسيم الأقراص باليد وليس باسخدام أداة حادة (على سبيل المثال: سكين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إذا تناولت كمية من باسكوبان أقراص مغلفة بالسكر أكثر مما يجب</em></strong></p><p dir="RTL"><strong>سواء استخدمت كمية كبيرة جدًّا من الأمبولات أو تشك في أنك استخدمت جرعة زائدة، اتصل بطبيبك أو اذهب إلى أقرب مستشفى على الفور</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تقتصر الأعراض الناتجة عن جرعة زائدة شديدة من مضادات الالتهاب غير الستيرويدية عادة على</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة (خمول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعورًا بالإعياء (الغثيان)، أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة المعدة (ألم في فم المعدة)</p><p dir="RTL">تتحسن هذه الأعراض بشكل عام عند التَّوقف عن استخدام عقار موبيك. قد تُعاني من نزيف بالمعدة أو الأمعاء (نزيف معدي معوي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التسمم الحاد قد يؤدي إلى تفاعل خطير </strong><strong>(</strong><strong>انظر قسم</strong><strong>: 4):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كُلوي حاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفض/ تسطح أو تثبيط التنفس (كبت الجهاز التنفسي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي (الغيبوبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنجية (تشنجات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط في الدورة الدموية (وَهَطٌ قَلْبِيٌّ وِعائِيّ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب (السكتة القلبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط الحساسية) السريعة بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول عقار براداكسا</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها. تناول الجرعة التَّالية في الموعد المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن استخدام عقار موبيك واستشر الطبيب أو أقرب مستشفى لك على الفور إذا لاحظت</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أي تفاعلات حساسية (فرط الحساسية)، والتي قد تظهر في شكل:</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بالجلد، مثل: حكة أو بثور بالجلد أو تقشر الجلد، والتي يُمكِن أن تكون (طفحًا جلديًّا قد يكون مهددًا للحياة (متلازمة ستيفنز جونسون وانحلال البشرة النخري التَّسَمُّمِيّ)، أو إصابات بالأنسجة الرَّخوة (إصابات بالأغشية المخاطية) أو احمرارًا متعدد الأشكال &nbsp;(انظر القسم: 2).</p><p dir="RTL">الاحمرار متعدد الأشكال هو تفاعل حساسية جلدية خطير يُسبب بقعًا أو كدمات حمراء أو أرجوانية أو مناطق بثور. يمكن أن تُؤثر أيضًا على الفم والعينين وغيرها من أسطح الجسم الرطبة.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الجلد أو الغشاء المخاطي، مثل تورم حول العينين والوجه والشفاه أو الفم أو الحلق، وقد يجعل التنفس صعبًا، تورم الكاحلين أو الساقين (الوذمة في الأطراف السفلية).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس أو نوبات الربو.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد. قد ذلك أعراض مثل:</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp; إصفرار الجلد أو مقلة العين (يرقان)</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&nbsp;</p><p dir="RTL">أي آثار جانبية بالجهاز الهضمي، خاصةً:</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف (ننتج عنها براز بلون القطران)</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح في الجهاز الهضمي (مما يسبب ألمًا في البطن)</p><p dir="RTL">&nbsp;</p><p dir="RTL">نزيف الجهاز الهضمي (نزيف بالمعدة والأمعاء)، تكوُّن تقرحات أو ثقب في الجهاز الهضمي والذي قد يكون أحيانا شديدا، وقد يؤدي إلى الوفاة، وخاصة في كبار السن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من قبل من أي أعراض خاصَّة بالجهاز الهضمي بسبب الاستخدام طويل الأمد لمضادات الالتهاب غير الستيرويدية، فاطلب المشورة الطبية على الفور، خاصةً إذا كنت من المرضى كبار السن. قد يراقب طبيبك تقدم حالتك أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لاضطرابات بصرية، فتجنب القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية العامة للأدوية المضادة للالتهابات غير الستيرويدية</strong></p><p dir="RTL">قد يُصاحِب استخدام بعض الأدوية المضادة للالتهابات غير الستيرويدية ارتفاع طفيف في نسبة خطورة الإصابة بانسداد الأوعية الشريانية (أحداث شريانية خُثارية)، على سبيل المثال: نوبة قلبية (احتشاء عضلة القلب) أو سكتة دماغية، بشكل خاص عند استخدام جرعات مرتفعة والعلاج طويل الأمد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تم الإبلاغ عن حدوث احتباس السوائل (وذمة) وارتفاع ضغط الدَّم وفشل القلب (الفشل القلبي) بمصاحبة العلاج بالأدوية المضادة للالتهابات غير الستيرويدية.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">الآثار الجانبية الأكثر شيوعا التي تم ملاحظتها (أحداث متعلقة بالجهاز الهضمي):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُرَح بالمَعِدَة والجزء العُلوي من الأمعاء الدقيقة (قُرَح هضمية/ مَعِدِيّة إثْنا عَشَرِيّة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب في جدار الأمعاء أو نزيف الجهاز الهضمي (قد تؤدي إلى الوفاة في بعض الأحيان، وخاصة في كبار السن)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية بعد تناوُل الأدوية المضادة للالتهابات غير الستيرويدية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (الغثيان)، أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز ليِّن (الإسهال)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ بالبطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْرُ الهَضْم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز بلون القطران بسبب نزيف الجهاز الهضمي (براز مدمم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء دموي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب مع تكون تقرحات في الفم (التهاب الفم التقرحي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم التهاب الجهاز الهضمي (على سبيل المثال: تفاقم التهاب القولون أو مرض كرون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم ملاحظة حدوث التهاب بالمعدة بشكل أقل تكرارًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية لميلوكسيكام </strong><strong>- </strong><strong>المادة الفعّالة في عقار موبيك</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong><strong>: </strong><strong>قد تُؤثر في أكثر من </strong><strong>1 </strong><strong>من كل </strong><strong>10&nbsp;</strong><strong>أشخاص</strong><strong>. </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp; آثار جانبية متعلقة بالجهاز الهضمي مثل: عسر الهضم، شعور بالإعياء (الغثيان)، أو الإعياء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل10 &nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>: قد تُؤثر </strong><strong>على ما يصل إلى شخص واحد من بين كل </strong><strong>100 </strong><strong>مريض، </strong><strong>&quot;</strong><strong>غير شائعة</strong><strong>&quot;:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة (شعور بخفة الرأس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة أو الدوران (الدوار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيمومة (نعاس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (خفض تركيز صبغة الدم الحمراء، الهيموجلوبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد (احمرار مؤقت بالوجه والرقبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء والصوديوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البوتاسيوم بالدَّم (فرط بوتاسيوم الدم) يُمكِن أن يؤدي هذا إلى أعراض مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في دقات قلبك (اضطرابات النظم القلبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان (عندما تشعر بأن قلبك يدق أكثر من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَجَشّؤ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الجهاز الهضمي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (فرط حساسية) فورية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورُّم الناجم عن احتباس السوائل (الوذمة)، بما في ذلك، تورُّم الكاحلين/ الساقين (وذمة بالأطراف السفلية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>-</strong>تورم مفاجئ للجلد أو الأغشية المخاطية مثل: التورم حول العينين والوجه والشفاه والفم أو الحلق، مما قد يجعل التَّنفس صعبًا (وذمة وعائية عصبية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات مؤقتة في اختبارات وظائف الكبد (مثل ارتفاع مستوى الإنزيمات الكبدية مثل الناقلات الأمينية أو ارتفاع في مستوى البيليروبين، صبغة الموجودة في العصارة الصفراوية). يُمكِن لطبيبك الكشف عن هذه الاضطرابات باستخدام اختبار الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود اضطرابات في نتائج الاختبارات المعملية التي تفحص وظائف الكُلى (على سبيل المثال: ارتفاع مستوى الكرياتينين أو اليوريا)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong><strong>: </strong><strong>نادرة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الحالة المزاجية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعداد الدم غير الطبيعي، بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعداد الدم التفريقي غير الطبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (قلة خلايا الدم البيضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد صفائح الدم (قلة الصفائح الدموية)</p><p dir="RTL">قد تُؤدي هذه الآثار الجانبية إلى ارتفاع نسبة خطورة الإصابة بعدوى وأعراض مثل التكدُّم أو نزيف الأنف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين بالأذن (طنين بالأذن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بدقات قلبك (خفقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُرَح بالمَعِدَة أو الجزء العُلوي من الأمعاء الدقيقة (قُرَح هضمية/ مَعِدِيّة إثْنا عَشَرِيّة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المَرِيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نوبات الربو (يظهر في الأشخاص المصابين بحساسية للأسبرين ومضادات الالتهاب غير الستيرويدية الأخرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نفطات شديدة بالجلد أو تقشُّر الجلد (متلازمة ستيفنز جونسون وانحلال البشرة النخري التَّسَمُّمِيّ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح القراص (أرتكاريا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بصرية بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المُلْتَحِمَة (التهاب مقلة العين أو الجفون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة (التهاب القولون).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا</strong><strong>:&nbsp; </strong><strong>نادرة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10,0</strong><strong>0</strong><strong>0 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية ينجم عنها ظهور نفطات (تفاعلات فقاعية) واحمرار متعدد الأشكال.</p><p dir="RTL">يُعد الاحمرار متعدد الأشكال تفاعل حساسية جلدية خطير مما يُسبب بقعًا حمراء أو أرجوانية أو مناطق بثور. يمكن أن تُؤثر أيضا على الفم والعينين وغيرها من أسطح الجسم الرطبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد. قد ذلك أعراض مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصفرار الجلد أو مقل العيون (يرقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل حاد بالكُلى (فشل كُلوي) خاصةً في المرضى الذين لديهم عوامل خطورة مثل: أمراض القلب أو مرض السُّكَّري أو أمراض الكُلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب في جدار الأمعاء (انثقاب)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong><strong>: </strong><strong>لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توهان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس وتفاعلات الجلد (تفاعلات تأقية/ تأقانية) وطفح ناجم عن التعرض لأشعة الشمس (تفاعلات حساسية للضوء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن الإصابة بفشل القلب (الفشل القلبي) بمصاحبة العلاج بالأدوية المضادة للالتهابات غير الستيرويدية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -فقدان كامل لأنواع محددة من خلايا الدَّم البيضاء (ندرة المحببات)، وبخاصَّة في المرضى الذين يستخدمون عقار موبيك جنبا إلى جنب مع العقاقير الأخرى التي يحتمل أن تكون مثبطة، مخمدة أو مدمرة لأحد مكونات نخاع العظام (الأدوية السَّامة للنُّخاع العظمي). قد يُسبب هذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى مفاجئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم في السيدات, تأخر التبويض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية جلدي مميز يُعرف باسم الطفح الدوائي الثابت، يتكرر عادة في الموضع نفسه (المواضع نفسها) عند التعرض المتكرر للدواء وقد يتمثل في صورة بقع احمرار مستديرة أو بيضاوية وتورم في الجلد، وبثور (شرى (أرتكاريا))، وحكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النَّاجمة عن الأدوية المضادة للالتهابات غير الستيرويدية، لكنها لم تظهر حتى الآن بعد استخدام عقار موبيك</strong></p><p dir="RTL">تغيرات في بنية الكُلى تُؤدي إلى الفشل الكلوي الحاد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات نادرة جدًّا من التهاب الكلى (الْتِهابُ الكُلْيَةِ الخِلَالِيّ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت بعض الخلايا داخل الكلى (نخر أنبوبي أو حليمي حاد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بروتينات بالبول (متلازمة كلائية مصحوبة ببيلة بروتينية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإبلاغ عن الآثار الجانبية </u></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض الخاص بك. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تُحفظ أقراص عقار موبيك في مكان آمن في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تَستخدِم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المُدوَّن على الشريط والعبوة الكرتونية الخارجية. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب التَّخزين داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميلوكسيكام</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>يحتوي القرص الواحد من أقراص عقار موبيك 7.5 مجم على 7.5 مجم من ميلوكسيكام.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>يحتوي القرص الواحد من أقراص عقار موبيك 15 مجم على 15 مجم من ميلوكسيكام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سترات الصوديوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاكتوز أحادي الهيدرات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليلوز دقيق التبلور</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوفيدون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليكا غروية لا مائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كروسبوفيدون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستيرات الماغنيسيوم</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل عقار موبيك؟ وما هي محتويات العبوة؟</strong></p><p dir="RTL">أقراص عقار موبيك 7.5 مجم هي أقراص دائرية ذات لون أصفر فاتح، على أحد جانبيها شعار الشركة ويُوجد &quot;59D/59D&quot; على الجانب الآخر. كل قرص من أقراص عقار موبيك 7.5 مجم به خط تقسيم. خط التقسيم هو لتسهيل كسرها؛ ليسهل بلعها وليس لتقسيمها إلى جرعات متساوية.</p><p dir="RTL">أقراص عقار موبيك 15 مجم هي أقراص دائرية ذات لون أصفر فاتح، على أحد جانبيها شعار الشركة ويُوجد &quot;77C/77C&quot; على الجانب الآخر. كل قرص من أقراص عقار موبيك 15 مجم به خط تقسيم ويمكن تقسيمه إلى نصفين متساويين.</p><p dir="RTL">تتوافر أقراص عقار موبيك في شرائط من الألومنيوم/الألومنيوم.</p><p dir="RTL"><strong>أحجام العبوة</strong><strong>:</strong></p><p dir="RTL"><strong>عقار موبيك </strong><strong>7.5 </strong><strong>مجم</strong> عبوات بها قرص واحد، قرصين، 7، 10، 14، 15، 20، 28، 30، 50, 60, 100, 140, 280, 300, 500 قرص.</p><p dir="RTL"><strong>عقار موبيك </strong><strong>15 </strong><strong>مجم</strong> عبوات بها قرص واحد، قرصين، 7، 10، 14، 15، 20، 28، 30، 50, 60, 100, 140, 280, 300, 500، 1000 قرص.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL"><strong>طرق أخرى لاستخدام ميلوكسيكام</strong></p><p dir="RTL">يتوافر ميلوكسيكام في بعض الدول على هيئة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميلوكسيكام أقماع 7.5 مجم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميلوكسيكام أقماع 15 مجم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميلوكسيكام 15 مجم لكل 1.5 مللي لتر محلول للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق وجهة التَّصنيع</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>مالك حق التَّسويق</strong><strong>:</strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم إنترناشونال المحدودة</p><p dir="RTL">173 شارع بنجر</p><p dir="RTL">55216-د إنجلهايم أيه إم راين</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong><strong>:</strong></p><p dir="RTL">روتندورف فارما جي ام بي اتش<br />61 &ndash; أوستینفیلدر ستراب 51<br />59320 انیجرلوه ألمانیا</p><p dir="RTL">للحصول على أي معلومات بخصوص ھذا الدواء یرجى التواصل مع الممثل المحلي (المكتب العلمي)</p><p dir="RTL">هاتف: +966115116504</p><p dir="RTL">فاكس: +966115116545</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تمت آخر مراجعة لهذه النَّشرة في يونيو </strong><strong>2023</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الاثار الجانبية:</p><p dir="RTL">&bull;السعودية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; المركز الوطني للرصد الدوائي</p><p dir="RTL">&middot;&nbsp;&nbsp; فاكس: +966-11-205-7662</p><p dir="RTL">&middot;&nbsp;&nbsp; مركز الاتصال الموحد بالهيئة العامة للغذاء و الدواء: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp; لبريد الإلكتروني npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp; موقع الويب www.sfda.gov.sa/npc</p><p dir="RTL">-الدول الأخرى:</p><p dir="RTL">يرجى الاتصال بالهيئة المختصة.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:639px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>هذا مُنتَج دوائي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مُنتَج يُؤثر على صحتك ويُعَد استعماله بطريقة مخالفة للتعليمات خطرًا عليك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع وصفة الطبيب بشكل صارم وطريقة الاستعمال وتعليمات الصيدلي الذي باعك الدَّواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما خبيران في الأدوية وفوائدها ومخاطرها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع فترة العلاج الموصوفة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر الوصفة الطبية دون استشارة طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ جميع الأدوية بعيدًا عن مُتناوَل الأطفال.</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتحاد الصيادلة العرب</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mobic 7.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 7.5 mg of Meloxicam.

Excipient(s) with known effect
Each tablet contains lactose monohydrate equivalent to 22.3 mg lactose anhydrous.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Light yellow round tablet with the logotype of the company on one side and a score with 59D/59D on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term symptomatic treatment of exacerbations of osteoarthrosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobic tablets are indicated in adults and children aged 16 years and older</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The total daily amount should be taken as a single dose. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exacerbations of osteoarthrosis: 7.5 mg/day (one 7.5 mg tablet).</p><p>If necessary, in the absence of improvement, the dose may be increased to 15 mg/day (two 7.5 mg tablets).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (two 7.5 mg tablets) (see also section &lsquo;Special populations&rsquo; below).</p><p>According to the therapeutic response, the dose may be reduced to 7.5 mg/day (one 7.5 mg tablet).</p><p>&nbsp;</p><p>DO NOT EXCEED THE DOSE OF 15MG/DAY.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly patients (see section 5.2)</em></p><p>The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day (see also sections 4.2 &lsquo;Patients with increased risks for adverse reaction&rsquo; and 4.4).</p><p>&nbsp;</p><p><em>Patients with increased risks for adverse reaction (see section 4.4)</em></p><p>In patients with increased risks for adverse reactions, e.g. a history of gastro-intestinal disease or risk factors for cardiovascular disease, the treatment should be started at a dose of 7.5 mg per day.</p><p>&nbsp;</p><p><em>Renal impairment (see section 5.2)</em></p><p>This medicine is contraindicated in non-dialysed severe renal failure (see section 4.3).</p><p>In patients with end-stage renal failure on haemodialysis, the dose should not exceed 7.5 mg per day.</p><p>No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min).</p><p>&nbsp;</p><p><em>Hepatic impairment (see section 5.2)</em></p><p>No dose reduction is required in patients with mild to moderate hepatic impairment (For patients with severely impaired liver function, see section 4.3).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Mobic 7.5 mg tablets are contraindicated in children and adolescents below 16 years of age (see section 4.3). This medicinal product exists in other dosages, which may be more appropriate.</p><p><em>Poor Metabolizers of CYP2C9 Substrates</em></p><p>In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin) consider dose reduction as they may have abnormally high plasma levels due to reduced metabolic clearance, and monitor patients for adverse effects.</p><p><strong>&nbsp;</strong>This medicinal product exists in other dosages, which may be more appropriate.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p><p>Mobic 7.5 mg tablets are swallowed with water or other fluid in conjunction with food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
This medicinal product is contraindicated in the following situations:

-	hypersensitivity to the active substance or to any of the excipients listed in section 6.1;
-	third trimester of pregnancy (see section 4.6 ‘Fertility, pregnancy and lactation’);
-	children and adolescents below 16 years of age;
-	hypersensitivity to substances with a similar action, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), aspirin. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs;
-	history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
-	active, or history of recurrent peptic ulcer /haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
-	severely impaired liver function;
-	non-dialysed severe renal failure;
-	gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders;
-	severe heart failure.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below).</p><p>&nbsp;</p><p>The recommended maximum daily dose should not be exceeded in case of insufficient therapeutic effect, nor should an additional NSAID be added to the therapy because this may increase the toxicity while therapeutic advantage has not been proven. The use of meloxicam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.</p><p>&nbsp;</p><p>Meloxicam is not appropriate for the treatment of patients requiring relief from acute pain.</p><p>&nbsp;</p><p>In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed.</p><p>&nbsp;</p><p>Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with meloxicam and with a past history of this type.</p><p>&nbsp;</p><p><u>Gastrointestinal effects</u></p><p>GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>&nbsp;</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).</p><p>&nbsp;</p><p>Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p>&nbsp;</p><p>In patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, anticoagulants such as warfarin, other non steroidal anti-inflammatory drugs, or acetylsalicylic acid given at doses &ge; 500mg as single intake or &ge; 3g as total daily amount, the combination with meloxicam is not recommended (see section 4.5).</p><p>&nbsp;</p><p>When GI bleeding or ulceration occurs in patients receiving meloxicam the treatment should be withdrawn.</p><p>&nbsp;</p><p>NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&rsquo;s disease) as these conditions may be exacerbated (see section 4.8 &ndash; undesirable effects).</p><p>&nbsp;</p><p><u>Cardiovascular and cerebrovascular effects</u></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with meloxicam.</p><p>&nbsp;</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs including meloxicam (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for meloxicam.</p><p>&nbsp;</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with meloxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p>&nbsp;</p><p><u>Skin reactions</u></p><p>Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Meloxicam. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment. If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Meloxicam treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. If the patient has developed SJS or TEN with the use of Meloxicam, Meloxicam must not be re-started in this patient at any time.</p><p>&nbsp;</p><p><u>Cases of fixed drug eruption (FDE) have been reported with meloxicam. </u></p><p><u>&nbsp;</u></p><p><u>Meloxicam should not be reintroduced in patients with history of meloxicam-related FDE. Potential cross reactivity might occur with other oxicams.</u></p><p>&nbsp;</p><p><u>Parameters of liver and renal function</u></p><p>As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Meloxicam should be stopped and appropriate investigations undertaken.</p><p>&nbsp;</p><p><u>Functional renal failure</u></p><p>NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of the renal function including the volume of diuresis is recommended in patients with the following risk factors:</p><p>&nbsp;</p><p>&sect;&nbsp; Elderly</p><p>&sect;&nbsp; Concomitant treatments such as ACE inhibitors, angiotensin-II antagonists, sartans, diuretics (see section 4.5. Interaction with other medicinal products and other forms of interaction)</p><p>&sect;&nbsp; Hypovolemia (whatever the cause)</p><p>&sect;&nbsp; Congestive heart failure</p><p>&sect;&nbsp; Renal failure</p><p>&sect;&nbsp; Nephrotic syndrome</p><p>&sect;&nbsp; Lupus nephropathy</p><p>&sect;&nbsp; Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score &ge;10)</p><p>&nbsp;</p><p>In rare instance NSAIDs may be the cause of interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome.</p><p>&nbsp;</p><p>The dose of meloxicam in patients with end-stage renal failure on haemodialysis should not exceed 7.5 mg. No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min).</p><p>&nbsp;</p><p><u>Sodium, potassium and water retention</u></p><p>Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Furthermore, a decrease of the antihypertensive effect of antihypertensive drugs can occur (see section 4.5). Consequently, oedema, cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. Clinical monitoring is therefore necessary for patients at risk (see sections 4.2 and 4.3).</p><p>&nbsp;</p><p><u>Hyperkalaemia</u></p><p>Hyperkalaemia can be favoured by diabetes or concomitant treatment known to increase kalaemia (see section 4.5). Regular monitoring of potassium values should be performed in such cases.</p><p>&nbsp;</p><p><u>Combination with pemetrexed</u></p><p>In patients with mild to moderate renal insufficiency receiving pemetrexed, meloxicam should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.5).</p><p>&nbsp;</p><p><u>Other warnings and precautions</u></p><p><strong><u>&nbsp;</u></strong></p><p>Adverse reactions are often less well tolerated in elderly, fragile or weakened individuals, who therefore require careful monitoring. As with other NSAIDs, particular caution is required in the elderly, in whom renal, hepatic and cardiac functions are frequently impaired. The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2).</p><p>&nbsp;</p><p>Meloxicam, as any other NSAID may mask symptoms of an underlying infectious disease.</p><p>&nbsp;</p><p>The use of meloxicam may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered (see section 4.6).</p><p>&nbsp;</p><p>Mobic 7.5 mg tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Risks related to hyperkalaemia</u></p><p>Certain medicinal products or therapeutic groups may promote hyperkalaemia: potassium salts, potassium- sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs, (low-molecular-weight or unfractionated) heparins, cyclosporin, tacrolimus and trimethoprim.</p><p>The onset of hyperkalaemia may depend on whether there are associated factors.</p><p>This risk is increased when the above-mentioned medicinal products are co-administered with meloxicam. <u>Pharmacodynamic Interactions</u></p><p><em>Other non steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid</em></p><p>Combination (see section 4.4) with other non steroidal anti-inflammatory drugs, acetylsalicylic acid given at doses &ge; 500mg as single intake or &ge; 3g as total daily amount is not recommended.</p><p>&nbsp;</p><p><em>Corticosteroids (e.g. Glucocorticoids)</em></p><p>The concomitant use with corticosteroids requests caution because of an increased risk of bleeding or gastrointestinal ulceration.</p><p>&nbsp;</p><p><em>Anticoagulant or heparin</em></p><p>Considerably increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa. NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4). The concomitant use of NSAIDs and anticoagulants or heparin administered in geriatrics or at curative dose is not recommended (see section 4.4).</p><p>In remaining cases (e.g. preventive doses) of heparin use caution is necessary due to an increased bleeding risk.</p><p>Careful monitoring of the INR is required if it proves impossible to avoid such combination.</p><p>&nbsp;</p><p><em>Thrombolytics and antiplatelet drugs</em></p><p>Increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa.</p><p>&nbsp;</p><p><em>Selective serotonin reuptake inhibitors (SSRIs)</em></p><p>Increased risk of gastrointestinal bleeding.</p><p>&nbsp;</p><p><em>Diuretics, ACE inhibitors and Angiotensin-II Antagonists</em></p><p>NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin-II antagonists and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter (see also section 4.4).</p><p>&nbsp;</p><p><em>Other antihypertensive drugs (e.g. Beta-blockers)</em></p><p>As for the latter, a decrease of the antihypertensive effect of beta-blockers (due to inhibition of prostaglandins with vasodilatory effect) can occur.</p><p>&nbsp;</p><p><em>Calcineurin inhibitors (e.g. cyclosporin, tacrolimus)</em></p><p>Nephrotoxicity of calcineurin inhibitors may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment renal function is to be measured. A careful monitoring of the renal function is recommended, especially in the elderly.</p><p>&nbsp;</p><p><em>Deferasirox</em></p><p>The concomitant administration of meloxicam with deferasirox may increase the risk of gastro-intestinal adverse reactions. Caution should be exercised when combining these medicinal products.</p><p>&nbsp;</p><p><u>Pharmacokinetic Interactions: Effect of meloxicam on the pharmacokinetics of other drugs</u></p><p>&nbsp;</p><p><em>Lithium</em></p><p>NSAIDs have been reported to increase blood lithium levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended (see section 4.4). If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.</p><p>&nbsp;</p><p><em>Methotrexate</em></p><p>NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended (see section 4.4).</p><p>The risk of an interaction between NSAID preparations and methotrexate, should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function. In case combination treatment is necessary blood cell count and the renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity.</p><p>Although the pharmacokinetics of methotrexate (15mg/week) were not relevantly affected by concomitant meloxicam treatment, it should be considered that the haematological toxicity of methotrexate can be amplified by treatment with NSAID drugs (see above) (See section 4.8).</p><p>&nbsp;</p><p><em>Pemetrexed</em></p><p>For the concomitant use of meloxicam with pemetrexed in patients with creatinine clearance from 45 to 79 ml/min, the administration of meloxicam should be paused for 5 days before, on the day of, and 2 days following pemetrexed administration. If a combination of meloxicam with pemetrexed is necessary, patients should be closely monitored, especially for myelosuppression and gastro-intestinal adverse reactions. In patients with severe renal impairment (creatinine clearance below 45 ml/min) the concomitant administration of meloxicam with pemetrexed is not recommended.</p><p>&nbsp;</p><p>In patients with normal renal function (creatinine clearance &ge; 80 ml/min), doses of 15 mg meloxicam may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events. Therefore, caution should be exercised when administering 15 mg meloxicam concurrently with pemetrexed to patients with normal function (creatinine clearance &ge; 80 ml/min).</p><p>&nbsp;</p><p><u>Pharmacokinetic Interactions: Effect of other drugs on the pharmacokinetics of meloxicam</u></p><p>&nbsp;</p><p><em>Cholestyramine</em></p><p>Cholestyramine accelerates the elimination of meloxicam by interrupting the enterohepatic circulation so that clearance for meloxicam increases by 50% and the half-life decreases to 13<u>+</u>3 hrs. This interaction is of clinical significance.</p><p>&nbsp;</p><p><u>Pharmacokinetic Interactions: Effect of combination of meloxicam and of other drugs on the</u> <u>pharmacokinetics</u></p><p>&nbsp;</p><p><em>Oral antidiabetics (sulphonylureas, nateglinide)</em></p><p>Meloxicam is eliminated almost entirely by hepatic metabolism, of which approximately two thirds are mediated by cytochrome (CYP) P450 enzymes (CYP 2C9 major pathway and CYP 3A4 minor pathway) and one-third by other pathways, such as peroxidase oxidation. The potential for a pharmacokinetic interaction should be taken into account when meloxicam and drugs known to inhibit, or to be metabolised by, CYP 2C9 and/or CYP 3A4 are administered concurrently. Interactions via CYP 2C9 can be expected in combination with medicinal products such as oral antidiabetics (sulphonylureas, nateglinide), which may lead to increased plasma levels of these drugs and meloxicam. Patients concomitantly using meloxicam with sulphonylureas or nateglinide should be carefully monitored for hypoglycemia.In general, the concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance.</p><p>&nbsp;</p><p>No clinically relevant pharmacokinetic drug-drug interactions were detected with respect to the concomitant administration of antacids, cimetidine and digoxin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p>&nbsp;</p><p>From the 20<sup>th</sup> week of pregnancy onward, meloxicam use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, meloxicam should not be given unless clearly necessary. If meloxicam is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to meloxicam for several days from gestational week 20 onward. Meloxicam should be discontinued if oligohydramnios or ductus arteriosus constriction are found.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose</p><p>*&nbsp; the foetus to:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal dysfunction (see above);</p><p>&nbsp;</p><p>*&nbsp; the mother and the neonate, at the end of pregnancy, to:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhibition of uterine contractions resulting in delayed or prolonged labour.</p><p>&nbsp;</p><p>Consequently, meloxicam is contraindicated during the third trimester of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>While no specific experience exists for meloxicam in humans, NSAIDs are known to pass into mother&rsquo;s milk. Meloxicam has been found in the milk of nursing animals. Administration therefore is not recommended in women who are breastfeeding.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>&nbsp;</p><p>The use of meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific studies on the effect on the ability to drive and use machineries have been performed. However, on the basis of the pharmacodynamic profile and reported adverse drug reactions, meloxicam is likely to&nbsp; have no or negligible influence on these abilities. However, when visual disturbances including blurred vision, dizziness, drowsiness, vertigo or other central nervous system disturbances occur, it is advisable to refrain from driving and operating machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>a) General Description</u></em></strong></p><p>&nbsp;</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4)<em>.</em></p><p>&nbsp;</p><p>Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.</p><p>&nbsp;</p><p>The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&rsquo;s disease (see section 4.4 - Special warnings and precautions for use) have been reported following administration. Less frequently, gastritis has been observed.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (see section 4.4).</p><p>&nbsp;</p><p>The frequencies of adverse drug reactions given below are based on corresponding occurrences of reported adverse events in 27 clinical trials with a treatment duration of at least 14 days. The information is based on clinical trials involving 15197 patients who have been treated with daily oral doses of 7.5 or 15 mg meloxicam tablets or capsules over a period of up to one year.</p><p>Adverse drug reactions that have come to light as a result of reports received in relation to administration of the marketed product are included.</p><p>Adverse reactions have been ranked under headings of frequency using the following convention:</p><p>Very common (<u>&gt;</u>1/10); common (<u>&gt;</u>1/100 to &lt;1/10); uncommon (<u>&gt;</u>1/1,000 to &lt;1/100); rare (<u>&gt;</u>1/10,000 to &lt;1/1.000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p><em><u>b) Table of adverse reactions</u></em><em> </em></p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders</u></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood &nbsp;&nbsp; count &nbsp;&nbsp; abnormal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; differential white &nbsp;&nbsp; cell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; count),&nbsp; leukopenia, thrombocytopenia</p><p>&nbsp;</p><p>Very rare cases of agranulocytosis have been reported (see section c).</p><p>&nbsp;</p><p><u>Immune system disorders</u></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions other than anaphylactic or anaphylactoid reactions</p><p>Not known: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reaction, anaphylactoid reaction</p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mood altered, nightmares</p><p>Not known: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusional state, disorientation</p><p>&nbsp;</p><p><u>Nervous system disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Dizziness, somnolence</p><p>&nbsp;</p><p><u>Eye disorders</u></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual disturbance including vision blurred; conjunctivitis</p><p>&nbsp;</p><p><u>Ear and labyrinth disorders</u></p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinnitus</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations</p><p>&nbsp;</p><p>Cardiac failure has been reported in association with NSAID treatment.</p><p>&nbsp;</p><p><u>Vascular disorders</u></p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Blood pressure increased (see section 4.4), flushing</p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p>Rare:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma in individuals allergic to aspirin or other NSAIDs</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p>Very common: Gastrointestinal disorders such as dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea</p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Occult or macroscopic gastrointestinal haemorrhage, stomatitis, gastritis, eructation</p><p>Rare: &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colitis, gastroduodenal ulcer, oesophagitis</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal perforation</p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p>&nbsp;</p><p>Gastrointestinal haemorrhage, ulceration or perforation may sometimes be severe and potentially fatal, especially in elderly (see section 4.4).</p><p>&nbsp;</p><p><u>Hepatobiliary disorders</u></p><p>Uncommon: &nbsp;&nbsp; Liver function disorder (e.g. raised transaminases or bilirubin)</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Angio-oedema, pruritus, rash</p><p>Rare:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dermatitis bullous, erythema multiforme</p><p>Not known: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Photosensitivity reaction,<u> fixed drug eruption (see Section 4.4)</u></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal and urinary disorders</u></p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Sodium and water retention, hyperkalaemia (see section 4.4.Special warnings and precautions for use and section 4.5.), renal function test abnormal (increased serum creatinine and/or serum urea)</p><p>Very rare: &nbsp;&nbsp; Acute renal failure in particular in patients with risk factors (see section 4.4.)</p><p><u>Reproductive system and breast disorders</u></p><p>Not known: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infertility female, ovulation delayed</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u></p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp; Oedema including oedema of the lower limbs</p><p>&nbsp;</p><p><em><u>c) Information Characterising Individual Serious and/or Frequently Occurring Adverse Reactions</u></em></p><p>&nbsp;</p><p>Very rare cases of agranulocytosis have been reported in patients treated with meloxicam and other potentially myelotoxic drugs (see section 4.5).</p><p>&nbsp;</p><p><em><u>d) Adverse reactions which have not been observed yet in relation to the product, but which are</u></em><em> <u>generally accepted as being attributable to other compounds in the class</u></em></p><p>&nbsp;</p><p>Organic renal injury probably resulting in acute renal failure: very rare cases of interstitial nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been reported (see section 4.4)<em>.</em></p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs and may occur following an overdose.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>Patients should be managed with symptomatic and supportive care following an NSAID overdose. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-Inflammatory and antirheumatic products, nonsteroids; Oxicams ATC code: M01AC06</p><p>&nbsp;</p><p>Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti- inflammatory, analgesic and antipyretic properties.</p><p>&nbsp;</p><p>The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation. As with other NSAIDs, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAIDs (including Meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute bioavailability of about 90% following oral administration (capsule). Tablets, oral suspension and capsules were shown to be bioequivalent.</p><p>Following single dose administration of meloxicam, median maximum plasma concentrations are achieved within 2 hours for the suspension and within 5-6 hours with solid oral dosage forms (capsules and tablets). With multiple dosing, steady state conditions were reached within 3 to 5 days. Once daily dosing leads to mean drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4 - 1.0 &micro;g/mL for 7.5 mg doses and 0.8 - 2.0 &micro;g/mL for 15 mg doses, respectively (C<sub>min</sub> and C<sub>max</sub> at steady state, correspondingly). Mean maximum plasma concentrations of meloxicam at steady state are achieved within five to six hours for the tablet, capsule and the oral suspension, respectively. Continuous treatment for longer periods of more than one year results in similar drug concentrations to those seen once steady state is first achieved. Extent of absorption for meloxicam following oral administration is not altered by concomitant food intake or the use of inorganic antacids.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%). Meloxicam penetrates into synovial fluid to give concentrations approximately half of those in plasma.</p><p>Volume of distribution is low, i.e. approx. 11 L after i.m. or i.v. administration, and shows interindividual variation in the order of 7 - 20%. The volume of distribution following administration of multiple oral doses of meloxicam (7.5 to 15 mg) is about 16 L with coefficients of variation ranging from 11 to 32%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Meloxicam undergoes extensive hepatic biotransformation. Four different metabolites of meloxicam were identified in urine, which are all pharmacodynamically inactive. The major metabolite, 5&#39;carboxymeloxicam (60% of dose), is formed by oxidation of an intermediate metabolite 5&#39;- hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP 3A4 isoenzyme. The patient&#39;s peroxidase activity is probably responsible for the other two metabolites, which account for 16% and 4% of the administered dose respectively.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Meloxicam is excreted predominantly in the form of metabolites and occurs to equal extents in urine and faeces. Less than 5% of the daily dose is excreted unchanged in faeces, while only traces of the parent compound are excreted in urine.</p><p>The mean elimination half-life varies between 13 and 25 hours after oral, i.m. and i.v. administration. Total plasma clearance amounts about 7 &ndash; 12 mL/min following single doses orally, intravenously or rectally administered.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>Meloxicam demonstrates linear pharmacokinetics in the therapeutic dose range of 7.5 mg 15 mg following per oral or intramuscular administration.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Patients with hepatic/renal insufficiency</em></p><p>Neither hepatic, nor mild to moderate renal insufficiency has a substantial effect on meloxicam pharmacokinetics. Subjects with moderate renal impairment had significant higher total drug clearance. A reduced protein binding is observed in patients with terminal renal failure. In terminal renal failure, the increase in the volume of distribution may result in higher free meloxicam concentrations (see sections 4.2 and 4.3).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Elderly male subjects exhibited similar mean pharmacokinetic parameters compared to those of young male subjects. Elderly female patients showed higher AUC-values and longer elimination half-lives compared to those of young subjects of both genders. Mean plasma clearance at steady state in elderly subjects was slightly lower than that reported for younger subjects (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of meloxicam has been found in preclinical studies to be identical to that of NSAIDs: gastrointestinal ulcers and erosions, renal papillary necrosis at high doses during chronic administration in two animal species.</p><p>&nbsp;</p><p>Oral reproductive studies in the rat have shown a decrease of ovulations and inhibition of implantations and embryotoxic effects (increase of resorptions) at maternotoxic dose levels at 1mg/kg and higher. Studies of toxicity on reproduction in rats and rabbits did not reveal teratogenicity up to oral doses of 4 mg/kg in rats and 80 mg/kg in rabbits.</p><p>&nbsp;</p><p>The affected dose levels exceeded the clinical dose (7.5-15 mg) by a factor of 10 to 5-fold on a mg/kg dose basis (75 kg person). Fetotoxic effects at the end of gestation, shared by all prostaglandin synthesis inhibitors, have been described. Nonclinical studies indicate that meloxicam can be found in the milk of nursing animals. No evidence has been found of any mutagenic effect, either in vitro or in vivo. No carcinogenic risk has been found in the rat and mouse at doses far higher than those used clinically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate Lactose monohydrate</p><p>Microcrystalline cellulose Povidone K25</p><p>Anhydrous colloidal silica Crospovidone&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package, in order to protect from moisture. Do not store above 30&ordm;C.<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium blister, boxes of 1, 2, 7, 10, 14, 15, 20, 28, 30, 50, 60, 100, 140, 280, 300, 500,</p><p>1,000 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder: 
Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein Germany 
 
Manufacturer: 
Boehringer Ingelheim Pharma GmbH & Co. KG 
Binger Straße 173 
D-55216 Ingelheim am Rhein 
Germany 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/jpeg; base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4SjARXhpZgAATU0AKgAAAAgABgALAAIAAAAmAAAIYgESAAMAAAABAAEAAAExAAIAAAAmAAAIiAEyAAIAAAAUAAAIrodpAAQAAAABAAAIwuocAAcAAAgMAAAAVgAAEUYc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFdpbmRvd3MgUGhvdG8gRWRpdG9yIDEwLjAuMTAwMTEuMTYzODQAV2luZG93cyBQaG90byBFZGl0b3IgMTAuMC4xMDAxMS4xNjM4NAAyMDIyOjA5OjE0IDEyOjU2OjM4AAAGkAMAAgAAABQAABEckAQAAgAAABQAABEwkpEAAgAAAAMwMAAAkpIAAgAAAAMwMAAAoAEAAwAAAAEAAQAA6hwABwAACAwAAAkQAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMjowOTowNyAxMTozMzowMAAyMDIyOjA5OjA3IDExOjMzOjAwAAAAAAYBAwADAAAAAQAGAAABGgAFAAAAAQAAEZQBGwAFAAAAAQAAEZwBKAADAAAAAQACAAACAQAEAAAAAQAAEaQCAgAEAAAAAQAAFxQAAAAAAAAAYAAAAAEAAABgAAAAAf/Y/9sAQwAIBgYHBgUIBwcHCQkICgwUDQwLCwwZEhMPFB0aHx4dGhwcICQuJyAiLCMcHCg3KSwwMTQ0NB8nOT04MjwuMzQy/9sAQwEJCQkMCwwYDQ0YMiEcITIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIy/8AAEQgBAAC6AwEhAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5&#x2B;v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5&#x2B;jp6vLz9PX29/j5&#x2B;v/aAAwDAQACEQMRAD8A6alxUALiigAooAKKADFGKAEIpKACkxQAYpaACigBaWgBKWgAooAKKAFooAKKADFFMAxRSASigBKTFMBcE9jS&#x2B;W56I35UAPEEx6ROf&#x2B;A0nlSDqjD8KQDcUUAFFABRQAtFAC8UcUAOHlkf6wBvRhgUwmRTxHA49pDTGILhV&#x2B;/aE/7sv/1qmF3YhS0kDoFBJJk4FMTKKeK/DHnBZrlY48Z8wPuH0wOafJ4y8GRji9Mh9Fib/CqSIdRIifx14QQZBmf/AHUpLXx94auruK1gsrkySNtVmUY/nQ0kriU7uxpf8JTpyj5LPP8AvD/69Rv4sg/gs4/xWvOeYQWx6Cwchn/CXHtaqPoB/hSv4snCKUQru&#x2B;nH6VDzC60RSweurK7&#x2B;Kr1wQSeeOtZo1OVCdhbn&#x2B;85IrJ4&#x2B;b2RosHFbmhYXD3UBeQAENt478CrVejSk5QUmcFSKjJpBRWhAUUAFLQAYoxQBVnbZubaTgZwOpqn/AGhFuQGOX5lLcJnAHqBzVANm1WytrNLu5lMELttBlQqc&#x2B;4IyOlNe9tL/AEy5ktLmGdBGwJjcNg46HHSgT2PHE6CphWhxscK0/D//ACHrL/rqKmfwsun8SO2B4pa&#x2B;We59SKDUr/6qL6H&#x2B;dUtmS90MpKlDZt6SP9DPu5P8qvV7&#x2B;H/hRPGr/wARhRWxkFFABRQAtFAFS6ClZN4yu05FYAWKUQOqsVa3kK5JOPc7flxVgQXMzL4ThZLzycMFLRgncOflyASPqPSnaHPZXGjXos7SS3ZQfN8wli7Eddx5NAnseYryBUgqzkHVqeHv&#x2B;Q/Z/wDXQVM/hZVP40dsOlFfLdT6kWpn/wBXF/un&#x2B;Zq18LJe5HRUobNfQpjNp5YxSRYkIw4wT71p19BRVqaR4tZ3mworQzCigBKWgApaAK1wPvfSuft/kW3OSw8mQdP/ANVWA1/NHhyH5pwiviUwZ37OemefSka41ZfD8LWtr9pLeYrG5bY4TcQhPuVxQJnlsO4qCQBxxUwFWcjHYrU8PD/ifWf/AF0FTP4WVT&#x2B;NHa4pcV8sfUrYAOalk&#x2B;5F/un&#x2B;Zq1syXuhlGKSGbmlf8ef/AjV2veofw0eNW/iMKK1MgooASloAWigCvMMsfpWQsTW91aIxHzFhg4Y&#x2B;vUmrAXXoTNpuAu5VkVmRZPLLAdQG7GoNCtBFp00peXdMWPlST&#x2B;YUUFtoznrjr9KAZ5REP3SH2qYVZxDsVqeHx/xPbP/AK6ClP4WXT&#x2B;NHa0V8qfU9BRUzqzJBtUn5D0H&#x2B;01axi2tDOTSauKtpcN0gk/FcVMul3bf8swv1YVrDC1JdCJYiEepo6Zs&#x2B;xKY5opV3H5423Dr61cr2KcXGCTPKqSUpNoKKsgKSgBKWgBaKAIZfv8A4VC0cbyqWALryvPIqwKOtwmfTGiEcT73RT5sfmKmWA3be&#x2B;Ki0SzihspAlvCkyl4GeFCiyBWbkA9OSfxzQBwVr4N16VFAsCuByXkVf5mtKD4f6zJ99rWIf7chP8gaq5zeybL0Pw5uD/rtSiT/AHIi38yK1dN8C21hdx3LXs0rxnIAUKP60pO6saQp2dzbXRrVepkb6t/hUq6ZZr0hB&#x2B;pJrjhg6aO6WJmydLaBPuwxj6KKkAAGABxXTGnGOyMXOT3FoqiCCOGK3jEUMaRxjoqKAB&#x2B;Ap1SwCikAUUANooAWigCKUZP1FZp8557HhQwL7iRngdqsDQOACScAdTWSNJTUNOjhk1K5OyQsJbabYfoT6c0AaGk6RDpSyeXcXUxkIJa4l3nj0rToAWkoAMUYpgFLQAUUARN940lQwEpaQBSUAMpc0ALmjNAEb8ms7aFlhV5W&#x2B;V22lQfyPtVgXpF3xOu0HKkYboaraXDJDAySwCJgx5BHzDPHT0GB&#x2B;FAzULrHGXY4VRkn2qlHrVlPpUmpQyGS3QEkgcnFAiWw1KG/02O&#x2B;H7uJxn5yBj61U1TWE06808PJGtrOX8yQnIAC5GPxpgMl1OCbUdPeC/8A3EiO2xVyJAB3PbFM/wCEmiNvNMtrOqoAY2deJATjI/KgDZt5fPto5sbd6hsemaloAMUmKAIX&#x2B;&#x2B;aTNQwEozSAXNJmgCPNGaAFzS0wGtzUflqWVucqeOaoDN8QXHk2MaKzh5JowoXq3zrkenf1rQsZLiW1RrqIxTchlIHY9eCf50DJdRbZpVy3pE38q4jTWaHR30gH5rmSFkH&#x2B;w3J/9BpoRa0pY7xdF0&#x2B;4&#x2B;a1ImcxnpIysQAfXA5xUVpNb21xYG6kQWMOpXSQtIcqIwBt/XNAD7e0kuRCYFIjuJ7p4SBwFIwPoDit7RmnvLJLS8054IIIlRjMuCzj&#x2B;77e9MDcQxr&#x2B;6QqNgAKg/dHapKQBSUAV5P9YaZmoAWikAUUARZozQAuaXNNAFJVAZHiI2ws4xeStFbmRSZMFlDBgQGXvkj&#x2B;dbKEMilSCCMgjpQMdeW7XenzW6sFaRCoJ6DNZlv4cjivNPunnzJaQ&#x2B;WVC8Oex/CgTJf&#x2B;Ea01tOispY3ljidnRmchwWOTyuKvJptjHbxQLZw&#x2B;VCpWNWQHaD1xn17&#x2B;tMCyFVVCqoCgYAA6Vm6vN5P2PdnyjcDzPoFY4/T9KAIdLlup9RMt3CIZmtl3oPTzH2HqecZ7027uJJtYtgkji1iZWLxtwXJZdp9jxQBbXV4pFkMa/cheQ5PTa2MEVk6d4mk1K&#x2B;sIY48q6n7QyRnaHxkAMfTH60Abkv&#x2B;tamVAwzS5pCDNGaAK&#x2B;aXPvQA7dS5poBw5paoCrqVnJfafLbxOqSMVKswyAVYN/Sri5AGeT3oGWV&#x2B;6KWgQZpaACoZ7aO6QJKMgMGH1FAD1iRHZ1UBmABPrjpXOXXhUNDO7319cIMtHbCXYuc5AougtcbaaR/ZcM/2WSztZpEVSxzJuHfPNadteWen2kdvBuYIuDhcZPrXPUxVOGhvDDzkS&#x2B;b5wEuMbucUua0TurmTVnYM0ZpkhmjNAFbzF9RR5i&#x2B;opjF8xfWl81fWgCaFgwOKlxVCK2oMyWEzISrADBH1FZuh6o17dtCZS4WPeQw5ByBzXHOc1XSWx1QjF0m3udIv3RS12HMFNeWOP78ir9TUynGO41FvYqyapap/wAtCx/2RVZ9aH/LOEn/AHjXFVx0Y6R1OmnhJPVlaTVrp/usqD2FZlzqqhgkt3gtkBi3AI7E&#x2B;tcTrVKzsdcaUKauV47v7XbOYGJdMAsBwxI7VI0Mks1uwYqsLEt/tcVnpF6l7rQ3YpCIUHoop/mt7V7lNe6jyZ/ExPNajzWq7Eh5retHmN60WEUtwpd1MYu6nBqALlkch/wq3igRV1If8S6b6D&#x2B;Yrn/C7OdRlElv5ZWAKGIILYxnr1wc1w1f46Oun/BZt3GuJAJAsEjlMggdSR6Csk&#x2B;K55re5lS3aHyVyRIuCTjPqaiWLcr8pccOl8RUi127ubCa6muI5BGpbZAx4wM4PvVP&#x2B;1boz7XgjVRIIyC5J&#x2B;Zdw9vrXM4ubfMzdNQSsiXSJ57lJJppCytt2ggDHHPHpWlXNVilNpG1NtxuxR1qGDw6JHWX7GWc/M5ccMT3yf6VpRjN6RIqygviNiLRZcDe6IPRRmrkekW6ffLOfc4rupYG2szkniukSpNiOaRFGFViAPSo99eglZWOO9xN1G6mAbqN1AinvpfMoGL5lOElAGjprbhJ&#x2B;H9av0CKuo/8eE30H8653wpM8t1cBpC4UEDLBsdO4A/XmuGsl7ZHXSf7pkk/FxN/vt/OsyBLkRP/AKOrNMzM3mcAegIrzItXdzvs7Kw&#x2B;HT5JI7rztokuhtIiyQo27eKvJ4fkm3MIXyzBgznABC7QfyraCnKXuoyk4xWpa0vwobJWLzRBmAB8uPaOPb1962I9JtU5YM5/2j/hXdHCJy5pnK8S0uWJcjhih/1cap/ujFPrrjCMVZHNKTluLRVEnO3UgF5OM/8ALRv51D5w9aAE84eo/Ojzh6/rQAecP7w/Ojzl9f1oAqbZKXbJ7VIxdkv94UeVL/eH5UwNbR0dRLuIPTHFalMRT1RPM0u5TONyEZ9KxPDFtJa3DpJL5gKZU5z6ZrhrSXtoo66S/dNmt/Y6vK7ySnDMSAo96tR6XaR/wFj/ALRop4KEXeQp4qTVkWkSOMfIqrjrgYpVkRjhXUnGcA9q7VFJWRzOTe46imIWigBpdVK5ONxwPekWZHbbnDZIwe&#x2B;KYHMXmkLLfXEm6T5pGPDn1qH&#x2B;w09X/wC&#x2B;zSAX&#x2B;w4/9v8A76NOGiJ6N/30aAHjRI/Rvzpf7Fj9D&#x2B;dAFoWDe9OGnt70AOGnn0qQaeaQFq3t/I3e9TUwK1//AMeE3&#x2B;7WB4WLmaXeCMSSgc543dvbt&#x2B;FcVZfvonXS/hM6W6nNtZTTqu9o0LBc9a5671&#x2B;aQxwjZbkhHaRTu2&#x2B;oP512nIRpHq97KNyyxxzHMhXgZKrnPtjNaui6bPYu0kgWNXhjUxht3zKoGc/h0pgbFLSAKo33nzN5EEZPy5Z9&#x2B;AM8Afz/ACoAjjtb2fy5LidUZDlUROPxNT2mnQ2rGQZeQ/xucketMRbNqGYtjqc0fZB6UguL9kHpSi0HpTAX7IPSl&#x2B;yD0oAcLUelO&#x2B;yj0oAcLYelO&#x2B;zD0oAgu4vLRT6mqlICvf8A/HjL9KwvD8UUWoyqjoznczYxkAnOD&#x2B;Oa4az/AH8TspfwpHTOiSRsjqCrDBB7iq8NvYWaHyY4YwowxUDP413nINfVLZeEbzCGCkL2JyByeOoxUMOpXF3dbbeFfISUI78tkc5weAOnv1oA1KKQC0mBnOBk0CFopgaccW6NT6gU/wAmgQvk&#x2B;1L5NAB5PtS&#x2B;SKAHeVS&#x2B;UKADysU4RCgChqiBYEP&#x2B;1/SsqkMgvebKYf7NYWhyRnVJEU/vFHz8Yznp/wDrrgrX9vE7KX8GR0NzEZ7aSIHBdSuazotCjzmeUyZXBUdP84rvOQvx2NtGG/dBy3Uv8xP51ZyaACigQuaM0wCl7UAb8EY8iP8A3RUnligQbKXZQAbBRsFAC7RRtFAC4pcUAZutDFtH/v8A9DWJSGiC8/48pv8AcNY&#x2B;k/8AIQX3U1wV/wCPA7aP8GR0NFd5xBS0DCjNAgzS0wDNLQB0cH/HvH/uipKBDc0ZoAXNLmgBuaM0ALupc0AZutHNrH/v/wBDWLSGiG7/AOPOb/cP8qxdKP8AxMI/of5GvPxH8eB20f4Mjoc0Zr0DiClzQAUUAFLTAKXNAHRRNiGMf7IpcmgQUUAKKWgApaACloAztZ/49U/3/wClYtIaIbr/AI9Jv&#x2B;ubfyrE0v8A5CMf0b&#x2B;Rrz8R/HgdtD&#x2B;DI6DNGa9A4gzS5pgGaKADNGaAIJrxIljIIO9toNTI8hYhowBkjIP5fnQB00f&#x2B;qT/dFOoEHNGKAHgUYoAKKAFx7UuKAM7WP&#x2B;PRf9&#x2B;sOhjRFc/8es3/AFzb&#x2B;VYel/8AIRi/H&#x2B;RrzsT/ABoHbQ/hSOgNNzXonEG6jdQAuaM0ALuqtctNIfIgYxuwyZCmQo5/WgBYbNUMe8&#x2B;Z5a4Ut1J7k1cHSgDpI/8AVr9BTqBCgU7FABRQAlLQAtLzQBn6x/x5f8CFYNA0RXP/AB6zf7jfyrD0w/8AExi/H&#x2B;Rrz8T/ABoHZQ/hSN5jzTc16BxjS3HJx9ajjuYZJGjSRWdeSAelMCTNG40ALupQ1IB4ang8UAdOn&#x2B;rX6U8LmgQ7FGDQAuKTFAgoxQAtLQBQ1gf6Af8AeFc9mkUiK4/49pv9xv5VhaZ/yEYvx/ka4MT/ABoHZQ/hSN6Q/NWU2oSySSRwouVUHHUjnnP4Zr0DjIBZ3l2We5laIOrDaDzz04HGQO9XrazhtcFNxYLtyT24/wAKYE0k8UUbPJIqqvUk9Kjt7uO5LiLJCYyxHBz6UATZo3UgFD4pwuFDBCw3N0GeTQB2EDq8S8jOB0NT0CCigQmaTNADcinZoAXilyKAKGsf8g9v94fzrnKRSI7g/wCjS/7h/lWFpn/IQi/H&#x2B;RrgxP8AFgdlD&#x2B;HI3ZT81VZJ7a0UK7xQjsvAr0DjILvUEto4ZFXzUkcLlTwAT1qkL27vWheGJooVkBYk/eXBB56Y6e9AENxZwjy5bq6LOdp&#x2B;X5ycDnk8kHmteyaF7VJII9iOMgEYP40AT5qA3CmQxxBppf7kYyfx7D8aALMWnXc3Nw4t0/uR/M5&#x2B;rdB&#x2B;FaEFpBajEUYBPVjksfqaBFlZGQ5UkfSrMd/IvDHNAFtL1WHNTCdTQA7ePWl3CgQ3PvSbqADzKXf70AUdWbNg/Pcfzrns0ikRzH9zJ/un&#x2B;VYemn/iYQ/U/wAq4MT/ABYHZQ/hyNydtu5sZwM1gXFwLe/tGduZBvd9xH8q9A4ySS5hhjjkESyoZmMeD0Oev5mmxS3eqZwoihSTGGXH3SOP59KYE9vpVtaRKZW8zbzuc8CrcUjzkJZW5kA742oPxoAvRaM8nzXs5Yf88ovlX8T1NaUUEFtH5cMSRqOyjFIQrGmE0AGabmgBQ5B4qZLgjvQBZS6qX7T70AT76QtQIbupN5oGQ3O2WBkfO3rx1rkpdSgiuGjkDIAcBmHBpMaJzIkkDFGDAqcEGsPTz/xMIvrXBif4sDsw/wDDkbs43ZX1GK546HNLeGSe4BjGNuOuB2r0DjNRja2kUavsVUGEB5P4VJCl7d/8e1v5UZ/5aSjH5CgDQt9DgVhJcu1xIP7/AN0fQVqLsRdqqFA9BQIQvUZNADc03NABmkzQAZozQA5WIp/mH1oA1Nx96TNABk/5NGTQAlZ99pkF2p3oMnvQM5q50Ge0YvaSsv8As561jwNPZX8ZuYiqq3LAdK5a9Pmkn2OijUtFo3Jr2HK7GMrMPlSMbiadHY6jd8vi0jPuGc/0FdRzmhaaVaWh3hDJIeskhyTV/dgf/XoEJvppb/OaBDS1JmgYmabmkAZPtSE0wDNLQAop3NAGrRQAUtABj/OKNue36UAMa1L9h&#x2B;VQNpEMn&#x2B;tUMPTFK1x3sImmW9uD5ESx564XrTGiZf8A9VMkjOe/8qaT70AJmjNADTnNIaBif56U386QC8&#x2B;9HPvTAADTwp96AHhPrT9n1oA0cUYJoAcENPERPrQBIIvrUyxigB2KYwoEQsv1qB09jQBA8Oexqs8JHrQBEUYdjTcH3oATmkxQMTFGKQC7aXb7UwHBPapAntQBKqVJsFAH/9n/4THkaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLwA8P3hwYWNrZXQgYmVnaW49J&#x2B;&#x2B;7vycgaWQ9J1c1TTBNcENlaGlIenJlU3pOVGN6a2M5ZCc/Pg0KPHg6eG1wbWV0YSB4bWxuczp4PSJhZG9iZTpuczptZXRhLyI&#x2B;PHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI&#x2B;PHhtcDpDcmVhdG9yVG9vbD5XaW5kb3dzIFBob3RvIEVkaXRvciAxMC4wLjEwMDExLjE2Mzg0PC94bXA6Q3JlYXRvclRvb2w&#x2B;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&#x2B;Tl5ufo6erx8vP09fb3&#x2B;Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3&#x2B;Pn6/9oADAMBAAIRAxEAPwD2WlxRtNPVTiucBm009VOKNppelACbTRtNOowaAG7TS9KXaaNpoAKKNpo2mgAwaNppQvvS7fegBu00bTTtvvRt96AE20m007b70bfegCNutG0mpNopCp7UAM2mjaadtNFADdpprA9KkpNpNAEW33o2&#x2B;9OZTnpSbT6UAJt96aVNP2mk2&#x2B;&#x2B;KAG7TSFTT9vvTSpoAbtNG0&#x2B;lOpQPegBApo2mnbfejb70AN2mlC&#x2B;9Lt96Np9aADb70Uu00bTQAYo2mnCigBu009VOKSnL0oATaaTpT6TaTQA2il2mjaaADaTRtNOCmigBu00bTTqKAGU5elJtNOCmgAoo2mjaaADBpQvvQF96Xb70AG33o2&#x2B;9FFABt96NvvRRQAbfejb70UUAJx60Y96dtpdp9M0ANopdp9KMVQBimnGeaevSg47kfnUgMx70hU0/cP7y/mKTGec5&#x2B;lADdpo2mnbfejafc0AN2mkKmnEDucfjSfQE/hQA3aaaynNPZgvUj3GeaNpznBoAj2mk2n1qTaf7rfkaY/wAp5GPrQAm0UUvv29aTcv8AeX86ADHvRRuUY5U/Q0Zycd6ACnqpK03BPRWP0UmnrFKygiOT/vg/yoANppOlSLa3LZItp2HtEx/pT/sN6Otlc/jAw/pQBBS7SamFjdswH2S4yf8Api3&#x2B;FMeN4WKSRtGw5KspBH4UAM2mnBTRyeRShfegBNpop233ppU0AFFG00bTQAoHvSFTShfel2&#x2B;9ADdpo2mnbfejb70ANwaUL70Bfel2&#x2B;9ABt96NvvRt96KAF2n60bTSg0ZFACbTRtNLkUZFACEbVLN8q4zubgfn3pYY3upNsUbzP/djQsf0FS291DYzJcS24udhyF3bQfqcf1rQ/tTStY3K91rOmhunk3rgD2HNXygV10HVGb5dLvv/AAFk/wAKevhrV26aXen/ALd3/wAKoXHgexunJi8X65huiy6lKP5NWVN8Or63O608Sam4z94avID/AOPGps&#x2B;xVkdK3hnWE5bTLpB/tRMP51H/AGDqbNgWcn4sq/zNc3/YPiLTn3R&#x2B;ItayP&#x2B;nsTD9TzU66l4xt1BTxJekeksMZP/oJ/nVfILI6RfC&#x2B;rFRiy/8AIqf409fCesnlbHaD/F5qf/FVz1v408aWrc61DPj&#x2B;G4tkP8lH861Lf4leJmaNLj7C&#x2B;44LRwbR&#x2B;RY1Vokmj/whmr8H7L1/i6/yNPk8G6jCpaVo4jgn5wy9PQEc9axfEnxstvCupR2N/wCJdDsL2SFZxFffZYzsYsoOZZlPVWHSuVuv2pmsfEVnAvizwlP4fKA3VxDqdnHPC&#x2B;4/dUSsDwB0zV8iI9pBaNnotv4OvLpisd7ZkA4&#x2B;WQn&#x2B;Qqf/AIV5fZ&#x2B;a4jPcbY5G/wDZayrj9ub4TwkRv4qtZp1QO7RRTSKx6E7o4iOvpWVcf8FBPhJFJsXVpJhn5vJsbzj8TCM/hV&#x2B;yRk8RC&#x2B;51y/Du7kxtuGAIzxbSf/E09fhndkjdPI3t9nI/nivLYf8Ago54HkmvA2makfLmAglW23&#x2B;am0c4ZkI9OfSoZP8AgpH4Qi3CLRNbY9sWEIH63Z/lT9miPrEO567H8MbxiAPPYdlRVU/qatJ8I7puXjuV9nK5/Q189Xv/AAUo05lYW/h3V3H8PmLbx/8As7Vz11/wUo1naVtfC90Iv4Q&#x2B;oxJ&#x2B;gtyB&#x2B;dHs0L6zHufVy/CU/KjB37lWudn9KuW/wfRsb9PVh6m8LH9BXz/8Of2t9Z&#x2B;JPg7WtbuLO90&#x2B;TTruO2FtHqQ2uGUHOViHr6VpS/Ha&#x2B;m3FoLxye0mpOR&#x2B;i14uKzPC4Op7Oo9fQ9nDYKvi6ftKa09T3&#x2B;P4P2GwGSyijPcvLIR/Kh/hbo1spLxWZ9dsjDH/fQFfN83xjvJGJOnIx/wCml1I365qrN8WL2bONL04Z/wCehmc/mJB/KuCXEWB6X&#x2B;47o5Liutj6Q/4QXwnbsTPLao3fMisf0cU7&#x2B;xfAdv8AfurXj/a/pk/zr5fb4jaow&#x2B;W306H2jikP/oUh/lTV&#x2B;ImtqvE1sv8A26of5rWD4lwn8rNv7DxHdH1A/wDwglv/AKt43x3TBH5bSf1pV8ReELNS0cbSKASAEI6f8Bx3r5jX4leIVX5bu3A/2bKD&#x2B;qZrT0P4g6/dLrHmXqkppk8ibbeFCrjbhgVT&#x2B;tVT4iw85WjFi/sWrBXckfRn/CfeF7R8f2K0&#x2B;Oxk2/0pknxQ0bra&#x2B;GI0HbdMSf5V8tN448RzqpfXtRPHa5dR&#x2B;hH8qqN4h1mRj5ms6kwPb7bL/wDFf1rgfE8P&#x2B;fZ0rIZ2&#x2B;NH1b/wtgwrui8PxxqerxqWJHp0rx/U/F/xSGsXbWNhJd6W8jGGSOSRJCvXBATbxnHB7V5bJqV25Ja8upGPUtO5P5ljVaW6mbJMshP8AtSHP&#x2B;cVi&#x2B;Jm9qf4m0chtvM9hsvGmtNbyf29pniWNgMyCxkW58o9tyDLLkYPzAZzkcYqOHXLPWSxkvrq3dFbYurW32YvjJ4Y8ZxnrXjcjNIx3NlCefU/ljP41XmjLKSDvPOA67uQPcgDr2op8QVKk1Hk3FUyWEIt82x7njk8ng45bd0460bfenzLtldeoBIH07Uyvtk&#x2B;ZXPk5LlbQbfejb70uKNppkibfejb70tJQAUUuKNpoASjHvS7TRQAm33oopcUAGKNppwooAbtNG006l2k0AM2mjaaftNJ0oAr3efIPpWWT0Hbgfn/&#x2B;qtW8UtCaylzuGOqkYOPU4x/OtVsAzBZd3T13Zo55XcQRz1rkrP4iSXGqJYt4V14br5rBL1bHdafLIyb/ADQePlUHnBH40zxB8T7Twr4pstD1TRdVt3vbjyLK5AglS4UsFDIiSmQLnGSVAByM8UwOyWSYAlXfbznax4xg/wBaGnm3HMj59GY5rhdS&#x2B;MvhnS/F1t4alOoy3s16mn&#x2B;dDp0zW4lcAqPM27SRuAOGOMc4xXVa5rmneFtNm1HWLyHTbGIqstxcHy40ZmAHOcYLMB170AXS7tyTz70fNtJ5J/lWLpXjzwvr0wj03xJpF/I3AS2voZG/IMTW9Ipjzu6DrzwOnX81oA&#x2B;Qf2zF3fEjQnJDN/YiKCw6EXE5zn6H0rwtI044XI7sM17v&#x2B;2Uu34h6Fng/2OBz/wBd5v8AEV4SvX8a6InhVv4jLMY7n5lJ5UcduB0qcfd5Zt3fBzVaNjxU61qchJj/AGuaeqnaOc&#x2B;9MpdxHFAD9pqRSFUA9ajVuKXIoKPov9nRgPhd4v5&#x2B;X&#x2B;04M/8Afta7rPJ571wn7Oqj/hUvixv72tQqP&#x2B;/KGu44bJr8j4k/31&#x2B;h&#x2B;vcO/wC5ocaSk4o4r5U&#x2B;lFpwI6UzbSrxQBIrADrW14db91rZ650q4H4/LWHkVteHeYNaA/i06ZfzKD/Cu7DfH8jkxHwmYrEDFGT/AJNN4PPrzSfSuJ7nUthd1Ix3Uu75cUlWhjdppyRlnRR99mCj8eB&#x2B;tFT6cvmalar2Mqfzrrw/8SPqjlrfw5fM9ouF/fvjpnio9pqV1Yu2eucUzpX7DD4Ufl0viYCiiirJEIpNpp1FAAKKXaTRtNACUhFO2mk6UANxThQKKACl2k0lOXpQAm00vSlooAKTaTS0YNAEF1xA1Y&#x2B;0Fhk7VPt1PGf0FbN0p8hqyAoLBWOATlq1iSeX/wBqX1n8RBDd6j4mj1u41COGOyhtHbRmsmdQx3rEUBMTknc&#x2B;4NG2ByAa8sXiDQ/ind3Ph3w1FdC5uo21E3d9aSPJFhMyxDeJo8YPy8g4z3rqf&#x2B;Eq8TXHi6KxtdH02TRo70Wt3crqUjXMMZt3l3tF5e1eRwC2SMEd8clfT&#x2B;HPB/xWbVr&#x2B;506zl81mnuLjSpxPLvtyscRuPL8tlzIScMeEUdqsoni1jWoPjZPowttWutKn1KO5XfpA&#x2B;xRItiQXS42Y3s74JL8FDXSfFa38LP8ADnWF8alR4WAiF8QsvaVduBGc534/OuN8U&#x2B;B9a1z4nzQRTeO7OG&#x2B;nhkXVtJ1UxaZHZrbIjiRM/fMqsc4H3q9A&#x2B;JOn6Bq3gvWrXxTM8Ph2aIC7u2mIeMK6lW3AEk7gCST1oA&#x2B;Qb7wD4d&#x2B;Il1NYfDP4Za9dqchNX1q9eG2IH8Q3E8d8Fj&#x2B;HQfS37Pvw11P4UeAv7H1a5trq7lvHvClk7MsQZIxsG76MeK8cX4oX/wAJVY&#x2B;EfiVovxE8MrtA0PXLzybuFQMZSU7QxHbJ4GB2r3n4T/FTT/jD4ZbWdOsrqzWC6&#x2B;yTwXbq2xwgclXXqMEfnQB89ftjKP8AhP8Aw7nbxpAHynI4ncn9CK8J28CveP2yv&#x2B;R38Ouf49LcDtz5rGvB423LW8TwKv8AEZJH8tTrgVCqnjNS7t3NaGBIPvUuf84pFHyjmnDpjNAxV6UtFLtJoA&#x2B;i/wBnYH/hUfif/sORf&#x2B;iErtl&#x2B;6K4v9nX/AJJH4mHf&#x2B;3Ih/wCQErtenFfkXEf&#x2B;&#x2B;v0P17h3/cohRRg0bTXyx9IKB70tIF96WrAX6Vs&#x2B;H8rb61/14MP/AB9Kx1&#x2B;9WzoZ/wBF1rPT7Cw/N0rtwvxv0f5HJX&#x2B;H5mSv3RS0gzgZ&#x2B;tLXG9zrEzS01utKoOKZItWtJU/2rZY&#x2B;Y&#x2B;fHkKMnlgB&#x2B;pFVdprkdQ&#x2B;KS&#x2B;HfiV4e8Pf2Mb1rm7tM3PnbQm&#x2B;bB4CduD1r0sFRlVqxstmjixdRU6UnI&#x2B;oJOJGBGCDimbSaVl2MVyG28ZXpRX62rpWZ&#x2B;Zy1baG7TRtNOopkjdpo2mnUUAJ0paMGigApNpNLRQAyl2k0lOBoATaaXpS0UAFGDRg0oX3oATaaUL70u33o2&#x2B;9AEVyD5DCsYqcn1FbVx/qzWQe579K1iSeMatLoOg/GiS&#x2B;u/E1jp8iX0c01m&#x2B;lzrNLK1isccf2nd5bAAl8Y4346iukt7i&#x2B;X4qmFZNanklnKJ5YZ9L/s/7ICyscNGsvmhztJWTuF2kEp4ikl0rx00zWXiWbSty6hcxWGnRXUE84h8pHBDGRVVVAOFHIP1rH8VajpGifFaTU9W8Q2Ng0Elu39kOlwouF8lgbmQgYadeFX&#x2B;EIFB5BqyjmviLoOieJvjlDBrPh/R7y2vjDbSXP8AaF5HqUshji2SRKsgUhBLtPHSPJr2XxlYaHe&#x2B;E9Wi8QqjeHBbb7tpJGbbAmGJypBYgKO9eafEr&#x2B;2bzxzZy6d490zQZY9RsrSxsrrS4pmeRxklZiAyuQZCVBPG31APY/HPSbvWPhH4zs7GN57yTTJ9kMIJZ/lDFVBJyCFI70AfPfgvWP2dvGHiWz0ZfB99o8l44is7rUZZPJuGIAAAExIyfUDrzX0z4P8Ah/oHw602bS/D2nJpdrJP508fnO4aUqU3AsSeieteB/Ff4rfDfxl8D7aw0E2r&#x2B;IpBZx6Rp0VqYri2vBKhIBZBjjfknjIPrXqf7Qlx8QrLR9Nk&#x2B;HYn/tI32LryLeGQmARtglZQcckcVW&#x2B;5J4r&#x2B;2cCPGXhf5QT9hl/HDnmvAIxxkDKjiuk&#x2B;L2q/EvUtW0qXx3HOt2kMgsvOtbeLCZAJ/dqO7D865ax&#x2B;0N5v2huS2RkYzW8TxsRFc97lzaRwetPQCjacDinovyj1qjkHDnpRtO7mlAK9aeFHXtQMTmnBTSfxHHSnde9AH0Z&#x2B;zqp/4VH4kPf&#x2B;34//AEnSuyXO0Z9K5L9nPH/CovEXf/ifx/8ApOldiq/KPpX5FxH/AL6/Q/XOH/8Ac4jQPenbT9aNtPVTivmT6YZtNG00/aaNpqhMI1H41raSv&#x2B;ha16fYwPzkQfzFZa8VraT/AMgzXn/u20Y/8jLXbhvjfo/yOSv8PzRkgHAo2ml2&#x2B;9Lt964zrE20u33o2&#x2B;9LtP1qhCbferejqg1rS2CK032uEh2RTjDjABxnqSaq7TVrR1La5pY7/a4yP&#x2B;&#x2B;1ruweleHqcmKSdKTfY9kZTuPJbnG4nOfek2mnsPmPNJt96/XFsfmD3G0UFTRtNMQUUbTRtNACge9IaUL70hU0AFFFJmgBtLtJo2k0vSgA6UtFFACge9Lt96QD3pdvvQAUUUUARz8xmsg9D9a2Jv8AVtWPjr6ZrWJJ5X4suvDugfFrTNTvda0ax1jzIkSS81UwT28ThVEYhAw4dkA5PHmE8AVtalDqzeOpHs9anMsL2P2fR4prcwtYyv5dw0sbgvuz5jBhkYYAdaveIjf3HiSCxTSLe40mR7a6vJ7q0Z1kjEoj2pIGXa67i&#x2B;ORhPWuS&#x2B;I1jaW/xZ0q8utYTT/tT2aTB/DtxcfadtznaLyM&#x2B;Wm9kRdpxjOTkAmrKOt1n4WaHrviyPxFdG8F3CLcrBHNshDQzxyhwuDh2EKxluDsPua1vF2tS&#x2B;FPC&#x2B;sa1FbC&#x2B;n0uymvBAG8vztkbZHII2kBuoraYHzHyedxB&#x2B;ueelc38RNAvPFXgHxRothIEv9Q0y4t7fLYXe0bBQx7ZYgfjQB8waL8dvhBpPiIeKLz4U3&#x2B;ja3K32hHhKSplzu3BXdVzzn5VH49T9BfCv43&#x2B;HvjI2rDQoNQt5dNkhadb6GNCTIZMbdrf7B/KvCvE37SWmap8JLj4c3HhHVI/F62K6RFZmCPyI50UIs4O7eACgbgc7s19TaXocGk2sSLaW9vetDGt1LbQKhldUxk49CWP40wPl79tQu3iDwQS/wAptrsYyezwE8Z9xXgGSrbTzjqxr6D/AG2FB1jwOyDANtqHfPe2/qRXz/t9fpXRT&#x2B;E8LEfxGPj/ADqRc7qiXip1U1RyD8etKFHajB/GnKrdxmgobxux3p6qMUvl/NmnhKoZ9Efs7g/8Kh8SY/6D8YH4W8Z/rXabT&#x2B;HauO/Z3G34Q&#x2B;I/&#x2B;xhH5/ZIv8a7PG3A9OK/IeJP99fofrvD3&#x2B;5xG7TTgpopQPevmD6UTaaNppePWge1UiRVU4rW0mNv7D8RN28iFfzmXH9azNpVcHIPvWvpKn/hG/ErYbAS15wcf64/4Gu/Dr3n6HJiPh&#x2B;4xsdx06ijaaEPygZ5AGadn5c/w&#x2B;uK4TqG7TThSMwCgk4B6EnANLHmVtqqzN/dVSTWkISlsiXOMd2FXNDX/iodJ9ftCH/x4f4GiDRdQuGAj0&#x2B;6bPRvJcL&#x2B;eMfrW9oPgzW7bW7K6lsHW3gkWR33rwPm7Zz69q9XCYWt7aEuR2v2OHFYil7KUeZXsehkfMee9G33o2/MwDZAYj9aNvvX6ofmwbfejb70bfejb70CE49aOKQqaNpoAXHvS7fekC&#x2B;9Lt96AGlTSFTT9vvTSpoAQGlplOXpQAtGDRRxQAoX3pdvvScUY96AFooooAZNypA61k4962SoKt9KyO5&#x2B;taxATcyqVXHrhhwWweevsvavPviNBe3HiTRYbW58URw&#x2B;ZayG10&#x2B;1il02cR3W4&#x2B;cSu5XC8g5xgV6F6fnT42dcqp&#x2B;VhkhWP6gGrAbKpWRs/Kc5weorN8QNqEOg6lLo8cc2sJaytZxTEhJZgjFFJ3Lj5sck45rQXDDIOR7frWb4o1iXw34V1vWYYfPm06wuLtIc/faOPcBxn/OfSgD571b4o/tC2tvNJd/DXTxqXktHFd2dr58kTMOoKzOD1z0r1/wb4u8T63441zRdb8OTabp9nZ2NxbapJEy/apJI1aXtjhy4x2xivGNL8FfFzQ/Bdv8AFGz&#x2B;I8&#x2B;oXklgNfn0G4mme0e2aPzWiU79uRGCOEHK9ycn6V0PWI/EWg6Xq1vG6W99bxXkcOCSm9A4HYYBY9qHsB8x/tuR&#x2B;ZqXgFiTjytRU5GP4rQ/yBr582lsE9TzX0P&#x2B;22PLuPALO2zC34LsQAciDBBPXoelfOy3EXyLuyx4Crkk/hW0X7p4eJTc9CZYz61Kqn61o2XhXW9QVTaaJqd2G6fZ7KWTP/fKmuk0f4J/EHWmC2fg/Vuev2uH7KB/3&#x2B;21d0c6pzeyON2ENnHFSKpxxuP0Fet2f7KPxIugPM0e1ss9WutQhOP&#x2B;&#x2B;Cxrf0v9jXxjPIBf6toVlH3aGSadh/wExqP1o5i1RqS6HgxBGMjH1pwz06/Svp&#x2B;2/YlRWBufGmf732bTApP4mX&#x2B;ldDpv7GvhC1YNeaxruoeqrNHCh/AISPzpe0RtHDVOqOJ/Z7U/8Kb8RsASP&#x2B;EkwSAf&#x2B;fKGuw3fNg8N6V6b4X&#x2B;D/hXwfodxo&#x2B;m2EsdhcXP2uYS3TOzy7AmSe/yqK1YPAeg25B/s5ZG7&#x2B;axdfyJx&#x2B;lfDZrk9bHYl1YNWPv8AK8yp4PDqlNO546zKvUgfjTUkEsgSPMjf3VG4/pXutvo2m2pHkafZw46eXbqP5CrmccLlcdNoIH8644cMS&#x2B;3M7JZ8mvdieI2/h/VrgDy9MumU9GMLAfmf8avweA9fnI26fsXu0kqDH4bs16&#x2B;0js2WYn8WP8zQuR04r0IcN0I/FJs45Z5W6RSPMofhfqrx/Nc2kX0dy3/oOK3NJ&#x2B;HTWmm6laXOobjf&#x2B;SrNHH9wIxY/McdcjtXZClr0qWS4OlrynFVzTEVVZs46P4X6buy1xdsM5KmQAc/QVoW/gHQYcE2PmP3Z5Sc10ODRtNdkMrwlPaCOaWNxEt5szIvC&#x2B;j27h49Ksg46PJApb8yM/rWnGxjQKDhR0CrgfkDRtNG011xo0obRX3HPKtUlu394vmNzg498nn8zXks&#x2B;i/FG&#x2B;&#x2B;Okd9/akdt8NrfkWbPFmTNuFb5VBf8A1hb7x/SvWdpqOVsKykcGr06GV5FUr26Y4xijb70UY96wEG33o2&#x2B;9G33o2&#x2B;9ABt96NvvRt96NvvQAbfejb70bfejb70AG33o2&#x2B;9G33o2&#x2B;9AEVOBpgNLQA7IoyKbRQA&#x2B;lA96aDSgj1oAdt96NvvScetHFAC9FOfSshlO4/Wtb1HtWY33j9a1jsBVgvI7i8uLWNZPOgUM77G29jtzjB4IrH1DXr7QPFtnZXqxyaNexTzfbGKQLZtDtKqSSC24vjjpnmoNU1CPS/iH4ds3vZoItbtryP7GoQxzzwLGylvlJ/1ckp9P3XPUA8749h1DWPil4Z03Qrq30/UJNH1Fpbu4h8xIY2utPbhSNrlhE6ccjdk8c1YHpassiq0bB4yBsZSGBXtgjgjHfvRtG07lSRSCGjkGVfIIwfYhmB/Co7Sae4s4JLqD7LctGplgyD5b4G5eOODnpx6VNg0AeQ&#x2B;Kvh/oPh34UyfDuHWtatNNuHkcT2sUk09tZibzZlfYDtj2FYgO44GcGu28WeL/Dnwo8IW2o6g722gW3k2UDW8TTKsZUCIfKCW4A5ArM&#x2B;K3w7vPHtrpv2LyJzZy75LS5kCIxBBSUSGOUgphvkAVW3Ak5zWxd/DfQ9a8Caf4S123TV9Mtbe3i2tI0ZdolCg5Ujrg/4DpQB57q37Q/wQ1xrY6tc22rJAxMYvNEnl2biAcboQBwvrXZ/Bv4qeCfiJcapaeC9Ma0GmrD5si6fFbo&#x2B;/OMY5/hbqB0rKT9lj4Vrhv8AhEl9h/ad4R&#x2B;Qlru/Bfwz8L/D2G5Xwzo8elfagomMcsjs&#x2B;3cRkuSx5buaolxTd7HWCd2XKSNsbkHJ5HbpxQzEodxJHYZI/rikVePl&#x2B;72pdppF&#x2B;gcsOmBSeX704L70u33pCGY28UtBU0bTQAUUbTRtNACbSaTaadtNG01QDdppelLtNG00wDBo2mlC&#x2B;9Lt96AEC&#x2B;9Lt96NvvRt96ADb70bfejb70bfegA2&#x2B;9QzKeam2&#x2B;9QXLFazYFbHvRt96RelLj3rAA2&#x2B;9G33o2&#x2B;9Jx60ALt96NvvScUcUALt96NvvSY96Xb70AG33o2&#x2B;9G33pOPWgCCnA1H9KXjvQBJRmovpS5oAkpVxTVIxRkUAPLClqPIpwYetADhxms5/vH61eZj2qg33jWsQMe/uNOu9es7Ke&#x2B;Sy1a3T7RZblgMrLIHRjEZkbH3CG2ngYz1rI8Ux2f/AAsbwVeXkSsFj1CLzHgVwAVgcElgNqg4J7DIPerXjTw7qOutpU2mXlxa3FlOXZYNSaxE0ZwSjSLFISCUUFcDhqp&#x2B;KtI0vxJqWh6Z4ku4dOulCO9iLkY1DeXJt1chWIJtgxIUZAUGrA7RkKttIwV4Of59qTOOpOaisLH&#x2B;zdPtbPznn&#x2B;zwpD5si7WfaoXcR2JxmpWycjNAHA&#x2B;KPEnj5fEkuneF9G8MTQ2&#x2B;1v8Aid6s8c96Ngc&#x2B;VHGDsI&#x2B;YfPjO3PQ11nhLX9Q1/S2k1bQrrw5qMUxguLG6lWYKwXIaOUEqykEHjpnB5BrzD45a9oz7NE1DW3&#x2B;HerC4iu7HxNdWZaC5j2PHIEnAIVlDsu1yucV6d4T8deH/AIhafNqXh6&#x2B;Go6dFOYPtSo6qxABIVmADdcErxkHmh7FG/CdwTHIwDkd&#x2B;K0VX5RjpVKFfn&#x2B;YAH2z/AIVeXAWgY9V460u33pY42l4RWPToM9c4/kaZuGMqcjtQQO2&#x2B;9G33rH8SeMvD/g2KKTXtc03RlmDGL7fdxwmTbjO0MQWxkdK0rO8g1Kyt7y2lWa1uY1mimjIKujAMrA&#x2B;4INAE233oCknGeeB19en8jQw2jJyBXP8AxC8QXXhDwP4g1y0jhku9N0&#x2B;a6ijuATGzIhIDYI71QG/wcc9RkUq4zgHJ9Bjj1J9B715/8CvHWrfE34b22v6vDbRXc95cRLHaIyoFVtq7dxJ9O/XNbfxK0XV/EXgLX9L0Kcw6peWkkVrk9X4G0Et8pYHb6d80wOlVhIqsjKyNnaynIbBx1/Cj73Ib9a82/Z6&#x2B;HuqfDX4W2Gh6scXrTS3Js45hKLRXBHlI2TuOF3EjuxrppPiN4SXxF/YH/CS6QmrtJ5ItPtcYYNgkIcnAbAOemOM9RQB0ePyHJbt&#x2B;NG33rl/GPxA0/wAGNa289pqGp6lP&#x2B;9Sy09I2lEW7G9vMZVUZB4JydrYBw2NrQtatfEmjWuqWTO9tcKcCVGR0YEq6OrAFWVgykEcFSKAL233o2&#x2B;9LtPpRtNABtP1opwpMH0oAbRTtp9KTafSgBKgulO0Ht3qxtNQ3ifuCc45xUyApD3peKaPrmjNc4DuKSkyKMikAtJmjIpDQA4Ypce9NBpN1AD&#x2B;PWkpN1GRQBXozUe40u6gB&#x2B;RRkUzIoyKAJVIxS1GGHrS7qAH0U3g80vFAC9j61Uk4c1a4qvKv7w4raIGZrUMs9qkUWsvoTyyKi3CCMs7E8Kofgng1jeMtNnv7/AMMrEZYmh1GNYbq2itnuVkFvdEuPOXYoAyxAHOeK6aS3inaLzoY5vLcSIJU3bWHRh6HrVLWNAsteXTzeLK7afepqFuUkKnzkR0GcdVKytx7VQFzT7WSzsoYJb6XUZUXDXUyIjyn&#x2B;8Qiqo&#x2B;gH1ycmrUcZLDnaP7zcKOvJJ&#x2B;hpv3u/t/8AXrK8VKy&#x2B;F9cdM710&#x2B;4KsvDZET9MfUUASaH4g0Pxtp8z6Xe2OuWcb/vFglWZUbJUZxkgjB6gVqpAIlSMIqxgABFXaoU9/qeK&#x2B;ePgfr2s&#x2B;B/AXw/Fl4SGq6BqWko9zqlq8UL2kyTuJS2fv9d2TkjdgV9FbBGSq8AE46f0AH5cUmUWLdjuGeuB&#x2B;HtVyqMHDVdHSmSfN37YvjLxD4dm8H2Oha3qOkLeJfPMunzmJ5CPIVTkY4G4/nXpf7Ofii58XfB3Qby9vJL&#x2B;&#x2B;tTLYTzTSNI7GKQqu5mJJJj8s/jXln7TEi3Hx0&#x2B;E9m6eYnnRF0IyGEl5EuPx8rH456Vpfse3TaRcePvB08h8/TNSEohfhiRut5GX2/dR/iwq7aAed/tcXMutfFl7dXaaDRtJt/MjJO2Nnl3l&#x2B;eMkTxDt19jX1H8JZl/4VF4HuHlWCJfD1k7zTHaEUWyEk5PGOnWvknxbNN4si&#x2B;OPilzviGpWmnRXAGVaP7TtCj3WOGH869G&#x2B;Inii70f8AY88IWtpI0T6zb2elSuv3lh8ti4GfURqD7Cn0A6PXf2zvB2ka0bPTtL1PWYI2KS30Dxxjg9I9xBb8R9Mjmuu8feMNK8dfs8&#x2B;Ldc0O5F1YXGjXmw4VWVlRgyuo6MCCPfGal&#x2B;Gfwr0KP4I6X4fewt5v7Y0tLq8mmiXeZpovMLAgZOxyFBBGBivnr4FaxcXP7Pfxn0yVtsNvp32qNs9DLBNG3P0hX880o7kifCvW/i3N8O2sfAVn9i0bSZZprnUFihaSZ2YNtHmkbgBwduelehaL8T9f&#x2B;M37OHiq6t9TGieLNEhWW7u7Nnty9vGPODAIAAzojrx18vnqM9x&#x2B;ySzD4M6KR8rNe3g8sn1lb5T7DJrxH4DxpJ4G&#x2B;P8AcwKy2D6RIEZumBDeHI/Bk/OrKNzwN8Rr3wf&#x2B;yXrGsLeXE2sXOpTWNlJcSM8iyyFcHeWJ&#x2B;WPzCDnGeO4qXS/2S7PxB8IdAvbS&#x2B;a28Y3ot9Rl1S5ld1EchWRlKL/EqMpDA8tu7VxE1jc3P7HttPHGWjs/FDXEvljkLtKD/AMfYD8fTmvoCP4yaH4J&#x2B;AHhnxYf&#x2B;JpENPsrRLO2lUSzSjy4pUXJ6qyOP&#x2B;A0EnB/H7RZb7Vzptxe2Y1sJFdtqeoNFbi8t0sL2FljZ2H7w3DEYBODcqxwASPdfh9&#x2B;88KxXX2V7RL26u76OCRdrCOa5lljYjAwWR1bkA/NyM1dtYbLxVpelXmo6TBIGWO7W31OGORoJGQHAyMKegLD0HFaysZDliSzHJ3Nk&#x2B;tQUJS7SaQEMAQcg804GgBNppelGRS0AFNbrTqTaTQA2q98cWrZ/vVY6VW1Di1Y/7QrNgZ24il3Uw4o4rAokozUeaM0Ej8ijIptFADsijIptFADsijIptFAFX6Uuah3mnq3FAElFRl6TzKAJad0qFc9afx3oAlDD1pdw9ah4pcnt/OqjuA9mOajb71LTW61sAUYNFHFAChfeuS&#x2B;I1p4hntdFk0Jbi4hS/wDJ1K3twnz20kMikncR0bHHXmutx71yfxA0nR9Wm8LjVLm&#x2B;iurfWYJdOWwcK0lxtfKScZMYRWcjn7vuAQDwz9nX4X/DX4l/CfTrLVPD099rMdpuv7udLqBGzMygpJkI5AVQQvQg5r6hs7OLTrWC0gi8mCCNYkjwRhVGB1Jz069&#x2B;tedfAfwf4u&#x2B;HHgu08KeIotFbT9Li22l3pl1O8tw7SuxLI6BeN&#x2B;PlPavSlAUBQfu8fl6&#x2B;9BRPDkutX9pqjB/rErQwaBny5&#x2B;0IzTftKfDGAcMsmnEHr1v2/wAKd4o1Kb4WftZeJNWgQRRav4fu7&#x2B;HH3OLZ5cEf9drNhz/z0q58aPDOt6x&#x2B;018P7uw0fUL2xtDp0txdwWkjwwql7I7l5ANq4XB5Irf/AGnPgv4i&#x2B;KGqeGrzw0lu81rDc2d1JNceXsjcDZ35XLSZAyfmNaGT3PNNA0VtN/YZ1a4cAHUtVS9DMPmbbcxQA884/du/41q&#x2B;ONGutY/Y38F6hagudIuI7qRVAY7MzRFsdSFJXp0617TrXwlk174HWfw/N/Dp06WNnbyXccJmiEkTxu7bSVPLB2rovh/4Ht/A3gHTfC8ky6zbWsEsMkk0IRblZJHchkLNgDfjr2p6lHkvh39pjwtpXwLsr6a8jg17TdMXTxpOSZvPijCK4wPuMAGLdOetcp8K/Bk/hX9knx9qF1b&#x2B;Tca1Y3MsaMP3jwxwtHGR7MxYjuRgjI5r1Wz/AGXPhrY6zHqC6HJIY5PNS2nunaBDnoEGMr/s9K9W2qilY1WFAuwRxjYqrtI24BOAPlH4UagfFHw7&#x2B;JHxH8A/D/8AsTSfC89/p2sxyy6ZfJbyO8G9ij4Kg7csh&#x2B;9gjOele5fCz4Naj4L&#x2B;AGteFrlYIvEOt2d29wrFlSOWaBoo0LDk7QVz7sccV7U80jMzb2Zi2chif84qLG339/X3/GjUDyn4V/Bx/Dfwf1HwT4oe2vk1CSZpjZM&#x2B;wBtpVgWAO5Sgb8a5fwn&#x2B;xz4b8PeJLbU9R1q6122t5hNFYNAsSFgcqXYMckH0Uf1r3xutAX0P3j09enH8qnmAzrrxRZR&#x2B;KrTw9vnm1W7s5r/bGgZYIEZE3t9XIUAcnnA61j/Erx8fhvodprU1is&#x2B;nf2nbW168jsFtoZHZDNwMkAlRtHP0Fcp8O73/AIST9oD4o38gzBpNtpmk22ByAySSzA46gSJ2/vc8Cuc1r4kQ/GL4M/FfTdR0c6Ld6PaMZrVpRIxTBkgk3KSC3yMDg5G3k/MMgHvcieWxQNvC/Lu3Bgce460i8nHbjr7/AP6qxPA91LqHgjw1cTtuluNLtJXOMZLQqaqfEjxVJ4L8Aa7rlu6x3VpaPJA0ylgJGXy422jkqGccY5OfQ4AN6HUbSa&#x2B;urFZla8too554erRq&#x2B;7YSPfy2/L3FWu5&#x2B;teC/C/Qnv/jtN4nj8RDWbO48H2Nyk6B4xdMzLbh9jAY2vbythgCPNxgdK94jdHeSJCrNCyxOFOdrbVYBvQlXVvfdx0OAB3&#x2B;OKTcBu5AC&#x2B;/TkD&#x2B;oqn4f1iz8UaTp&#x2B;qaXcLeadfRedbTqDh1YqFIz04zwea4z4UfGTT/i5qviWz0&#x2B;yltY9Gu0himkm3rdxMXCy7cccxk/hQB33BwQRyAevtVPVGP2Q/wC9ivNPA/xmvfGXxi8R&#x2B;GpLP7N4fhs3m0q6kjKvd&#x2B;VKY5WDYAILK2PbFem6sM2xPQGYL&#x2B;f/AOqs5bAZW71oyKZuoyKwKH7h60bh61GaUGgkfupeDzUeRRuNAEvFHFMVuOTRuHrQA/ijim7h60ZFAGfupwkqDmjJoAsbs80ZFQBjS5NAE4Y09W4qBWAXnrTvM9KAJtw9aUN71DuzzShjVxAmyO5pNp7U1W4zUnXnNagN2mjaadt96NvvQAgX3rkPib4Z1XXtP0W/8PlZPEHh/U49VsrSVgkd2QrRvCxZto3JIcE4AK8nnnsNvvUtiyx3kMjEERyKdmeTjnjv6/lQB4j&#x2B;zT8TPGvxGsbu68Q6ZI2lSWslxa6vJbrCplE7p9lUD/WqqADdgYYEc4zXuH8R5yO2BjjtXgv7KOqeIYdJ1fw5q2h6jYaRpssl1aXF5YtbrG73EhMKs3Lggh8hcfNjNe9KNvbH4YoKJ4f9YK0se9ZsP&#x2B;sFaWPegY9ZGjGFds5yAASpx0BGR3JPSmplVGTk49c/rikooIF204UgNGRQAtFJkUtUAUUUUwGt1oX74OcdMfgcn8&#x2B;KG60h5U9veoA&#x2B;eZPt/hfxX&#x2B;0ZZWby211JpdvrFpNGCHKm2k85l9SpYrx3Hsa0/G/wz0D4P/BHxNp3hG1uJdY8Q/ZNKE11dPLLeTSTBApy23O2RzwO1eoXngOzvPHC&#x2B;J/Ok8&#x2B;bR5dFvLUcx3MDSB0Bz0IO8cf3q19T0HTdYXTxd2iTf2bdLeWW5mCwzKrLG&#x2B;B1K7s/hVAT6bpcej6fY6ZEd0dnBHarJn&#x2B;FFC5/EV5/r0mv/Ebw14p0nTdH0nU7STV5tK26hO8cNrFCsYaRwgJkkEyylR0AxXo/mBW3gcLghPUDop/SvlHx1&#x2B;zn8R9S8feJLnQr&#x2B;KLRdW1CW/Vv7SeCI&#x2B;axZhJGAScZxwO1BJ6Y1vo3wV&#x2B;Jnguyv9VttO0uHwfNpD3N7KsUbSxXEDq7FsfeLTtXMaF8evCPgfx38RJrjXbnxHpeq3drf2A0uBpWZjB5cw3Y2gLtjUZ7YxXMW/7Gv9n6RJqfi3xpp&#x2B;mxxIstwYLUSxqAeB50pGMnafuj8etZN34b&#x2B;EPhX4d614obTNa8Xmw1w6Eov79VhuHUli8TR/w7MH5gB2zxT0A96&#x2B;BMJP7P&#x2B;ix6RJIgW21COykmwHQC5uFiDAHG5VCgc5Oa&#x2B;ZvB&#x2B;ufE&#x2B;PVrzRfCnh99H1iWxtNIvha6eysqRb1WSRmwFLK2C/GQOM9a&#x2B;iPGPxA1X4C6PaWuk/Dp73wysKtpg0&#x2B;4kb7JKw3vFPGAf&#x2B;WjOQwyMEd8itL4BeE9b0rw9q3iTxU8q&#x2B;K/FdyLy6E0jZit1H7iE9OB97GBgPg0/MDhfg7&#x2B;zt4u&#x2B;GvxK03VtR1ez1LRbG0uLeJY55S6BzkKqMMDLFjwec5r3zWMx2KnAH75WwPbP&#x2B;NXFQqoGCqAYGew9KzNcuoWtjCs0byqwJRXG4D3HWueVSLdrmkYO12jK3beCaXg96YT/jShhjrWYx&#x2B;Pel2&#x2B;9RF6PMoAl6d6Mio9w9aNw9aCCTIoyKj3D1pdw9aAH5Pak3UwvRuHrQBn7qTfUfmbeKXdnmgolElOElQZFOXpQMm3Z5pQwx1qMGjIoAnVhjrS7qr&#x2B;ZinBs0ATs3y1ajBKDis/ceMVpW5Pkp6H/GtokCbT6U9V4oPWlXpVAJtFOXPAXIKsGXOCNwPH86MGpLVR9qTcMjKjOemT2/IVnKapptq9tTSEW5JLqEy7VAztGBjzDnI6jGTRtZuec9Tk14nY&#x2B;MPEFjAgTVJsKv3XQOD7YNdd4V&#x2B;IN/q2sWWn3tva4lLDzowUckKWyR06A/lXhYfPMPXq&#x2B;yd0z16uV1qcPaPY9Ch&#x2B;&#x2B;K0h0FZ6KwZc9fYYrQX7or6E8cKKKKCdQooooELil6UL0oIoAWik4Xrx9aNwPAoARutJTmU56UMpWMuwwg6seg&#x2B;pNRKcY/EyoxlLZBwFFIQdx45rLufFei2KlptRh9hATKT/AN8g4rGvvihpscTC3tLi5btu&#x2B;VPzJP8AKvOq5lhqOjmjsp4GvU2gdeY2X&#x2B;Ej6ilQO3CqxHoBnFeZ3XxO1OSPbbWtrbZ/iYGQj&#x2B;Q/SsW68UazeRss2pSlW6rENmf&#x2B;AgfyryKvEOHp/AnL8D0qWTV5fE0j0D4leD9D8eeD7/w/4hujbaXeBfN23AjLFWDKTuxxkYqlPe&#x2B;BdP0KXRo7Szm0wvu&#x2B;xQWvmI0gGN&#x2B;SAu76GvNLmSWG3lnjj8&#x2B;RELqMliSASOeccjFVvDt/J4g8P6bqJtzA91bR3DRbt23coPXA9a8urxBiJQvSjZHp08mpRf7yV2epz/FiNd32LTZN8n/PZwgHT&#x2B;Fc55buf0BrEuviRrlzgrLFZ7&#x2B;T9nhBPPuxJH51wPiLVLjSZNEeBPMt5tThtLnttjlV4wc/77p9OvrhPCLXV3oqXVyTJLePJeKApO2KWVnjX2wjKPwrzKmYYyrDnlN6ndTwOGhLkUdTpbrVr/Ucm4vriYNzsadip4Pbp2PatXwVEsVxe7QuPlUjHqf/AK1eE3F0mtfHCBLaTUILzT38ho1QfZvsxgDEvzlmMjHHHH0r3fwhIN18SNpJTjr3NduAjNYqnzTvdXObF8rw07K1jp2YZPbvSc9ulVWvF9M&#x2B;9H25f7tffanxRa&#x2B;vWjHvVb7cuPu0n25f7tFmBboqk18uelH270HFVygXNwpdx7VT&#x2B;3e1J9uPpRykF2iqX24&#x2B;lIb6TsvH1p8rAofbk6YyaT&#x2B;0EXgiszIA9TQGp8hZp/2knpR/aK9lyKzNw9aerDFHIBpLqHy8Cl/tA&#x2B;lZqsegp24dzijkA0P7QPpTl1BscCs7g96erYHFOwGgt8eTW9pzGaxt3x13f&#x2B;hGuTVs11Ohndo9t6/N/wChGqBltV4560u0Uu00bTQQJtPbpUltlbhCf76/of8A69IKfEp86P8A3h/OuWt8MjWn8aPl/wARahrWh/Zb7TtO/tTT4w4voImxcKABtePJwcenX2NaXwl8ZQeJ/itZR2F55&#x2B;mLbrIseza0UjCdX3hgGz93qPpxVW&#x2B;kgj8U6FnUbi3ucXISzhGY5gVUO0n&#x2B;6MY9zW58Kv8AhH9S8dWmr6G9jPc3BYXElu6sz4jYqZFXo1fneFdONaN43d9/mfeYnndKVpaW/Q&#x2B;gEGGUHr3q9VCM7pFA6s2B&#x2B;Y/qRWgFOBX6XzJK7Z8HZt2QlOAPUDIqje6zYaa2y6vreB/7rSKG/Lr&#x2B;lYd/8RtFsWUo890x4xDDtH5vgH8K5auOw9Je/NG8MLWm7RizqV&#x2B;Zcjn6Chht68Z6ZrzLxF8ctO0GNGkFpp4cEpLqFyke/H&#x2B;znn8Ca5ex&#x2B;Pi&#x2B;MNSmstF1qB5oU3TrY274AzgfM4/lXl1M5oU480U5L0O6GWVZy5ZWR7vtZc56DrnHFUb7X9L0yPfc6hAh7qH3EfgOf0rxe91K/wBWAF3eT3YU/dklLKPw4C/lWBqHirQdL0&#x2B;a8utVsobWCQROyTCQK56ABV3Z&#x2B;grxpcQ1an8Cnc9SOT04/wAWZ7XefEzRrePNt598x/54psH4luaxrz4p3BUiy02KJiceZPIX/TpXlEnjrQV8KzeJYr5brSolIDoCCXBA27SAwOSO1clp/wAUNd1TxnpWi/8ACNR6TFd7Zib18StBhy0gxwfu5x146VxSx2ZYmMmvdSOpYHBUWovVs9pvPHmvXiGM35hX0t0WP9QN361iXE018266nkuT1zcO0jfmSKRlCsQBgCkr5qeJr1fjm38z2oYejT&#x2B;GKBlHDAkN34FP4plFc17vU35ew/gfTGetYreMtJj8QXOiLcx/2vHbmYxSkIh&#x2B;UFVLk8HkH6HHWtqMjcOx3fxZIxkA15vdfCm08datfanr2r3Mlu15cQw2dqFjWFElMeNxBJJ2Z4x1r0cLClKT9q7I5MTKcY2pq5F4f&#x2B;MEWkahqGneNbi0t7iCTfFdWOZ4mQggoxTPY9wK51/HF7r&#x2B;neG7Hw7puqyR6RJbia5t428vcroq5xyVCbj&#x2B;Ndn4R&#x2B;G&#x2B;g28d8194Vs7R0u5Etzcv9peSLja5y3XOa79GW3j8qMCJFAQIg2oFHQ4GAPzNelWxGGhJ&#x2B;xhf5nFClXqRXtJWM7xNpsmteH9SsLdlgluoZFibtDIVJXH&#x2B;62Kj1PSJZ4dHtbO5ns0s72CaRoWGXhRSNjD&#x2B;6eK0kl85wseZZCfuxAuc/lWvY&#x2B;E9bv5AsWnzY7tJiMD/AL6IzXn0o4iq7Qg/uOyVSlT1nJIyo1SGZ5VVI5nGHdEGXHTk1ueHR8tyUPdB1z3NbNn8L7qTH2rUYok7rCpJqbVvDdr4VgtxaSySNcM5dpv9kLjA7csK&#x2B;myrLsTDExrVVZHhZhjqE6MqcGVVJx1o3DuaiMh78HHrmm&#x2B;ZX3h8kTFqTdUPmbjjvQX28ZoAn3D1pN1QeZ70eZ70EE/NHNQbv9qk8wjvQBY3Gl8zHeq/me9Hme9AGV5nvR5nvVbzPelEwHFBZZEv404SZqp5ue9OWQetAFtXx1NO8wetVfMzRvoAtiT3pyyVVWTjrTlfvQBbWTaa63w&#x2B;C2i2592/9CNcV5nNdt4ZOdBtv&#x2B;Bf&#x2B;hmgHsaO00bTTsGjaaCBu0&#x2B;lPjO2RSfUfoc/40BfejB/X&#x2B;hrCp8LNqb99fI&#x2B;YfFWnavHqFlq&#x2B;jQQ31/p/nQGxmk8tZo5Fwct7FR3o&#x2B;BvhKbwr8RNKSSziti2lIbhrdf3bTBpS4LDqQpUfhVvxdJ4mt5IZPDtlZ6kfNcTWt1IYncZ6Rt09K3PhHrk/iPU7C4udPbSryO6ltJraSbzCrohDc/U1&#x2B;c4aVWMo6Kzf6n3NdQlCXe36HrvjDVLrSfD91c2UnlXCNHiTAJGZUU8dO4rzK71i&#x2B;1BiZ726lBP3WmIX/vkcD8q9E&#x2B;IGT4Wv/8AfiP/AJHjrzAdBRn1arDEKMZNK21zPKKcHRbcU2cT4wHj&#x2B;bVtnhyOxtdM8vH2ufy2YtxnhgSOvXbj3rP&#x2B;E95r2oa94lOtaw2pPYSLY7Y2xFvBO/aNg6dOnUHr1rvdU1aLQ9Lu9SnGYrKCWdueoVCcfjn9K434K2osPAEeoSgQzahcTXUpkYDB3bFyTx/DXHCt7TByvFX2Xc7fZ8mJT5nbdnOfGO80iPxt4Wi16Oa502K3meWJSd7gnA24wWyRiuv&#x2B;HHiHwjrUd1D4c09dJnhG6SGS3VZCpbAO4MScE9Cc1t39v4bXxNZyX72S63FCxt2uJQrLGGOSAxx1&#x2B;lcJ4HVNZ&#x2B;MfivW7AiTTEiSITIMK8m2IEDgZwVaujmjVwnK01yrcxUZUq97pqT/QsfFi1m1fxN4K0tLyazgvp5oJnhkKsQTGGPHse/rWX4P8DaFY/GbWNNFgs1lY2sdzDBcfMqyskRLEdCfnc810njzSr288c&#x2B;BZbW1luIbW5laaSKIlUTMeCTjj7pP4VoaP4Zv7b4sa7r0gQabdWkcMfzBi5EcaklRyMFW69cVpQxEaVCMebXl/Uzq0XUqt8ul/0PKNNsYJvgr4viaVLVYtdEke/Plu4FuqqfTJK/nXe&#x2B;ETca949ttd8RahpNvqFnaC0sNOs72OSTJ3bnYbj1DHisbxV4T/AOEA&#x2B;Geo2k8y6pBqWtRz3Pk2xDwxELuC/NgkGNe1QeHPD/h/XPGHh6Xwhpl5DpulytPe6tceYu87flUbjyc9cDrXdOcK9CfK979Dn5XGtFNdj2zYFAAIAx0GaVR2HJpYIZb2UJDFNNI3O1ELnJ&#x2B;grdtfAOuXUkaNZG1jb7z3DKMf8BzuH5V8tTwdetL93B2PbliKVNe/JGDtI6jFG0&#x2B;ld7ZfC12Yfb9RXYP&#x2B;WdvGw/Vj/St2y8B6HYMXFoblvW4befy4X9K9qjkGKq/EkjzKubYeHw6nlEMTzvsijeWTPKxoWPr2H0rT0b4f6zJDKbeyaISStK73EgjClmLH5Tz1J7V7BaW8FlD5dtBFbRjokUaqPXoKmZyy8jK/3e9e5R4dhBfvZX9DyKmdSl/DjY89s/hXcMn&#x2B;m6kieq26E/q3&#x2B;Fbtn8PNEsgu&#x2B;CS8k9biVio/AAfyrpFPHJ5pdpPNe7RyvCUdoXPKq5jiam8mRWtpbWaAW9vBBjj93Eq4&#x2B;hFTMzHnczg&#x2B;rEn8e1N2ml6V6kacYq0VY4HOUvidwrlPiBIFbSQTwfOP5GP/ABrrK4z4jsFOkH/r5/lFTIOcZ/mIz04pN9VDM2TR5xoKLLSYoEhxyar&#x2B;ZR5o9aBlnfRuqr53vSGQ&#x2B;tAFrfS7qp&#x2B;d707zTtzniggtbqTfVTzvel8w&#x2B;v61QGR5ppfMrO&#x2B;0988Un2wetZXRZped70efWb9s9KDeY64ouBrLN8o5pfO96yBfj/Z/76FO/tNV4LKPxoA1vP8AenrcfLWK2pR9TKo/Gmf2tF2mWgDfE&#x2B;c816B4RYPoFsc9CwP13GvIBrECsczc/Q/4V6r4AuEuvCtvLGd48yTJx6E0R3EzotvvRt96B/LiirJDb70d8d&#x2B;o/DP&#x2B;NFGM9PvYIH5VlU&#x2B;CXoXH4kfKPxZXQUW0bXbzUtNUXEwiv9LLK0RyM7iueOM8/Stv9nSS1muITa3k2pI2qzj7dLndcKUG1uQDnGBz6VxHj/xFqui&#x2B;PNZGl6ti4e5MR026RHh&#x2B;ziKNt&#x2B;08jLs/zDjivTfgzfTahqNikos2uLTUJbZpdPx5MoC7w4x/ssM&#x2B;&#x2B;a&#x2B;BjGUOTzf6n2spKXP6foet&#x2B;Psf8InqJ7ZiP/kaM/0NeX9cY9K9T&#x2B;IG3/hFNRO5f&#x2B;WZ6/8ATVa8sBGQA3J6Y5zXFxBGUsXFJdDbJ5KOHbfc5f4labq2teDrvTNItlubq8eONm3qnlxhtzH5iM52449aj8UeAZPEHgXTvDltdixW1&#x2B;zqZtpKyLGuGB6deTx3rvbHw7q2pPi0sLhx/eZdin8TgGt&#x2B;x&#x2B;F&#x2B;rXDbrqS3sR6Ft7/iF4/8erlw1HGzhGFKGiOqtWwsZynUkrnk2sfCvw54ggsF1G2a4ksrdLZLgSeWzIoA&#x2B;br1I9a6DR9J03w5p6Wmm28VjbD/AJZqxbJznqfevWLH4X2EK7ry7uLt&#x2B;6r&#x2B;7X8Op/Wt7T/C2k6YrC106Af7c2XcfietexTyXG14clWdkeXPNMLRfNCN2ePWNnd3/wA1nbTT88mON2GenJFb1h8O9dul&#x2B;eKG0X&#x2B;Frkjdj6ITXrCyNGgRMBO6g7f0H&#x2B;NIM9M8fTFerR4doR1nJyOCrnVSXwKxxNp8K7ddpu9SmlbusMaqB&#x2B;JGf0rdtfBWhWgTGnpPt6Ncgy59yuQv5CtrpRXt0Mvw9FWhBHj1cbXqPmlJhGFgQRxKEUcBQAB&#x2B;AHH6U7djgcCm0V6EIxgrJHI5Se7H0UgNLVEhRRRQAU4Gm5pMigCSimq3H/1qX738uaADNcL8UJNsmjc/8/H/ALR/xFdztJrx/wDaAsdWvJvDh0y6a2Mf2reQAevkEfyNAFH7QOx4&#x2B;hpDdD/INeb/ANk&#x2B;LDydWfP&#x2B;4KP7C8UvydVbP0xQP5Ho/wBq7j&#x2B;VJ9qJ/wD1V5w3h3xM3XVJCfakXwx4jPXVJc/Wgdz0Y3X1/I0fav8AOK88HhnxEP8AmJTGnL4X108nUZc/UUEnoX2j3/Sjzu&#x2B;CTXBL4V1phzqE2f8Aep48J6x3vpSf981IHdfavXIPpg0n2oZ71xC&#x2B;E9VHW8lz/v1KvhPVO91J/wB9mqA2v7LYnlqeuk8ferS8tm5CnFPWF8fdqOUq5lf2Sm7JZs&#x2B;xpf7JjJ53GtTyG/u/pSi3b&#x2B;7Ryhczho9v3X86VdGtt2TGDWotm7KOKeli3pT1C5mLo1uP&#x2B;WSke9P/ALJt/wDn3j/KtUWT&#x2B;lTLp77aQXMhNKgwMRIPbFejeBbcW/htUUBf30gwPoK5RdNb&#x2B;7muz8Kx&#x2B;TorIeP3zfqopok1eBwOlFKepPqc0lUAU5f502nL94H05P8An8axqfCy4/EjwLVtEsL7W7u6msop7kGa2MzJlvLZjuQn0NWfhj4dsPCuvWdrYQtbwTXnmeWGyqFgFIHtnFcn8Vrq78PWmqa5YzXQurK&#x2B;RTEs7&#x2B;U6m5VCpTOOrDt3rtvAstxNrHh&#x2B;a8txaXMjwvLCOiMdpI/A1&#x2B;YQVSNWEubTmP0Cpyexkra8p7Pd2cOoW72t3Es0Em3fG3IOGU9PwPenabpVhpPzWllb2zEctDEqP&#x2B;J5J/OpD941KtfpzpU377ir&#x2B;h8D7SavFSdh7SFm&#x2B;ZmYdtw/pupdxboPwUYFJ5b7chHbqQFBJOO4HcDv6fSnJbtJkFWkTJztzzyFOD/d71slZWRm3fUM/LuIIGducdOM0oyzKo5LYxj3rzHwb8btD1q/v7HXNS0nR9VXXLrSbGzE2GmSJ1UE&#x2B;hJPU8c4rCsPiZdeF9S&#x2B;Jk189xrEieIbfTNI0&#x2B;4uSqedKiqiBiNsaDDMTkDqSeRTEe1cldxBwO/bnoPqecfQ05VLKHByhIAYdDnoR&#x2B;tfLnxH&#x2B;Ieu/EnRNI0zNn4e1HSPG&#x2B;m2F29i/wBrBeQj7LPFJkIQMuWRuPXPBrd8RJqvhn43aHP46sdc13QZZtMsdD12yuzBbRXJVVkaeBBjLyljtb&#x2B;9QB9CYzgg8dqWg5YklsnvwB/Kjb70AFFFFABTl6U2jmgB&#x2B;aTIptKqlgSo3YPJHbp/iKAF5bOKaeO/OM49vWuF&#x2B;IHja98M2upIZl05A1pFDqUMDXD2UMzSI9yyYONpjcDsOvrjoo/EemaM0Fhc6lJHFDZ21xFq1048uZZGaNHEp&#x2B;Vn&#x2B;Qk4JHzjnBBNAW7rXLKz1bT9KkkaTUb4M8NvGpZ/LUZZyB91P9o4BOQDkEVFdatcWfinTrJYoTazWl1dSSSMd&#x2B;Ymh27R3B8w8j0rzTQfirpGvfETTL7w3qza5aaxCtheaNZ2jT/YI1LtHK1wikRnJG6MkZJxVbxjeeObjVvEkcsWhwaJp9/cWsF5cs85aGa2RFiW2jTLk5V2LuoVlIzxTA9n&#x2B;1Q/aprRbiOS5gVWkiV1LoCSFYgdMkVyvxCs/tUmlYABBm7e8dJ4Q&#x2B;Hj&#x2B;GfEGqa9qGv6hr&#x2B;t6lEkdzJcrHHANv3NkYDFQBgYLnpW5rVj9r&#x2B;yEL90yAcY67P8GqZAedropwPm59qd/Yp6bvzFdj/Y43ZxinLpIz92kBxn9hf7RP0pV0P3/Ou0/skf3RThpYx92gDizoppRoYxyOa7VdK46Yp39lr3XNArs4ldDPYVIuhjqRXZjSx/dp66WMfdoEcZ/Yi&#x2B;n6Uv9ir/AHf0rs/7LH0pw03igRxa6Fx0qVdDG0ZTNdmumfKMDFPXTeOtAHFjRV6eXUiaJzwgArs104L2zUn9mo3OOaAON/sH5s7OPwpy6H833K7NdNGOV5pRpoz92gDkV0MdStSrooHautGmjHSnrpq4p8oHKLo4x0q7bW/2WFUHdifxxW/9gUdqo6lD5LRqBjPIpAUew&#x2B;lFFFBYU5ev1AH603HvSrxj1zn8iP8AGs5/Cxx3R8r/ABytpf7H1e7jmmLWt9lbZCNkhN5Gfm78bc12XwwtdStbrw/Fq8nm6m0/mz4/hZpt23/gIIX8K5r40WxuPDPiwGYQ&#x2B;VcvLvGNyhblWJGQewPWt74d2s58S6Vff23catYXUseyO5iiTDNIOQUQE4PHPpX5xD3pRvb4z7yVuWXofQJ4Y5BB96kVh&#x2B;FQqp9/xNSKvHWv0pbHwZ4Z42j8UX/7UXg610/U7LTLT&#x2B;zpZYWkhaYtGpJnDKSFDEZAPYAZxXL&#x2B;IvEV9afEjw1q2l&#x2B;J/EeuO3jGHTLrUeLfR0iaRl&#x2B;xxQ9XKoqhnTKbw3Nen&#x2B;Pfh34o1b4oeGPFXhjUNMsXs7Sewun1BHdkjkIy8YAILbS456VV0P8AZv0nSrjTjeeIdb1S10jVP7V0myMixw2spdn5QcHJZjz61YjyHVrfw5ffDn4haVbx6XN44v8AxzLbabAFja9z9rjYbeQyoEVstwuB1rofFXw/1fxVe&#x2B;PnsNE/ttdN8Z2WpNp8xEa38KRKsiRtJhcDOf8A6&#x2B;a91034b&#x2B;E9D12XW7Dw7YQaxJLLN/aHlhrjc7Fz&#x2B;868szd&#x2B;OldKZGPVt20lhkkN6Z56jHemB4lJ8KNZ8XeAVgttI0X4a38WuWuq6ZZWNus/2ZYOFM7KSrsx3uMZxvAPINdbb/B62n13T9Y1vxJ4g164tZLe6NhNd&#x2B;VpzXcSKqyiBRgfcB685z3rvt27aOvTG3nPuPXpn6c05eSBlSxGeuc/T1z&#x2B;tAC53ck89zjGfejihlKltwI243A8bc5xn06GkqAF4ox70lHFADtvvRt96THvS7fegA2&#x2B;9Z/iDUH0rRb27iga8uIYGMMMe1ZGkPCKpf5VJYj5jxxz0FaG33qlrGmDWNLvLF5DEtzC0RkX7yZBG5fcbs59qAOG0nwh4&#x2B;uLW1fUvGY0m6kt2t9QW1so7maSMTStCnmuAg2pMUP7tvu9e9VPC/wR0Ox1G7/tjSBr9jZpHBpreILo377Rkuwjb91EpwiqFXI25xzXqbyeYxc5y3Pzdfx96bVEjHt4/sP2JF8mHy/L/cu0e0ezJtZT7A9ah0bSrPQtPisrC3&#x2B;z2kZYhGO45Y5Z2JyxbJyST1NWacDTEOZizMWJZickk5yanS3E0Ck8lW4qv2z2rZ0eFJrRi3Tfj&#x2B;tAGebD2xSizGOlbjWoZiQODSfYx6UCMX7CPSnLYHHHStr7GB2pfsnt&#x2B;tArmL9h9RzR9jxW2LMU77IPSgLmIthuGduaeLEelbH2X/Zpy2vHSgLmL9hHpTv7P9q2ltV9KVrXngcUDMZbEbR8uactiPStpbUY6U4Wox0oEY/2EelAseelbYtv9mk&#x2B;y&#x2B;1AGQLPHapPsO7nFaot&#x2B;KetuNvSgDJWzCjGKX7H7Vr/AGUelL9l9qAMj7CPSuf8UQ&#x2B;RPbY4&#x2B;U/zrt/s3tXK&#x2B;NoTHPYEdSHx&#x2B;BH&#x2B;IoewR3OXooGMDHTFFQWFH8Q/H&#x2B;a0UvHGfr&#x2B;orOWzLh8S&#x2B;R4dr1nb6lq2r2d3bx3cEl5cK0MyBlYGQ8c59qn8I2cGn69otpaQQ28UV3EPs9uoRUJkBI2gDHJNQeJrdLjVNYt5J2g8y7mVZI5NjJl25ByPmrJ&#x2B;Gnh0eH/F9ssthvnlvbfOpSSM73K71AVwzFlI4H4V&#x2B;XU/94u5dT9Cn/Adl0Po3&#x2B;I&#x2B;lOpjcsSPU0oHvX6otj89luPU54HTIXOccnt9f5fjS4KrkjPGfyxkfUAgkdq818TeNtS0X41eFdIE3/FO3Vk8eoRsoKxvK0gimY&#x2B;m6JVHua4bw14j1lfDtzpkE19Dqut69NeXV7HcQo1tHJpsN4ELy4VArzBSM5KqAATViPeP7WtANQLXMcaafKsNzJIdiRuVRgCW4I2yoQQedx7g1Rl8b6Hb39paJfJfXE8sCRWthieSTzVkZHUg7SpWIkHO35DkjcAfMI7jV7uTS9Q1OCbX7O31qzvNb/sqF50mkbR0VJgqruZBceWdu3HT0NXfCfw/1y117w1rsVnBoTaOrpHYTFWza3M9xNLbkoTtaCOSFIyTw6ydiMsDpfDvj2&#x2B;1iHTVt7eG6WLSrO&#x2B;1XUdQl&#x2B;z7DPEzEqkakMBt3kEgEMBnJxXDr4k1nxdJoOk6lrN39hvvECQzT2cP9mSS2r6VLchAqMXRWkVSN2GxjODXbaf8J7CzuLKSa/upYk0&#x2B;2sL2xjAS0v2gjZUlcAB1GT90NjG3pjFdB4d8I6L4UtUi0nT47Ta6yCWUmaUOFKby7ksSEcqOeAABwKAOU&#x2B;C/h3&#x2B;x9Js777LOtzeeHtKlurm4cvJPc5uGlLSNuZmBdAMngYHavRFbKrlt3AGfwpC5baefl2kKzN2HHX0oGMcdP5&#x2B;9QA&#x2B;ikBoyKAHAe9Lt96aMUvFBIu33o2&#x2B;9JxSbgO9UIdt96Kbwe9LxTAWikx70e2eaAJNw2V0XhVFmsZ/RZcfjtB/rXNN92ur8C2&#x2B;7Tr4jktdZ&#x2B;mI1FApGp9l28Y6cUC3GelaZg5NH2egkzvswPaj7N7Vo/Zz6UotzjpQMzfs9OW34rR&#x2B;ze1L9nHpQBn/Zfal&#x2B;z&#x2B;1aPkUeTQBnfZx6UotxjpWh5NHk0AUxb8U4W49KveT6Cl&#x2B;z0AUhbjHSl&#x2B;zj0q59npwhoApfZR6Uv2Yf5NXVjHTvTvs2eaAKPke1OEHtVz7PinCH2oAo/Zx6VxvxGjEMmlsP7sn6Mn&#x2B;Nd/8AZx64rhvicvltpI/67fzjpMI7nD&#x2B;wpKKKksKFwWwfp&#x2B;ZH&#x2B;FGPehfvD6g/qKiWxpHdHh/ji1tZ9U1sX8YktVuZZWHfhiwI55HWq/gHxFZ&#x2B;ItS0a5styRLd2u6GRSjoDIhXIPOCvI9iK0PEw8zxFqqkKw&#x2B;0yLtbJBBJBB9MgmsTwJ4R03wpr0ElgsoNze2x/eybtqqyqoHsAAB7V&#x2B;WL2f1l82/MfoD5vYK21j6JOQSD1zRxScLx0xS1&#x2B;qR2R&#x2B;ePc4zxh8L7bxpfaxNdX81tBqGlQaYVgUCSMx3DzrKrdeCQD9a2rjwJ4euvtcc&#x2B;kwXUN1dJfSLdr5wEyQpCrjdwP3caDAwDitnil4qhjl2wqgVFUDGFjBUJgYGMEdvc0u48855zzxTMe9LQAtJRRQAU4Gm0UEj6KQGjIoEPBoyKZkUZFUA/IpDTcijIpgPBpaZTgaAF4pR96ko4oAc3Su3&#x2B;HyFtJvDj/l4I/wDHFrhm5HFd58Ov&#x2B;QLeY/5&#x2B;j/6LWgUjp/JpRCKkwaKCSPyRSeXUmaMigZH5dHl1JkUZFADRHR5dOyKWgBnl0eXTs0tADdoo2&#x2B;lLkUZFACbTTlXikyKNw9aAF2c5706kDDHWloIFxRtNKvSloATafSuB&#x2B;KnytpH/AG1/nHXoINef/Fj72kf9tv5x0DW5wVGPeikOKg0F2&#x2B;9Hv3BH8xSY96X&#x2B;Ej/PJH&#x2B;FRLY1p/EjxzxUgXxPqoHTzyaq6YSurae3927hP5OD/jV3xXn/AISjVM/89c/oKo2LBNQtGbgCePP0zX5L/wAxn/b36n6Kv91Xoe5NwzDvk0q9KJDmRznILEj86Aa/XI7I/N5bsWikyKMimSLxS8U3IoyKCx3FGPeko4oAdt96KTijigkWik4o4oELRScUcUALRSY96WqAcDRkU2imBIpGKXIpgNLQA/8Ahrvfhv8A8gS8/wCvoj/yGtcD1Wu/&#x2B;HLBdFuuf&#x2B;Xtj/5CWgUjq&#x2B;KSm7h60xpMN1oJHt1pu4etRtJz1pjOd1AyVm5pN1RbjRuNAE6sMUeZjvUG40bjQBYB3DNO3Dpmq6yfnT1NABupdx9KZkUm49hQBJuNGTSKMr1xRx60AODGnCQ4pgo/z0oAl3mnBqiHSnK3Hf8AKggfurg/it8w0j/tsP1jrus/5xXC/FMZj0pj0VpQfx2f0BoGjhOvejn60gBPOaXb71BoGPfFAxke2Cfzo2&#x2B;9CgjJ7cVMloXD4keP&#x2B;MPl8UakD18xf/QRWbbti6tz/wBNoz&#x2B;TVpeMvm8Valj&#x2B;&#x2B;n/oC1lQsPtEX/XRT/48K/I5f74/8R&#x2B;kw/3Veh7w3ysRSZFLN/rCe1Mr9cj8KPzWW7HZFGRTaKokfRSA0ZFADwaMimZFGRQA/IoyKZkUZFAD8ijIpmRRkUAPyKWo8ijntVAScUvFMU8c0u4etMB3FHFM3D1paAH04GmbguMnGfWlGW6UAPDHBxXe/Dsj&#x2B;wrk9/tbD/yGtcF0yM4IGcfXiu&#x2B;8AALoMw9blvzCgUCZ0Rk5NNZiTQ33j9aTHvQITmlwfWjb70bfegA2&#x2B;9Jx6/rS7fek/wC&#x2B;T9aAFFLim8euPpT1x2oAQfL1qT73IPFHl57Uu0igAwKcFFJsNLtP&#x2B;TQAbfek&#x2B;77inbT6/qKPLPfH5igBFbjpS7vr&#x2B;dG3HAx&#x2B;dG36fnQAdaXb7t&#x2B;BpV6dR&#x2B;dG0fX8aAD8T&#x2B;dcR8UlJtdM9C8g/Egf4V2&#x2B;0en61xfxQA&#x2B;waa38Kztn/vkn&#x2B;hoJR5&#x2B;ORnNLt96QKfWjj1qDQXb70nO4AeuaMe9IPlas5bMuHxI8j8bLs8WakD/ejP8A5DWsZT5bq5&#x2B;6GBP4HP8AjW14648Xaj/2z/8ARa1gzZ2n06/pX5RV/wB9f&#x2B;L9T9Ih/ui9D32bhiPTiotwHepJDliahJ5r9Yh8KPzeXxMduHrS8HvUeRRuNakEm4DvRwe9R7qNxpgSbgO9KGGOtR0oYetAElGaj3UbvegCTIopm4etG4etAD6cDUXmfjSjDc0ASZFIabxSbsZoAdS7ioPfALfkM/40wsF&#x2B;8doxuJPAxg5PPH8J71zOkaxHqvjHUZLS&#x2B;hvNNm0y1MTxybohIs92sjBhxwQqn3GO1AFnXfFKWurW&#x2B;lW07Q3S3VrHeS&#x2B;QGSNJZVVYyx6O2RjB6EVdvNWu7PxPoVqbZW0zUI54pX6PFOqq8YPsVWTPuv8AtAHznztZ8XfFi8SAywWVmkcU1v5MqxB4NQRgxZiEcmNWb5ckY29eD6rNAt00L4K&#x2B;VJ5qLnPzFHXr9HpgQaRrQ1TUNWsxa3EDadPFC0si/u5t8SSHYT6F9v4V6j4BX/iQyEBsfaG6nP8ACK4Fm3L8rfKCSoI49AT&#x2B;GK9B8BYHh9sbsec36KKQG&#x2B;eppNpPrTufRvypR/wKgkZt96NvvTjn0b8qTafSgBv50bWPQ1KvTpRtPpQBGFP1p6oR24o28/xfnUqjj/GgACnHpS7T6Zp6qcUbW/yaAGD6Z/Gj8P1FG3/Yx&#x2B;NLt/2R&#x2B;dACfgv4mjaf7q/mKXb/ALK0v/AU/OgAVeOi/nS49l/OlG3HIUH60u0H&#x2B;FcfWgBu0f3V/Ol/BRTwnoEApdh/2KAGf981xfxSU/2TYn&#x2B;H7SRx6mNv8K7bYf8AZrjfijGf7DsicY&#x2B;2KOPeN6p7Ex3POcZ5zTTSr8yg560hrI0Dijvn0opD901MtmVHdHk/jo48X3/H/PP/ANFrWBIcxt/nsa6Dx5/yNmof9s//AEWtc/L8sZ&#x2B;n9DX5NX/31/4v1P0Wj/uy9D3uRhuIz3qBvvGp2UNkkd6rSMvmHBwK/Wafwo/O5/ExDik3Ad6YxOeOaTPrWpBJvX1pPM9KiYjNGRQBLvo31D5mOKN2aAJt9ODcVCrDFLu9KAJd1OVhjrVfzPenKw65oAn8wCjeai3D1o8zHegCXcaZPceVGueAXRfxdwgwO5JIH403fVHWtLttc0u5sLoSm3uNpcwzvC4KEMhBXngj1oA5PxxpfiHxlquoaLomsWFlpPkQR6obiJ53SRWdjEsQIViVMZJc9OK1/Dvgt/AXh02Ph5oJtRYPvurw&#x2B;VGGeSSQsEiXbgNM&#x2B;F6AKuSTydXw/oOn&#x2B;GdNGn6Za/ZrbzDI2WZizkkmRmZmYsc9z9OOK1EOef6UwIdF03&#x2B;w9HtrBLiW78oEyXExw00jEtI5HqzFm/4FV5fb9KZj3pVJBxSAmHC16F4Dz/wj5&#x2B;9/rn6f7orzxSMZNei&#x2B;Ax/xTIYbuZn6fSgDf/77pMD0b86ftP8AtUbT6Ggkb9Cw/Gl2jvu/Ol2n0pVU0ACrgdD&#x2B;dSKp29KAvHTNSL93pigBuz8KXaaXA/yaXb6D9aAE2&#x2B;360m32/Wnbfb9aaynP3f1FBBHu/wBmnBSwzsX8SKb5Y/55P&#x2B;dOCf7BH1oLDYf7n5EUu0/3V/Gjaf7v6inBTj7tBA3af7i/nTlj77PyYUbB3Tn60oHbyz&#x2B;dAC7T/dH50v8AwBaUBe6HNLtHZeKAEw3YIB9a5H4oK3/CO2vTP25Dx/uPXXbT/cFcp8TVI8NQkjGLyM/kj0DR5euNoopMijIqDQWmt3pcim/xUpbMpdDynx0c&#x2B;LL0j/pn/wCi1rAmb9030/oa3vHGP&#x2B;Eovc/7H/oC1z03ETfQn9DX5NiP99f&#x2B;L9T9Fof7rH0PffX61TkPzGrQzx9KoyMPMOTX6zT&#x2B;BH55U&#x2B;Jisx7UwsO5pGb5aZk4J64ycY5OOwHc81qZj89&#x2B;tG4cAnGSB&#x2B;f/AOqmE7mMa8npgdf88VVj1O0bUDp5mxemL7SY9p/1e7b97GM5/hzn2pgW9248DJxk45xShl253Lj1zgfnXH6p8TtM0i0u5L60uD9muJoWt7UBn&#x2B;zwOiyTtnhVXevHUk4AJBA5nUfHXii20zVNWuBO2kWmvXFpdXGjwwyXVvZxb8ErLgOdxXKgZweBwaAPVz8vByp9CMU3fTMq3KY2t8w2qF689AAAfYCjNAEoakL1F5mOKXdnmgCUSUeZUVG4etAE4ko35qv5mKVZO9AFpX7VKj4qmJBnOaf5p7VIF7zN1OWqccvqcVOkg9aALe4YFekeA/8AkVYyd2DNJ3968zVhxXpnw9b/AIpeIHp50mKAOhb7x&#x2B;/1ox676cG7EsPoKdHGXbJZtvagkRYcjJVz&#x2B;NSLGoXlXqQY6ZYn1p20erUAR7V9HpCB/depfxb8qOP9v8qCCLYDz5bH605VGPuGn/8AfdL/AN9UAM2/7NNKn&#x2B;7Uv&#x2B;eaQgejH6UAQbfd6X/vugbcf6w0v0ZiKAEwPSSl&#x2B;X0enLnHVqN3&#x2B;01ABtX&#x2B;45o2Ddna4pd5/vN&#x2B;VLuP95vyoAXYv91/zo4HGGo47s2aX/vo0AG1e6ufxrlfidGW8KgKCP8ASU6/7rD&#x2B;orq9w9WrlviT83hWT0E8ZP5mgaPJ9wyfrSZFIetJUGg7IoU/NTaQ5zxUvZlR3PK/HTBfFV79EP8A44tc9N88ZA9D&#x2B;oNb/j5v&#x2B;KqvCf7kf/oIrAdtoYn/ADw1fk&#x2B;K/wB9n/iP0Oh/usfQ97U5hB9s1nzEeY1XY2/cr/uj&#x2B;VUJv9Y1fq1P4Efn1T4mVb7U7PS0he9uo7VJp47aMyNjdJIwVFA7ksQPxrm9U&#x2B;IEGn&#x2B;IotMbTbh9O/tCLSrnUg6gRXc0QeKLYT8ynzIct2LH0JEXxRvtO03wzDd6i8CLb6np08bSAMVKXkLMyr1LbQ5wAeF9SAciTw7qureJ76wuNOYaDN4ih19dXjuIykiR28eyEIG3h/OQ5JXGOM1sZlrVPGmsQeKvF&#x2B;nItna6fplpYPbTmJ7mUy3ErR5WIDDEkMBuIxgE8c15n4i/4rKxQa1FNqOvz6Df2WmsIyhF4l6yQsxiOxGAi5Jbbz15Feu638P9M8Tapql5qE93JDqkNvFcWUc3kx74JDJFIHjVZFKszcB8YNdBZ2drpduttYW0dnbRgqkMKhAgJLHGB3YkknkkknJOaoDz28&#x2B;F&#x2B;p3uuRX0kmms8N7fktqUBn2rO0LC4iGQBKDBj5uAH6ZzXUR/Dvw&#x2B;bu5mureTUlk1B9RSK&#x2B;cyRxSsQGKICBz8zHPcmt5pH3HcevOc5oTLsFTLHOB7H1&#x2B;lMCR5SzEsxZu7Hue/4Ubhxk7e&#x2B;Txn8aijIby2XlJAGQg5BFYGu&#x2B;OrDwpbzy6yTbQ/avsloluGuJLtvs4mx5ag7SPnGDjOM9xQB0nLM2ATjrtGcfWkaSOFFZ5EQM6xqWcAMzHCgZ75ry3xF8XrpmSbw7ax3NvBZNqMv2yJzKUaza4QouflXd5Knqcs3o2KWh282ueKvBFxqs667Eo1C7jmjBuoLYtFCUVpNigkHcVzwuQO1AHsBJ9MUlNbduOevfn/ADzTcmgB&#x2B;4etJ5mO9R5o3D1o1Ak3ml83HGag301pMdeKALaze/FTJcDGS2B9aoLudgq9T29aztW8Rafoa/6VdKJCcCGMb3J9Nq5I/GpA6qO4TywzOoHua9T&#x2B;Gd4k3hllV8tHO4wQR1UHr3614Ppcmv8AiFVaw0r7HZk5N1fvtJHsor2XwvrDaHZw2bQxCJepjJJO7OTzQLU9DVd3Jfb7EVJu28CQY&#x2B;lZFj4iiulXDR7schjzWkl4r4w0f0oMyZW7&#x2B;YPypcg/xg0zzmPO6Ol3HuyUAOyP7/5Ubh/fNN3H1X8qTzB3ZBQArNz95qbvH95vyNBb3z9Kbu/2wPwoAUsufvNSqwx1amH/AHwabn/ppigBACByVp3/AAIfhUXH/PNjRn/pm350ATK3bev5075u0iVXGc58n86erY/5ZUATc/8APRaUN28xc1H5n&#x2B;wB&#x2B;FO3HGRGpoAk5/56LS72HHnKKjDHvGM0Z/6ZigCTzD3lBPsDXLfEsk&#x2B;EZz5mR50Zxj0z/jXTbmA4TH41zHxIYt4Pu&#x2B;gO9D1/2gP6igaPIhwAPTil4701mBYnPejcPWoNBdwHegEHvzTCwzTQx3cdKiXUqO55d4&#x2B;XHiq4B6FI&#x2B;fwH&#x2B;Fc9N86MQc9/0P8AiK6L4gf8jRJ6mND&#x2B;Fc4zAR8nt/PH&#x2B;FflOM/32fqfoeG/3WPoe9QcwxEdPLU/pVGdhvardqwe1gI6NEp/8dFULpj5zV&#x2B;q0/gR&#x2B;f1fjY0S7cAKGOdwznA4698t&#x2B;ApGkZsdST6nJqPPTJxn8&#x2B;hPHqcK31xXM&#x2B;IvG66Ve3Om6Zpr69rFtF51zbrIsNtZL/euZn&#x2B;WL/cHzYxgGtjI6ZuAcDjrmop7qCzt5Lm5mjtbeJS8k07rHGi45LMcAAY6k1xN94q8c&#x2B;HU/tDW/DGl3WmJ&#x2B;8ml0LUpJ7mKPGTIqSQoHAHOBk4rd1TUrbVPBuo3dlPFPa3WmzzwyKNoZWiOMgHuP4emc9KYD9P8baBrEV6bbVYXFjHFNcSOWjREkGY33MAGVh0ZSQazbz4naDb32iWcEraourmILPayxtHFHIzLGx5BO4pIDtzt2c44NeSaPp&#x2B;rSRxwQW0euwR23hm&#x2B;vvsMBimWFGANocyENhQkjD0fPTgd/wCFfhrqei61Hq/9ow6bLc20i3dp9mSSa3kNxc3CrDJuYIFMxTgEfLVAcPoetapa/CO20&#x2B;91NdJtY4dAkim0&#x2B;V7ZxDc3kkUod92XBSPPQYziuzl8I38muXtto2m/ZLa38QteR3F45VXjOlpbHGcs5MhflRgkccYqWGbwn8M1mtrO0mubyyk0yymuLjDtGJZWjgYvIAm1WLt8ueWPeuk1Dx1pFlfaVZrMb59SMaQm1lV02O5RNzE52ltw/dglSSTgA0agcd4P&#x2B;Fus6Hr1tJqep3Mlhp8FtYwwpeMsF5bw2axFHtwAMFzITuPPXHOK9NsbS30mxis7K2itLWFQqQ26LEgAPQKoA5zzkdc9eteIWfie81LSPDdtZ38nh7RrjStMuhp1o/zsbi&#x2B;ETgyt87Dy89D2r0b4S28un/D&#x2B;wtpo7mIpLc7Fuwwk8s3EhjJ3c4KFSM9iKAOvzjI644ye9G73poYetJncTjoOpxx&#x2B;NSA8&#x2B;vaoywyCTj60l1PBY25muriK3hxndLIFz9Mnn8K5CT4hHVJzb&#x2B;F9NuNZmztMzKY4FPrjGW/ECizC52O07S3RR1Y9B9c1zOo/ELR7GcW9oJdZ1Atj7NYoWA7ZZ8bav2Hwl17xVsm8Waz5MH/QP08GNfxx1r0jw74N0TwrbLHptnBb8/NJs&#x2B;dvqaepNzzPT/C3jXxlse7nj8Macx3eXCC8zr6ZPSu18NfDPw74RYywWLXd91N1eN5jk9c110jlmOZfxxUTEHgSMfcUhjWIk&#x2B;8nHpkj9KlUbexP1NQ9cYf86eWz3zQImXAbdtwfrV&#x2B;31mWHHyjHpmsnd70nmL/eoA6&#x2B;08RFlGUWtW31fzAP3a154txtbhzj6GrMOobW5kagD0Zb7d/CB7A1MtySv3FPua4W31heAHc1oQ6suB8zZoA6wTN/dApd5Paufh1FWAyzZqyt4p/iagg19zf3V/Gjce4WqC3i7RzmnLcKegoAn3D/AJ6NSeZ/00ambz3TJ&#x2B;tNMvP&#x2B;rNAEnmD/AJ6tRvH/AD2P51XZyWzsNG8/88/zFAFoSgf8tTS&#x2B;aneU5&#x2B;tUmmIP&#x2B;rWlEzf881/OgC75if8APRj&#x2B;NNaRc/ff86q&#x2B;a391RThI2PuflQBOXQjl2rm/iBsPhK9wdxDRn/yItbbTOG&#x2B;4v41gePJGbwjqB24C&#x2B;WTj/roP6A0DR5XuGT25pM0hyM55NN3D1qDQduHc0isd3FNpNxDVL2ZUdzzX4g5/4Sg&#x2B;pt0I/M1zb/NGT2xXR/EXP/CSof71oh/8ff8A&#x2B;JNcyx3KQD6n8xX5Njv99n6n6Lhf91j6HvGm86fZf9e8f/oIqldf6xqsaS5bSrA&#x2B;ttEf/HBVW6I81s1&#x2B;s0v4cfQ/PavxyMDxbrl3oOjbtMMP9t3sy2GmrMpZPtEmNruP7qAM5x/CrjqRnivGmmaJ4Q8P6fpt4Wu/D8cd5qd9Zspa51eeCLzdssnA28Fjk98DpXVartufiD4Xt3TcLez1DUYueBKrW1uD9dt05/4DXEfHdk&#x2B;wW0IlRpE03Vwy7gdubB8AjtWsdzI6j4WjT7Lw3e22l2Uun2Fnql9arby3T3CgRzPGQpb5gpAb5fRsdqreGfsOm&#x2B;EfEWk3sf2fRNJ1G&#x2B;tdqhii2&#x2B;TNt2jJYL5jIABnC9K5Dwn8TI/Cs&#x2B;pae9tEIV1q6uZ7uVvlWGXVJY8DH8Q2H67uM4OOsjM0Hwn1e6vYRaXF3Z3&#x2B;pSxMclGnZ5Ame5VXC/8AAasDoNJ1Tw5oek6Nb6ZNYaPpl95f2C1UrbeaJfugKSG&#x2B;YY5OMEEccCuWvviubm5vNP03TJw2&#x2B;1htrxwrpcNLO0O7y17YjcjeysBjI5FcZpPhe91fWNLvLDR5JljsvDs8l60W1PLgDvLtYj5ztKDC&#x2B;uOoONT4X&#x2B;BbzXNLuG8Q&#x2B;dNpV2IroafPafY5ILsSMx2OpMmF3EfN16jgikBFfNqHia6e31OzS51Jm8OC9t7Yeaq&#x2B;XPLLIp25AABBPOOeO1bPgf4aanpGraZrlwLbSWXTBZ3Fi1urXMOyeeRBFKGIQ4mGcA/dxXpVvHDZwiK1hWBAgTEf3ivypyepO0YGT2NSruk3MTwoyzcY&#x2B;tK4GJ4b8F6P4VsrC1sbRWksbcWsVzP&#x2B;&#x2B;kVAeBk8qAzFuB2rebc7At8pbp82c44wPXHSuV1v4haLpEggidtUu2&#x2B;5b2Sbzn3fGB&#x2B;tQ2Ol&#x2B;PfHsY8ryvDWmv8AfYud7r0&#x2B;ZiM5&#x2B;gFMDb1jxRpXhzB1O/jtm/hRQXkJ9Nq5IrCg8SeKfGEyReGdEa0t84N7qHzNj1Rfuj8zXd&#x2B;EPgXoXh11urpf7VvevnXHIB9s16JFElrD5cISFP7iqVH6UCueTaP8Bbe6mW78V6hc67dZ3BWkOxD6YIr0/TdGsdHgEVlaQ20eMfu1wf0q7u9GAHpUckn&#x2B;2KVzMGKquAnH1J/nUTMMfcpGm/2/0qJpPRqRQrMMfcNRhgufkpGZv74H4U0njl&#x2B;aBhvH92l80gcLxUX/AAOlz8v36AFMpJ6Um4&#x2B;n60zn&#x2B;9TWbnrQBJ83p&#x2B;oo3svbn61Dkf3qXcPX9KAJ47h15xVuG&#x2B;as3cPX9KVZMfxYoA3odQfj/GrsOpvxkcfWuXWfHcmp47occmgDr49QyByBVmO&#x2B;LdP51ycN4u0cmrcN4OuTQB2nmf8ATT86jaT5j&#x2B;8P4VW84jjywfqKXzh3TFBBNuz/AMtGpjMN3&#x2B;tYVE0wz92mNIM/dNAE&#x2B;5f7&#x2B;frTGcbuHqEyf7FHmL3TmgCTzP8AbpDKB/y0YVEzjP3TSFiRwKCib7SF/izVTWLddY0u5shKsfnKBubpkHihmbpiomYqQdiseo3DigZ5xrejyaGwF3NAEZtiSeaqhjjPAzmstuxyDnmm/Fa31rVofJuIkNqh3I9unzg&#x2B;5P8ASvIE8S&#x2B;IfCtxlHN7aZx5VwvIHsayb1LsewFtp/p3pOK4nQ/irpeoFYrzzdMujwBNjYf&#x2B;Bf4110dwkigxuGU8hgcipexS3OA&#x2B;I3y&#x2B;IoD2&#x2B;xoP/H5P8RXLt9w47Z/9BrqPiN/yGLVsHm3APHo7EfzrlEcqnPXBJ/Kvy3HK2Mm/M/QsL/u0fQ900UltE04nr9kh/wDRYqveY81qk0OTdoum4/59If8A0AVBdZ81s9a/UqH8OPofn9X45HD/ABAvJPDOoeH/ABX5ck2n6XLLb6mkSlnWznUb5FA5JV4ojgAk54Bwa8Dtbia60W4lnmkuLh9FJd5CWYsdCUk49Tgn6n3r6s3FcnCkdCCu4MMj5SD14zWSPD2jpctcppdk1wy7GkaEZxsEfzc/3Bt6dK6DI8u8H/DI614k1a&#x2B;1q2KaO15M0du5AMskep3cq7gOdoBjPPXNexyiO6VxcJG8cqkNGyjYB3BX9B6UjM0jFiSxY5DEct7iqGsa/pXhyNJNSvorMP8AdVzukf2VOp/AU9QNKPiJI4lKwrtwsZ&#x2B;VcD5RweOKS5uY7e3M93cww28f/LSWQIvA7sxx&#x2B;tcB/wAJ7rPiWY23hbQJi4yq3d9Hkjnqq5GPxrotH&#x2B;Ad94gnhv8AxpqM19cKPlhJDmMHsAflUfnRqK6Mu7&#x2B;KdlPKbXQLS4124ZvmZQYoAenJxub8ODVyz&#x2B;GPivx0ySeIdUbSrDO5LOyAj49Djk/jXsGg&#x2B;EdL8NQrHpunQ2qqMbsAsffNba7&#x2B;uAf97rRqTc5Dwn8L/DvhGMNZ2CtOxw1w4G7612MaxKcBGIXjB6fl0pCz57D6UySSbb8hUfiKNRkzEL1yajaRc9KY00g4JGaiaST8akCR5AexqCRk/uk03zJKYzN3NBAb1H8HFNMg7LSNu7GmbZPWgBxcf3ajZ13Hiht69SKbvf2oKDzB/cJo8wf3aTc/t&#x2B;dNy3dgKBjuDzimlvak3HOA1Id/rQAu9e680oORkDim7j3PNGGbkNgUAP8AwpNzdlpuG/v0nzf36AH7j3FOVyO1R/N/epfqaALKTH0qdLl14C8fWs8detSqx9aAPQmkkzSb39M/iKhKg/xUm0f3qBEjSSZ7D8abmQ81G3B&#x2B;9R&#x2B;NAyT5/Wjc/wDeqPYDzvxS7QP4qAH7n/vUbn/vUzaP71G0etADvmPOaDnGKZ5Y/v4pdoH8VAFe8s/tUe1gGBHTiuB8R/D23vlfCKrHvxXouBu5fiq9xbo0eC2T9KNBnzN4o&#x2B;FNzGsmII54wc445/OuNgt9f8JzZ0&#x2B;7miXP/HvLIWjPtyOPwr6yvNLWRThgB7iuR1zwXaXzN5gBb&#x2B;8orOUS4yPnfxB4zkvmtpNStWsp4gUaSJ98bZ6Y4yPxxVaO8SeENG6yAqclCD29RXoviX4VvIkhtpVZD1jkGQa8uvvAd3o8zyW3m6c3cRHfG3Xt2/Cvkcdlntajqx3Z9Vg8eoU1TnsfQPhy5VtD0v5lJ&#x2B;yxdx/cFNvGJmb068VwHgLx8NPsbbTNWZLR4Ywguoi3lP8A7ykcenBrY1vx9ptnhLMHVLx2wLW1O4fUkDA9eK&#x2B;po3UIp9j5io05to6FVZmK7Wz1xjNc9r3jjRvDsyx3NwLi66La2uJpM&#x2B;hzwn4kVn2ngzxz8Q5ALy4/sHSmOfJhBQFc9Gb7x/IV3XhP4J&#x2B;GvCzK7A3845LTYWPOeuBn9a6TE83tdQ8deO2aLQtPTQrVjhpnwZWX3dsAf8BzXX&#x2B;Ev2f7CxkF3rVy2qXzHc25yQD/ALxGfyxXqixRwx7Yz8i8BY1AA/Kn7hgEce1BNyOx0m30y3EVrFHbIvAWFQP1q4uR/Eo&#x2B;hzVbcD1PNG5PWgktMxH8dRtNg/fqBpIx2Yn2NM8xPQ/jQBa8wNyXqN8bifMqvuQ80FkxjFAEuR/fpjHn79R7l9KaWHpQA9sbvv0xhz96o2Zdx4NG5aCh3H9&#x2B;k3D&#x2B;/TCy&#x2B;lNZhmgkeyhud9RcLxuzQzD0pnH92oKH7lo3J61EVHpShUxytUMe0ijoaAxbnNJ8v92j5fSmAHHc0mV96RmAP3c0n4YoAXK0vy&#x2B;9N&#x2B;XuuTTl6cDAoAcGAGM04MPWmgn&#x2B;7S8/3aAHhhinqwxTFz/dp6q39w/lQB3fH09qTcv96k3D0zRuTutAC/Ke/wClJx60bx2HFG/2oAX5e65pfl9KA3tRuH93NACZX0peO2cUox6UbwvGKAG8dwTRlf7pp&#x2B;4Yz2&#x2B;lG8HoKAG/J9KawVvp9KlH0/SnLHu/hzQBQmiQkjHFULi2QsRt4&#x2B;ldALMuc7eKeNNGeUqB/M4W809GLYTP4VlzeE0vhtMG9T/CQMCvUP7NjXny8/hTltlUZWPHtip5Ex87R5BL8FdMv23TIFB6rgYrU0f4c6P4W/48tPhWQ9ZdgDV6S0fzElf0qGVAcgx5q0uUyuzjpk6llc&#x2B;wJ/kKZu/2BXTz26c/u/0rOuLUbiQlUBkeYvdKPMUj7tWZonXP7viq7KV6rigBm8f3ab5i&#x2B;lOZ/l5FM8zb/DQAeYO1IXyOlNZtxzim&#x2B;YV4AoAeJMcYpDIPSk3Z6ikLN26UALuprSbe1Lub0zTHY9xQUIZN3OKTOaVWOOlIWP8AdoGNZgtN849hmnMzfQ0z56gBfMJ/hqNmO4/LTiz&#x2B;lNLNQAm4&#x2B;lL5ntSbnpy7zQAvmH0o3n0pjb9xpRv9aoBS3tSbvalw3cZNGxj2/WmAZY9OlOAk9aVYyO361II2J4/nQBGokzUoV2FPWGTNTLDJ60ARRxvU6xyerfnTlgfPWp44H9aAOo3H0oyfSnc&#x2B;lG0&#x2B;9ADcn&#x2B;7Sbvan7T709VP93NAEY&#x2B;lHPpVgRt/dpyRH&#x2B;7QBAu7ptNLtP90/lV5YW9KlWN/7tAFGOMsB8vFSrBj&#x2B;H9KvrG3pUyq3TH6UAUo4eB8lWY7f/Yq1HuHGKnUHqcUAV44to&#x2B;7gfSpNv&#x2B;xmpufal/edsYoIK7N224/CoJM&#x2B;n6VbbfuNRPv59aAKEm7nioH3/wB2r8iyelQPv9KAM&#x2B;VWI6VVkjOOn6VoyRyNzVeSORe1BJkzRtyNtUprYtnj9K3GRz2qtJDJzxQUc9PbsvRCRVaRZPSuikhkx1xVSS1ZuvWgDC/eelMYyA5xWlNaurEAcVWktJm5H86AKu5xRub&#x2B;7n8aka1lz1/WmtA469aAGbn&#x2B;lMZn3VIY5PTIphVvT9aAGbn9aX5z3pdpo8lj/wDroKGlZPWk2t360MrKcUbTQMa24Hg0wqTyakMZo8k1AEe1&#x2B;x4pVR&#x2B;uM/jT/JNPWM7etUBH5b/SnLG2Omak8ljT1hfb97FMCHy29KVYGJz/AFqbyX/vU5YW&#x2B;v40AR&#x2B;S3&#x2B;TT0t36j&#x2B;dT&#x2B;Qx/ixT44fVuaAI1hcdev1qVYjUn2Yt0bIqaK2wBk80AMjtyasR25p6Q&#x2B;9TpGPWgVzYbrTl7UUUDHrU0dFFAEv8ADT46KKALK9KkjoooIJl&#x2B;9Tx96iigCVfvUN940UUAC9KWiigCNvvGkoooAa33arS9TRRQBXeon/1dFFAFVqrS96KKAIG&#x2B;7VSb7xoooArvVWb7xoooArSdahb7tFFADP4RULfeNFFADG603&#x2B;KiigBjfeNKvSiigBrdaKKKAJF&#x2B;6KevSiigoWnj7ooooGKvSnLRRQBIPvVMnSiigCxH2qT&#x2B;KiigglWp17UUUAf/2Q==" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="data:image/jpeg; base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4SjARXhpZgAATU0AKgAAAAgABgALAAIAAAAmAAAIYgESAAMAAAABAAEAAAExAAIAAAAmAAAIiAEyAAIAAAAUAAAIrodpAAQAAAABAAAIwuocAAcAAAgMAAAAVgAAEUYc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFdpbmRvd3MgUGhvdG8gRWRpdG9yIDEwLjAuMTAwMTEuMTYzODQAV2luZG93cyBQaG90byBFZGl0b3IgMTAuMC4xMDAxMS4xNjM4NAAyMDIyOjA5OjE0IDEyOjU2OjM4AAAGkAMAAgAAABQAABEckAQAAgAAABQAABEwkpEAAgAAAAMwMAAAkpIAAgAAAAMwMAAAoAEAAwAAAAEAAQAA6hwABwAACAwAAAkQAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMjowOTowNyAxMTozMzowMAAyMDIyOjA5OjA3IDExOjMzOjAwAAAAAAYBAwADAAAAAQAGAAABGgAFAAAAAQAAEZQBGwAFAAAAAQAAEZwBKAADAAAAAQACAAACAQAEAAAAAQAAEaQCAgAEAAAAAQAAFxQAAAAAAAAAYAAAAAEAAABgAAAAAf/Y/9sAQwAIBgYHBgUIBwcHCQkICgwUDQwLCwwZEhMPFB0aHx4dGhwcICQuJyAiLCMcHCg3KSwwMTQ0NB8nOT04MjwuMzQy/9sAQwEJCQkMCwwYDQ0YMiEcITIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIy/8AAEQgBAAC6AwEhAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5&#x2B;v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5&#x2B;jp6vLz9PX29/j5&#x2B;v/aAAwDAQACEQMRAD8A6alxUALiigAooAKKADFGKAEIpKACkxQAYpaACigBaWgBKWgAooAKKAFooAKKADFFMAxRSASigBKTFMBcE9jS&#x2B;W56I35UAPEEx6ROf&#x2B;A0nlSDqjD8KQDcUUAFFABRQAtFAC8UcUAOHlkf6wBvRhgUwmRTxHA49pDTGILhV&#x2B;/aE/7sv/1qmF3YhS0kDoFBJJk4FMTKKeK/DHnBZrlY48Z8wPuH0wOafJ4y8GRji9Mh9Fib/CqSIdRIifx14QQZBmf/AHUpLXx94auruK1gsrkySNtVmUY/nQ0kriU7uxpf8JTpyj5LPP8AvD/69Rv4sg/gs4/xWvOeYQWx6Cwchn/CXHtaqPoB/hSv4snCKUQru&#x2B;nH6VDzC60RSweurK7&#x2B;Kr1wQSeeOtZo1OVCdhbn&#x2B;85IrJ4&#x2B;b2RosHFbmhYXD3UBeQAENt478CrVejSk5QUmcFSKjJpBRWhAUUAFLQAYoxQBVnbZubaTgZwOpqn/AGhFuQGOX5lLcJnAHqBzVANm1WytrNLu5lMELttBlQqc&#x2B;4IyOlNe9tL/AEy5ktLmGdBGwJjcNg46HHSgT2PHE6CphWhxscK0/D//ACHrL/rqKmfwsun8SO2B4pa&#x2B;We59SKDUr/6qL6H&#x2B;dUtmS90MpKlDZt6SP9DPu5P8qvV7&#x2B;H/hRPGr/wARhRWxkFFABRQAtFAFS6ClZN4yu05FYAWKUQOqsVa3kK5JOPc7flxVgQXMzL4ThZLzycMFLRgncOflyASPqPSnaHPZXGjXos7SS3ZQfN8wli7Eddx5NAnseYryBUgqzkHVqeHv&#x2B;Q/Z/wDXQVM/hZVP40dsOlFfLdT6kWpn/wBXF/un&#x2B;Zq18LJe5HRUobNfQpjNp5YxSRYkIw4wT71p19BRVqaR4tZ3mworQzCigBKWgApaAK1wPvfSuft/kW3OSw8mQdP/ANVWA1/NHhyH5pwiviUwZ37OemefSka41ZfD8LWtr9pLeYrG5bY4TcQhPuVxQJnlsO4qCQBxxUwFWcjHYrU8PD/ifWf/AF0FTP4WVT&#x2B;NHa4pcV8sfUrYAOalk&#x2B;5F/un&#x2B;Zq1syXuhlGKSGbmlf8ef/AjV2veofw0eNW/iMKK1MgooASloAWigCvMMsfpWQsTW91aIxHzFhg4Y&#x2B;vUmrAXXoTNpuAu5VkVmRZPLLAdQG7GoNCtBFp00peXdMWPlST&#x2B;YUUFtoznrjr9KAZ5REP3SH2qYVZxDsVqeHx/xPbP/AK6ClP4WXT&#x2B;NHa0V8qfU9BRUzqzJBtUn5D0H&#x2B;01axi2tDOTSauKtpcN0gk/FcVMul3bf8swv1YVrDC1JdCJYiEepo6Zs&#x2B;xKY5opV3H5423Dr61cr2KcXGCTPKqSUpNoKKsgKSgBKWgBaKAIZfv8A4VC0cbyqWALryvPIqwKOtwmfTGiEcT73RT5sfmKmWA3be&#x2B;Ki0SzihspAlvCkyl4GeFCiyBWbkA9OSfxzQBwVr4N16VFAsCuByXkVf5mtKD4f6zJ99rWIf7chP8gaq5zeybL0Pw5uD/rtSiT/AHIi38yK1dN8C21hdx3LXs0rxnIAUKP60pO6saQp2dzbXRrVepkb6t/hUq6ZZr0hB&#x2B;pJrjhg6aO6WJmydLaBPuwxj6KKkAAGABxXTGnGOyMXOT3FoqiCCOGK3jEUMaRxjoqKAB&#x2B;Ap1SwCikAUUANooAWigCKUZP1FZp8557HhQwL7iRngdqsDQOACScAdTWSNJTUNOjhk1K5OyQsJbabYfoT6c0AaGk6RDpSyeXcXUxkIJa4l3nj0rToAWkoAMUYpgFLQAUUARN940lQwEpaQBSUAMpc0ALmjNAEb8ms7aFlhV5W&#x2B;V22lQfyPtVgXpF3xOu0HKkYboaraXDJDAySwCJgx5BHzDPHT0GB&#x2B;FAzULrHGXY4VRkn2qlHrVlPpUmpQyGS3QEkgcnFAiWw1KG/02O&#x2B;H7uJxn5yBj61U1TWE06808PJGtrOX8yQnIAC5GPxpgMl1OCbUdPeC/8A3EiO2xVyJAB3PbFM/wCEmiNvNMtrOqoAY2deJATjI/KgDZt5fPto5sbd6hsemaloAMUmKAIX&#x2B;&#x2B;aTNQwEozSAXNJmgCPNGaAFzS0wGtzUflqWVucqeOaoDN8QXHk2MaKzh5JowoXq3zrkenf1rQsZLiW1RrqIxTchlIHY9eCf50DJdRbZpVy3pE38q4jTWaHR30gH5rmSFkH&#x2B;w3J/9BpoRa0pY7xdF0&#x2B;4&#x2B;a1ImcxnpIysQAfXA5xUVpNb21xYG6kQWMOpXSQtIcqIwBt/XNAD7e0kuRCYFIjuJ7p4SBwFIwPoDit7RmnvLJLS8054IIIlRjMuCzj&#x2B;77e9MDcQxr&#x2B;6QqNgAKg/dHapKQBSUAV5P9YaZmoAWikAUUARZozQAuaXNNAFJVAZHiI2ws4xeStFbmRSZMFlDBgQGXvkj&#x2B;dbKEMilSCCMgjpQMdeW7XenzW6sFaRCoJ6DNZlv4cjivNPunnzJaQ&#x2B;WVC8Oex/CgTJf&#x2B;Ea01tOispY3ljidnRmchwWOTyuKvJptjHbxQLZw&#x2B;VCpWNWQHaD1xn17&#x2B;tMCyFVVCqoCgYAA6Vm6vN5P2PdnyjcDzPoFY4/T9KAIdLlup9RMt3CIZmtl3oPTzH2HqecZ7027uJJtYtgkji1iZWLxtwXJZdp9jxQBbXV4pFkMa/cheQ5PTa2MEVk6d4mk1K&#x2B;sIY48q6n7QyRnaHxkAMfTH60Abkv&#x2B;tamVAwzS5pCDNGaAK&#x2B;aXPvQA7dS5poBw5paoCrqVnJfafLbxOqSMVKswyAVYN/Sri5AGeT3oGWV&#x2B;6KWgQZpaACoZ7aO6QJKMgMGH1FAD1iRHZ1UBmABPrjpXOXXhUNDO7319cIMtHbCXYuc5AougtcbaaR/ZcM/2WSztZpEVSxzJuHfPNadteWen2kdvBuYIuDhcZPrXPUxVOGhvDDzkS&#x2B;b5wEuMbucUua0TurmTVnYM0ZpkhmjNAFbzF9RR5i&#x2B;opjF8xfWl81fWgCaFgwOKlxVCK2oMyWEzISrADBH1FZuh6o17dtCZS4WPeQw5ByBzXHOc1XSWx1QjF0m3udIv3RS12HMFNeWOP78ir9TUynGO41FvYqyapap/wAtCx/2RVZ9aH/LOEn/AHjXFVx0Y6R1OmnhJPVlaTVrp/usqD2FZlzqqhgkt3gtkBi3AI7E&#x2B;tcTrVKzsdcaUKauV47v7XbOYGJdMAsBwxI7VI0Mks1uwYqsLEt/tcVnpF6l7rQ3YpCIUHoop/mt7V7lNe6jyZ/ExPNajzWq7Eh5retHmN60WEUtwpd1MYu6nBqALlkch/wq3igRV1If8S6b6D&#x2B;Yrn/C7OdRlElv5ZWAKGIILYxnr1wc1w1f46Oun/BZt3GuJAJAsEjlMggdSR6Csk&#x2B;K55re5lS3aHyVyRIuCTjPqaiWLcr8pccOl8RUi127ubCa6muI5BGpbZAx4wM4PvVP&#x2B;1boz7XgjVRIIyC5J&#x2B;Zdw9vrXM4ubfMzdNQSsiXSJ57lJJppCytt2ggDHHPHpWlXNVilNpG1NtxuxR1qGDw6JHWX7GWc/M5ccMT3yf6VpRjN6RIqygviNiLRZcDe6IPRRmrkekW6ffLOfc4rupYG2szkniukSpNiOaRFGFViAPSo99eglZWOO9xN1G6mAbqN1AinvpfMoGL5lOElAGjprbhJ&#x2B;H9av0CKuo/8eE30H8653wpM8t1cBpC4UEDLBsdO4A/XmuGsl7ZHXSf7pkk/FxN/vt/OsyBLkRP/AKOrNMzM3mcAegIrzItXdzvs7Kw&#x2B;HT5JI7rztokuhtIiyQo27eKvJ4fkm3MIXyzBgznABC7QfyraCnKXuoyk4xWpa0vwobJWLzRBmAB8uPaOPb1962I9JtU5YM5/2j/hXdHCJy5pnK8S0uWJcjhih/1cap/ujFPrrjCMVZHNKTluLRVEnO3UgF5OM/8ALRv51D5w9aAE84eo/Ojzh6/rQAecP7w/Ojzl9f1oAqbZKXbJ7VIxdkv94UeVL/eH5UwNbR0dRLuIPTHFalMRT1RPM0u5TONyEZ9KxPDFtJa3DpJL5gKZU5z6ZrhrSXtoo66S/dNmt/Y6vK7ySnDMSAo96tR6XaR/wFj/ALRop4KEXeQp4qTVkWkSOMfIqrjrgYpVkRjhXUnGcA9q7VFJWRzOTe46imIWigBpdVK5ONxwPekWZHbbnDZIwe&#x2B;KYHMXmkLLfXEm6T5pGPDn1qH&#x2B;w09X/wC&#x2B;zSAX&#x2B;w4/9v8A76NOGiJ6N/30aAHjRI/Rvzpf7Fj9D&#x2B;dAFoWDe9OGnt70AOGnn0qQaeaQFq3t/I3e9TUwK1//AMeE3&#x2B;7WB4WLmaXeCMSSgc543dvbt&#x2B;FcVZfvonXS/hM6W6nNtZTTqu9o0LBc9a5671&#x2B;aQxwjZbkhHaRTu2&#x2B;oP512nIRpHq97KNyyxxzHMhXgZKrnPtjNaui6bPYu0kgWNXhjUxht3zKoGc/h0pgbFLSAKo33nzN5EEZPy5Z9&#x2B;AM8Afz/ACoAjjtb2fy5LidUZDlUROPxNT2mnQ2rGQZeQ/xucketMRbNqGYtjqc0fZB6UguL9kHpSi0HpTAX7IPSl&#x2B;yD0oAcLUelO&#x2B;yj0oAcLYelO&#x2B;zD0oAgu4vLRT6mqlICvf8A/HjL9KwvD8UUWoyqjoznczYxkAnOD&#x2B;Oa4az/AH8TspfwpHTOiSRsjqCrDBB7iq8NvYWaHyY4YwowxUDP413nINfVLZeEbzCGCkL2JyByeOoxUMOpXF3dbbeFfISUI78tkc5weAOnv1oA1KKQC0mBnOBk0CFopgaccW6NT6gU/wAmgQvk&#x2B;1L5NAB5PtS&#x2B;SKAHeVS&#x2B;UKADysU4RCgChqiBYEP&#x2B;1/SsqkMgvebKYf7NYWhyRnVJEU/vFHz8Yznp/wDrrgrX9vE7KX8GR0NzEZ7aSIHBdSuazotCjzmeUyZXBUdP84rvOQvx2NtGG/dBy3Uv8xP51ZyaACigQuaM0wCl7UAb8EY8iP8A3RUnligQbKXZQAbBRsFAC7RRtFAC4pcUAZutDFtH/v8A9DWJSGiC8/48pv8AcNY&#x2B;k/8AIQX3U1wV/wCPA7aP8GR0NFd5xBS0DCjNAgzS0wDNLQB0cH/HvH/uipKBDc0ZoAXNLmgBuaM0ALupc0AZutHNrH/v/wBDWLSGiG7/AOPOb/cP8qxdKP8AxMI/of5GvPxH8eB20f4Mjoc0Zr0DiClzQAUUAFLTAKXNAHRRNiGMf7IpcmgQUUAKKWgApaACloAztZ/49U/3/wClYtIaIbr/AI9Jv&#x2B;ubfyrE0v8A5CMf0b&#x2B;Rrz8R/HgdtD&#x2B;DI6DNGa9A4gzS5pgGaKADNGaAIJrxIljIIO9toNTI8hYhowBkjIP5fnQB00f&#x2B;qT/dFOoEHNGKAHgUYoAKKAFx7UuKAM7WP&#x2B;PRf9&#x2B;sOhjRFc/8es3/AFzb&#x2B;VYel/8AIRi/H&#x2B;RrzsT/ABoHbQ/hSOgNNzXonEG6jdQAuaM0ALuqtctNIfIgYxuwyZCmQo5/WgBYbNUMe8&#x2B;Z5a4Ut1J7k1cHSgDpI/8AVr9BTqBCgU7FABRQAlLQAtLzQBn6x/x5f8CFYNA0RXP/AB6zf7jfyrD0w/8AExi/H&#x2B;Rrz8T/ABoHZQ/hSN5jzTc16BxjS3HJx9ajjuYZJGjSRWdeSAelMCTNG40ALupQ1IB4ang8UAdOn&#x2B;rX6U8LmgQ7FGDQAuKTFAgoxQAtLQBQ1gf6Af8AeFc9mkUiK4/49pv9xv5VhaZ/yEYvx/ka4MT/ABoHZQ/hSN6Q/NWU2oSySSRwouVUHHUjnnP4Zr0DjIBZ3l2We5laIOrDaDzz04HGQO9XrazhtcFNxYLtyT24/wAKYE0k8UUbPJIqqvUk9Kjt7uO5LiLJCYyxHBz6UATZo3UgFD4pwuFDBCw3N0GeTQB2EDq8S8jOB0NT0CCigQmaTNADcinZoAXilyKAKGsf8g9v94fzrnKRSI7g/wCjS/7h/lWFpn/IQi/H&#x2B;RrgxP8AFgdlD&#x2B;HI3ZT81VZJ7a0UK7xQjsvAr0DjILvUEto4ZFXzUkcLlTwAT1qkL27vWheGJooVkBYk/eXBB56Y6e9AENxZwjy5bq6LOdp&#x2B;X5ycDnk8kHmteyaF7VJII9iOMgEYP40AT5qA3CmQxxBppf7kYyfx7D8aALMWnXc3Nw4t0/uR/M5&#x2B;rdB&#x2B;FaEFpBajEUYBPVjksfqaBFlZGQ5UkfSrMd/IvDHNAFtL1WHNTCdTQA7ePWl3CgQ3PvSbqADzKXf70AUdWbNg/Pcfzrns0ikRzH9zJ/un&#x2B;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&#x2B;VQNpEMn&#x2B;tUMPTFK1x3sImmW9uD5ESx564XrTGiZf8A9VMkjOe/8qaT70AJmjNADTnNIaBif56U386QC8&#x2B;9HPvTAADTwp96AHhPrT9n1oA0cUYJoAcENPERPrQBIIvrUyxigB2KYwoEQsv1qB09jQBA8Oexqs8JHrQBEUYdjTcH3oATmkxQMTFGKQC7aXb7UwHBPapAntQBKqVJsFAH/9n/4THkaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLwA8P3hwYWNrZXQgYmVnaW49J&#x2B;&#x2B;7vycgaWQ9J1c1TTBNcENlaGlIenJlU3pOVGN6a2M5ZCc/Pg0KPHg6eG1wbWV0YSB4bWxuczp4PSJhZG9iZTpuczptZXRhLyI&#x2B;PHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI&#x2B;PHhtcDpDcmVhdG9yVG9vbD5XaW5kb3dzIFBob3RvIEVkaXRvciAxMC4wLjEwMDExLjE2Mzg0PC94bXA6Q3JlYXRvclRvb2w&#x2B;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&#x2B;Tl5ufo6erx8vP09fb3&#x2B;Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3&#x2B;Pn6/9oADAMBAAIRAxEAPwD2WlxRtNPVTiucBm009VOKNppelACbTRtNOowaAG7TS9KXaaNpoAKKNpo2mgAwaNppQvvS7fegBu00bTTtvvRt96AE20m007b70bfegCNutG0mpNopCp7UAM2mjaadtNFADdpprA9KkpNpNAEW33o2&#x2B;9OZTnpSbT6UAJt96aVNP2mk2&#x2B;&#x2B;KAG7TSFTT9vvTSpoAbtNG0&#x2B;lOpQPegBApo2mnbfejb70AN2mlC&#x2B;9Lt96Np9aADb70Uu00bTQAYo2mnCigBu009VOKSnL0oATaaTpT6TaTQA2il2mjaaADaTRtNOCmigBu00bTTqKAGU5elJtNOCmgAoo2mjaaADBpQvvQF96Xb70AG33o2&#x2B;9FFABt96NvvRRQAbfejb70UUAJx60Y96dtpdp9M0ANopdp9KMVQBimnGeaevSg47kfnUgMx70hU0/cP7y/mKTGec5&#x2B;lADdpo2mnbfejafc0AN2mkKmnEDucfjSfQE/hQA3aaaynNPZgvUj3GeaNpznBoAj2mk2n1qTaf7rfkaY/wAp5GPrQAm0UUvv29aTcv8AeX86ADHvRRuUY5U/Q0Zycd6ACnqpK03BPRWP0UmnrFKygiOT/vg/yoANppOlSLa3LZItp2HtEx/pT/sN6Otlc/jAw/pQBBS7SamFjdswH2S4yf8Api3&#x2B;FMeN4WKSRtGw5KspBH4UAM2mnBTRyeRShfegBNpop233ppU0AFFG00bTQAoHvSFTShfel2&#x2B;9ADdpo2mnbfejb70ANwaUL70Bfel2&#x2B;9ABt96NvvRt96KAF2n60bTSg0ZFACbTRtNLkUZFACEbVLN8q4zubgfn3pYY3upNsUbzP/djQsf0FS291DYzJcS24udhyF3bQfqcf1rQ/tTStY3K91rOmhunk3rgD2HNXygV10HVGb5dLvv/AAFk/wAKevhrV26aXen/ALd3/wAKoXHgexunJi8X65huiy6lKP5NWVN8Or63O608Sam4z94avID/AOPGps&#x2B;xVkdK3hnWE5bTLpB/tRMP51H/AGDqbNgWcn4sq/zNc3/YPiLTn3R&#x2B;ItayP&#x2B;nsTD9TzU66l4xt1BTxJekeksMZP/oJ/nVfILI6RfC&#x2B;rFRiy/8AIqf409fCesnlbHaD/F5qf/FVz1v408aWrc61DPj&#x2B;G4tkP8lH861Lf4leJmaNLj7C&#x2B;44LRwbR&#x2B;RY1Vokmj/whmr8H7L1/i6/yNPk8G6jCpaVo4jgn5wy9PQEc9axfEnxstvCupR2N/wCJdDsL2SFZxFffZYzsYsoOZZlPVWHSuVuv2pmsfEVnAvizwlP4fKA3VxDqdnHPC&#x2B;4/dUSsDwB0zV8iI9pBaNnotv4OvLpisd7ZkA4&#x2B;WQn&#x2B;Qqf/AIV5fZ&#x2B;a4jPcbY5G/wDZayrj9ub4TwkRv4qtZp1QO7RRTSKx6E7o4iOvpWVcf8FBPhJFJsXVpJhn5vJsbzj8TCM/hV&#x2B;yRk8RC&#x2B;51y/Du7kxtuGAIzxbSf/E09fhndkjdPI3t9nI/nivLYf8Ago54HkmvA2makfLmAglW23&#x2B;am0c4ZkI9OfSoZP8AgpH4Qi3CLRNbY9sWEIH63Z/lT9miPrEO567H8MbxiAPPYdlRVU/qatJ8I7puXjuV9nK5/Q189Xv/AAUo05lYW/h3V3H8PmLbx/8As7Vz11/wUo1naVtfC90Iv4Q&#x2B;oxJ&#x2B;gtyB&#x2B;dHs0L6zHufVy/CU/KjB37lWudn9KuW/wfRsb9PVh6m8LH9BXz/8Of2t9Z&#x2B;JPg7WtbuLO90&#x2B;TTruO2FtHqQ2uGUHOViHr6VpS/Ha&#x2B;m3FoLxye0mpOR&#x2B;i14uKzPC4Op7Oo9fQ9nDYKvi6ftKa09T3&#x2B;P4P2GwGSyijPcvLIR/Kh/hbo1spLxWZ9dsjDH/fQFfN83xjvJGJOnIx/wCml1I365qrN8WL2bONL04Z/wCehmc/mJB/KuCXEWB6X&#x2B;47o5Liutj6Q/4QXwnbsTPLao3fMisf0cU7&#x2B;xfAdv8AfurXj/a/pk/zr5fb4jaow&#x2B;W306H2jikP/oUh/lTV&#x2B;ImtqvE1sv8A26of5rWD4lwn8rNv7DxHdH1A/wDwglv/AKt43x3TBH5bSf1pV8ReELNS0cbSKASAEI6f8Bx3r5jX4leIVX5bu3A/2bKD&#x2B;qZrT0P4g6/dLrHmXqkppk8ibbeFCrjbhgVT&#x2B;tVT4iw85WjFi/sWrBXckfRn/CfeF7R8f2K0&#x2B;Oxk2/0pknxQ0bra&#x2B;GI0HbdMSf5V8tN448RzqpfXtRPHa5dR&#x2B;hH8qqN4h1mRj5ms6kwPb7bL/wDFf1rgfE8P&#x2B;fZ0rIZ2&#x2B;NH1b/wtgwrui8PxxqerxqWJHp0rx/U/F/xSGsXbWNhJd6W8jGGSOSRJCvXBATbxnHB7V5bJqV25Ja8upGPUtO5P5ljVaW6mbJMshP8AtSHP&#x2B;cVi&#x2B;Jm9qf4m0chtvM9hsvGmtNbyf29pniWNgMyCxkW58o9tyDLLkYPzAZzkcYqOHXLPWSxkvrq3dFbYurW32YvjJ4Y8ZxnrXjcjNIx3NlCefU/ljP41XmjLKSDvPOA67uQPcgDr2op8QVKk1Hk3FUyWEIt82x7njk8ng45bd0460bfenzLtldeoBIH07Uyvtk&#x2B;ZXPk5LlbQbfejb70uKNppkibfejb70tJQAUUuKNpoASjHvS7TRQAm33oopcUAGKNppwooAbtNG006l2k0AM2mjaaftNJ0oAr3efIPpWWT0Hbgfn/&#x2B;qtW8UtCaylzuGOqkYOPU4x/OtVsAzBZd3T13Zo55XcQRz1rkrP4iSXGqJYt4V14br5rBL1bHdafLIyb/ADQePlUHnBH40zxB8T7Twr4pstD1TRdVt3vbjyLK5AglS4UsFDIiSmQLnGSVAByM8UwOyWSYAlXfbznax4xg/wBaGnm3HMj59GY5rhdS&#x2B;MvhnS/F1t4alOoy3s16mn&#x2B;dDp0zW4lcAqPM27SRuAOGOMc4xXVa5rmneFtNm1HWLyHTbGIqstxcHy40ZmAHOcYLMB170AXS7tyTz70fNtJ5J/lWLpXjzwvr0wj03xJpF/I3AS2voZG/IMTW9Ipjzu6DrzwOnX81oA&#x2B;Qf2zF3fEjQnJDN/YiKCw6EXE5zn6H0rwtI044XI7sM17v&#x2B;2Uu34h6Fng/2OBz/wBd5v8AEV4SvX8a6InhVv4jLMY7n5lJ5UcduB0qcfd5Zt3fBzVaNjxU61qchJj/AGuaeqnaOc&#x2B;9MpdxHFAD9pqRSFUA9ajVuKXIoKPov9nRgPhd4v5&#x2B;X&#x2B;04M/8Afta7rPJ571wn7Oqj/hUvixv72tQqP&#x2B;/KGu44bJr8j4k/31&#x2B;h&#x2B;vcO/wC5ocaSk4o4r5U&#x2B;lFpwI6UzbSrxQBIrADrW14db91rZ650q4H4/LWHkVteHeYNaA/i06ZfzKD/Cu7DfH8jkxHwmYrEDFGT/AJNN4PPrzSfSuJ7nUthd1Ix3Uu75cUlWhjdppyRlnRR99mCj8eB&#x2B;tFT6cvmalar2Mqfzrrw/8SPqjlrfw5fM9ouF/fvjpnio9pqV1Yu2eucUzpX7DD4Ufl0viYCiiirJEIpNpp1FAAKKXaTRtNACUhFO2mk6UANxThQKKACl2k0lOXpQAm00vSlooAKTaTS0YNAEF1xA1Y&#x2B;0Fhk7VPt1PGf0FbN0p8hqyAoLBWOATlq1iSeX/wBqX1n8RBDd6j4mj1u41COGOyhtHbRmsmdQx3rEUBMTknc&#x2B;4NG2ByAa8sXiDQ/ind3Ph3w1FdC5uo21E3d9aSPJFhMyxDeJo8YPy8g4z3rqf&#x2B;Eq8TXHi6KxtdH02TRo70Wt3crqUjXMMZt3l3tF5e1eRwC2SMEd8clfT&#x2B;HPB/xWbVr&#x2B;506zl81mnuLjSpxPLvtyscRuPL8tlzIScMeEUdqsoni1jWoPjZPowttWutKn1KO5XfpA&#x2B;xRItiQXS42Y3s74JL8FDXSfFa38LP8ADnWF8alR4WAiF8QsvaVduBGc534/OuN8U&#x2B;B9a1z4nzQRTeO7OG&#x2B;nhkXVtJ1UxaZHZrbIjiRM/fMqsc4H3q9A&#x2B;JOn6Bq3gvWrXxTM8Ph2aIC7u2mIeMK6lW3AEk7gCST1oA&#x2B;Qb7wD4d&#x2B;Il1NYfDP4Za9dqchNX1q9eG2IH8Q3E8d8Fj&#x2B;HQfS37Pvw11P4UeAv7H1a5trq7lvHvClk7MsQZIxsG76MeK8cX4oX/wAJVY&#x2B;EfiVovxE8MrtA0PXLzybuFQMZSU7QxHbJ4GB2r3n4T/FTT/jD4ZbWdOsrqzWC6&#x2B;yTwXbq2xwgclXXqMEfnQB89ftjKP8AhP8Aw7nbxpAHynI4ncn9CK8J28CveP2yv&#x2B;R38Ouf49LcDtz5rGvB423LW8TwKv8AEZJH8tTrgVCqnjNS7t3NaGBIPvUuf84pFHyjmnDpjNAxV6UtFLtJoA&#x2B;i/wBnYH/hUfif/sORf&#x2B;iErtl&#x2B;6K4v9nX/AJJH4mHf&#x2B;3Ih/wCQErtenFfkXEf&#x2B;&#x2B;v0P17h3/cohRRg0bTXyx9IKB70tIF96WrAX6Vs&#x2B;H8rb61/14MP/AB9Kx1&#x2B;9WzoZ/wBF1rPT7Cw/N0rtwvxv0f5HJX&#x2B;H5mSv3RS0gzgZ&#x2B;tLXG9zrEzS01utKoOKZItWtJU/2rZY&#x2B;Y&#x2B;fHkKMnlgB&#x2B;pFVdprkdQ&#x2B;KS&#x2B;HfiV4e8Pf2Mb1rm7tM3PnbQm&#x2B;bB4CduD1r0sFRlVqxstmjixdRU6UnI&#x2B;oJOJGBGCDimbSaVl2MVyG28ZXpRX62rpWZ&#x2B;Zy1baG7TRtNOopkjdpo2mnUUAJ0paMGigApNpNLRQAyl2k0lOBoATaaXpS0UAFGDRg0oX3oATaaUL70u33o2&#x2B;9AEVyD5DCsYqcn1FbVx/qzWQe579K1iSeMatLoOg/GiS&#x2B;u/E1jp8iX0c01m&#x2B;lzrNLK1isccf2nd5bAAl8Y4346iukt7i&#x2B;X4qmFZNanklnKJ5YZ9L/s/7ICyscNGsvmhztJWTuF2kEp4ikl0rx00zWXiWbSty6hcxWGnRXUE84h8pHBDGRVVVAOFHIP1rH8VajpGifFaTU9W8Q2Ng0Elu39kOlwouF8lgbmQgYadeFX&#x2B;EIFB5BqyjmviLoOieJvjlDBrPh/R7y2vjDbSXP8AaF5HqUshji2SRKsgUhBLtPHSPJr2XxlYaHe&#x2B;E9Wi8QqjeHBbb7tpJGbbAmGJypBYgKO9eafEr&#x2B;2bzxzZy6d490zQZY9RsrSxsrrS4pmeRxklZiAyuQZCVBPG31APY/HPSbvWPhH4zs7GN57yTTJ9kMIJZ/lDFVBJyCFI70AfPfgvWP2dvGHiWz0ZfB99o8l44is7rUZZPJuGIAAAExIyfUDrzX0z4P8Ah/oHw602bS/D2nJpdrJP508fnO4aUqU3AsSeieteB/Ff4rfDfxl8D7aw0E2r&#x2B;IpBZx6Rp0VqYri2vBKhIBZBjjfknjIPrXqf7Qlx8QrLR9Nk&#x2B;HYn/tI32LryLeGQmARtglZQcckcVW&#x2B;5J4r&#x2B;2cCPGXhf5QT9hl/HDnmvAIxxkDKjiuk&#x2B;L2q/EvUtW0qXx3HOt2kMgsvOtbeLCZAJ/dqO7D865ax&#x2B;0N5v2huS2RkYzW8TxsRFc97lzaRwetPQCjacDinovyj1qjkHDnpRtO7mlAK9aeFHXtQMTmnBTSfxHHSnde9AH0Z&#x2B;zqp/4VH4kPf&#x2B;34//AEnSuyXO0Z9K5L9nPH/CovEXf/ifx/8ApOldiq/KPpX5FxH/AL6/Q/XOH/8Ac4jQPenbT9aNtPVTivmT6YZtNG00/aaNpqhMI1H41raSv&#x2B;ha16fYwPzkQfzFZa8VraT/AMgzXn/u20Y/8jLXbhvjfo/yOSv8PzRkgHAo2ml2&#x2B;9Lt964zrE20u33o2&#x2B;9LtP1qhCbferejqg1rS2CK032uEh2RTjDjABxnqSaq7TVrR1La5pY7/a4yP&#x2B;&#x2B;1ruweleHqcmKSdKTfY9kZTuPJbnG4nOfek2mnsPmPNJt96/XFsfmD3G0UFTRtNMQUUbTRtNACge9IaUL70hU0AFFFJmgBtLtJo2k0vSgA6UtFFACge9Lt96QD3pdvvQAUUUUARz8xmsg9D9a2Jv8AVtWPjr6ZrWJJ5X4suvDugfFrTNTvda0ax1jzIkSS81UwT28ThVEYhAw4dkA5PHmE8AVtalDqzeOpHs9anMsL2P2fR4prcwtYyv5dw0sbgvuz5jBhkYYAdaveIjf3HiSCxTSLe40mR7a6vJ7q0Z1kjEoj2pIGXa67i&#x2B;ORhPWuS&#x2B;I1jaW/xZ0q8utYTT/tT2aTB/DtxcfadtznaLyM&#x2B;Wm9kRdpxjOTkAmrKOt1n4WaHrviyPxFdG8F3CLcrBHNshDQzxyhwuDh2EKxluDsPua1vF2tS&#x2B;FPC&#x2B;sa1FbC&#x2B;n0uymvBAG8vztkbZHII2kBuoraYHzHyedxB&#x2B;ueelc38RNAvPFXgHxRothIEv9Q0y4t7fLYXe0bBQx7ZYgfjQB8waL8dvhBpPiIeKLz4U3&#x2B;ja3K32hHhKSplzu3BXdVzzn5VH49T9BfCv43&#x2B;HvjI2rDQoNQt5dNkhadb6GNCTIZMbdrf7B/KvCvE37SWmap8JLj4c3HhHVI/F62K6RFZmCPyI50UIs4O7eACgbgc7s19TaXocGk2sSLaW9vetDGt1LbQKhldUxk49CWP40wPl79tQu3iDwQS/wAptrsYyezwE8Z9xXgGSrbTzjqxr6D/AG2FB1jwOyDANtqHfPe2/qRXz/t9fpXRT&#x2B;E8LEfxGPj/ADqRc7qiXip1U1RyD8etKFHajB/GnKrdxmgobxux3p6qMUvl/NmnhKoZ9Efs7g/8Kh8SY/6D8YH4W8Z/rXabT&#x2B;HauO/Z3G34Q&#x2B;I/&#x2B;xhH5/ZIv8a7PG3A9OK/IeJP99fofrvD3&#x2B;5xG7TTgpopQPevmD6UTaaNppePWge1UiRVU4rW0mNv7D8RN28iFfzmXH9azNpVcHIPvWvpKn/hG/ErYbAS15wcf64/4Gu/Dr3n6HJiPh&#x2B;4xsdx06ijaaEPygZ5AGadn5c/w&#x2B;uK4TqG7TThSMwCgk4B6EnANLHmVtqqzN/dVSTWkISlsiXOMd2FXNDX/iodJ9ftCH/x4f4GiDRdQuGAj0&#x2B;6bPRvJcL&#x2B;eMfrW9oPgzW7bW7K6lsHW3gkWR33rwPm7Zz69q9XCYWt7aEuR2v2OHFYil7KUeZXsehkfMee9G33o2/MwDZAYj9aNvvX6ofmwbfejb70bfejb70CE49aOKQqaNpoAXHvS7fekC&#x2B;9Lt96AGlTSFTT9vvTSpoAQGlplOXpQAtGDRRxQAoX3pdvvScUY96AFooooAZNypA61k4962SoKt9KyO5&#x2B;taxATcyqVXHrhhwWweevsvavPviNBe3HiTRYbW58URw&#x2B;ZayG10&#x2B;1il02cR3W4&#x2B;cSu5XC8g5xgV6F6fnT42dcqp&#x2B;VhkhWP6gGrAbKpWRs/Kc5weorN8QNqEOg6lLo8cc2sJaytZxTEhJZgjFFJ3Lj5sck45rQXDDIOR7frWb4o1iXw34V1vWYYfPm06wuLtIc/faOPcBxn/OfSgD571b4o/tC2tvNJd/DXTxqXktHFd2dr58kTMOoKzOD1z0r1/wb4u8T63441zRdb8OTabp9nZ2NxbapJEy/apJI1aXtjhy4x2xivGNL8FfFzQ/Bdv8AFGz&#x2B;I8&#x2B;oXklgNfn0G4mme0e2aPzWiU79uRGCOEHK9ycn6V0PWI/EWg6Xq1vG6W99bxXkcOCSm9A4HYYBY9qHsB8x/tuR&#x2B;ZqXgFiTjytRU5GP4rQ/yBr582lsE9TzX0P&#x2B;22PLuPALO2zC34LsQAciDBBPXoelfOy3EXyLuyx4Crkk/hW0X7p4eJTc9CZYz61Kqn61o2XhXW9QVTaaJqd2G6fZ7KWTP/fKmuk0f4J/EHWmC2fg/Vuev2uH7KB/3&#x2B;21d0c6pzeyON2ENnHFSKpxxuP0Fet2f7KPxIugPM0e1ss9WutQhOP&#x2B;&#x2B;Cxrf0v9jXxjPIBf6toVlH3aGSadh/wExqP1o5i1RqS6HgxBGMjH1pwz06/Svp&#x2B;2/YlRWBufGmf732bTApP4mX&#x2B;ldDpv7GvhC1YNeaxruoeqrNHCh/AISPzpe0RtHDVOqOJ/Z7U/8Kb8RsASP&#x2B;EkwSAf&#x2B;fKGuw3fNg8N6V6b4X&#x2B;D/hXwfodxo&#x2B;m2EsdhcXP2uYS3TOzy7AmSe/yqK1YPAeg25B/s5ZG7&#x2B;axdfyJx&#x2B;lfDZrk9bHYl1YNWPv8AK8yp4PDqlNO546zKvUgfjTUkEsgSPMjf3VG4/pXutvo2m2pHkafZw46eXbqP5CrmccLlcdNoIH8644cMS&#x2B;3M7JZ8mvdieI2/h/VrgDy9MumU9GMLAfmf8avweA9fnI26fsXu0kqDH4bs16&#x2B;0js2WYn8WP8zQuR04r0IcN0I/FJs45Z5W6RSPMofhfqrx/Nc2kX0dy3/oOK3NJ&#x2B;HTWmm6laXOobjf&#x2B;SrNHH9wIxY/McdcjtXZClr0qWS4OlrynFVzTEVVZs46P4X6buy1xdsM5KmQAc/QVoW/gHQYcE2PmP3Z5Sc10ODRtNdkMrwlPaCOaWNxEt5szIvC&#x2B;j27h49Ksg46PJApb8yM/rWnGxjQKDhR0CrgfkDRtNG011xo0obRX3HPKtUlu394vmNzg498nn8zXks&#x2B;i/FG&#x2B;&#x2B;Okd9/akdt8NrfkWbPFmTNuFb5VBf8A1hb7x/SvWdpqOVsKykcGr06GV5FUr26Y4xijb70UY96wEG33o2&#x2B;9G33o2&#x2B;9ABt96NvvRt96NvvQAbfejb70bfejb70AG33o2&#x2B;9G33o2&#x2B;9AEVOBpgNLQA7IoyKbRQA&#x2B;lA96aDSgj1oAdt96NvvScetHFAC9FOfSshlO4/Wtb1HtWY33j9a1jsBVgvI7i8uLWNZPOgUM77G29jtzjB4IrH1DXr7QPFtnZXqxyaNexTzfbGKQLZtDtKqSSC24vjjpnmoNU1CPS/iH4ds3vZoItbtryP7GoQxzzwLGylvlJ/1ckp9P3XPUA8749h1DWPil4Z03Qrq30/UJNH1Fpbu4h8xIY2utPbhSNrlhE6ccjdk8c1YHpassiq0bB4yBsZSGBXtgjgjHfvRtG07lSRSCGjkGVfIIwfYhmB/Co7Sae4s4JLqD7LctGplgyD5b4G5eOODnpx6VNg0AeQ&#x2B;Kvh/oPh34UyfDuHWtatNNuHkcT2sUk09tZibzZlfYDtj2FYgO44GcGu28WeL/Dnwo8IW2o6g722gW3k2UDW8TTKsZUCIfKCW4A5ArM&#x2B;K3w7vPHtrpv2LyJzZy75LS5kCIxBBSUSGOUgphvkAVW3Ak5zWxd/DfQ9a8Caf4S123TV9Mtbe3i2tI0ZdolCg5Ujrg/4DpQB57q37Q/wQ1xrY6tc22rJAxMYvNEnl2biAcboQBwvrXZ/Bv4qeCfiJcapaeC9Ma0GmrD5si6fFbo&#x2B;/OMY5/hbqB0rKT9lj4Vrhv8AhEl9h/ad4R&#x2B;Qlru/Bfwz8L/D2G5Xwzo8elfagomMcsjs&#x2B;3cRkuSx5buaolxTd7HWCd2XKSNsbkHJ5HbpxQzEodxJHYZI/rikVePl&#x2B;72pdppF&#x2B;gcsOmBSeX704L70u33pCGY28UtBU0bTQAUUbTRtNACbSaTaadtNG01QDdppelLtNG00wDBo2mlC&#x2B;9Lt96AEC&#x2B;9Lt96NvvRt96ADb70bfejb70bfegA2&#x2B;9QzKeam2&#x2B;9QXLFazYFbHvRt96RelLj3rAA2&#x2B;9G33o2&#x2B;9Jx60ALt96NvvScUcUALt96NvvSY96Xb70AG33o2&#x2B;9G33pOPWgCCnA1H9KXjvQBJRmovpS5oAkpVxTVIxRkUAPLClqPIpwYetADhxms5/vH61eZj2qg33jWsQMe/uNOu9es7Ke&#x2B;Sy1a3T7RZblgMrLIHRjEZkbH3CG2ngYz1rI8Ux2f/AAsbwVeXkSsFj1CLzHgVwAVgcElgNqg4J7DIPerXjTw7qOutpU2mXlxa3FlOXZYNSaxE0ZwSjSLFISCUUFcDhqp&#x2B;KtI0vxJqWh6Z4ku4dOulCO9iLkY1DeXJt1chWIJtgxIUZAUGrA7RkKttIwV4Of59qTOOpOaisLH&#x2B;zdPtbPznn&#x2B;zwpD5si7WfaoXcR2JxmpWycjNAHA&#x2B;KPEnj5fEkuneF9G8MTQ2&#x2B;1v8Aid6s8c96Ngc&#x2B;VHGDsI&#x2B;YfPjO3PQ11nhLX9Q1/S2k1bQrrw5qMUxguLG6lWYKwXIaOUEqykEHjpnB5BrzD45a9oz7NE1DW3&#x2B;HerC4iu7HxNdWZaC5j2PHIEnAIVlDsu1yucV6d4T8deH/AIhafNqXh6&#x2B;Go6dFOYPtSo6qxABIVmADdcErxkHmh7FG/CdwTHIwDkd&#x2B;K0VX5RjpVKFfn&#x2B;YAH2z/AIVeXAWgY9V460u33pY42l4RWPToM9c4/kaZuGMqcjtQQO2&#x2B;9G33rH8SeMvD/g2KKTXtc03RlmDGL7fdxwmTbjO0MQWxkdK0rO8g1Kyt7y2lWa1uY1mimjIKujAMrA&#x2B;4INAE233oCknGeeB19en8jQw2jJyBXP8AxC8QXXhDwP4g1y0jhku9N0&#x2B;a6ijuATGzIhIDYI71QG/wcc9RkUq4zgHJ9Bjj1J9B715/8CvHWrfE34b22v6vDbRXc95cRLHaIyoFVtq7dxJ9O/XNbfxK0XV/EXgLX9L0Kcw6peWkkVrk9X4G0Et8pYHb6d80wOlVhIqsjKyNnaynIbBx1/Cj73Ib9a82/Z6&#x2B;HuqfDX4W2Gh6scXrTS3Js45hKLRXBHlI2TuOF3EjuxrppPiN4SXxF/YH/CS6QmrtJ5ItPtcYYNgkIcnAbAOemOM9RQB0ePyHJbt&#x2B;NG33rl/GPxA0/wAGNa289pqGp6lP&#x2B;9Sy09I2lEW7G9vMZVUZB4JydrYBw2NrQtatfEmjWuqWTO9tcKcCVGR0YEq6OrAFWVgykEcFSKAL233o2&#x2B;9LtPpRtNABtP1opwpMH0oAbRTtp9KTafSgBKgulO0Ht3qxtNQ3ifuCc45xUyApD3peKaPrmjNc4DuKSkyKMikAtJmjIpDQA4Ypce9NBpN1AD&#x2B;PWkpN1GRQBXozUe40u6gB&#x2B;RRkUzIoyKAJVIxS1GGHrS7qAH0U3g80vFAC9j61Uk4c1a4qvKv7w4raIGZrUMs9qkUWsvoTyyKi3CCMs7E8Kofgng1jeMtNnv7/AMMrEZYmh1GNYbq2itnuVkFvdEuPOXYoAyxAHOeK6aS3inaLzoY5vLcSIJU3bWHRh6HrVLWNAsteXTzeLK7afepqFuUkKnzkR0GcdVKytx7VQFzT7WSzsoYJb6XUZUXDXUyIjyn&#x2B;8Qiqo&#x2B;gH1ycmrUcZLDnaP7zcKOvJJ&#x2B;hpv3u/t/8AXrK8VKy&#x2B;F9cdM710&#x2B;4KsvDZET9MfUUASaH4g0Pxtp8z6Xe2OuWcb/vFglWZUbJUZxkgjB6gVqpAIlSMIqxgABFXaoU9/qeK&#x2B;ePgfr2s&#x2B;B/AXw/Fl4SGq6BqWko9zqlq8UL2kyTuJS2fv9d2TkjdgV9FbBGSq8AE46f0AH5cUmUWLdjuGeuB&#x2B;HtVyqMHDVdHSmSfN37YvjLxD4dm8H2Oha3qOkLeJfPMunzmJ5CPIVTkY4G4/nXpf7Ofii58XfB3Qby9vJL&#x2B;&#x2B;tTLYTzTSNI7GKQqu5mJJJj8s/jXln7TEi3Hx0&#x2B;E9m6eYnnRF0IyGEl5EuPx8rH456Vpfse3TaRcePvB08h8/TNSEohfhiRut5GX2/dR/iwq7aAed/tcXMutfFl7dXaaDRtJt/MjJO2Nnl3l&#x2B;eMkTxDt19jX1H8JZl/4VF4HuHlWCJfD1k7zTHaEUWyEk5PGOnWvknxbNN4si&#x2B;OPilzviGpWmnRXAGVaP7TtCj3WOGH869G&#x2B;Inii70f8AY88IWtpI0T6zb2elSuv3lh8ti4GfURqD7Cn0A6PXf2zvB2ka0bPTtL1PWYI2KS30Dxxjg9I9xBb8R9Mjmuu8feMNK8dfs8&#x2B;Ldc0O5F1YXGjXmw4VWVlRgyuo6MCCPfGal&#x2B;Gfwr0KP4I6X4fewt5v7Y0tLq8mmiXeZpovMLAgZOxyFBBGBivnr4FaxcXP7Pfxn0yVtsNvp32qNs9DLBNG3P0hX880o7kifCvW/i3N8O2sfAVn9i0bSZZprnUFihaSZ2YNtHmkbgBwduelehaL8T9f&#x2B;M37OHiq6t9TGieLNEhWW7u7Nnty9vGPODAIAAzojrx18vnqM9x&#x2B;ySzD4M6KR8rNe3g8sn1lb5T7DJrxH4DxpJ4G&#x2B;P8AcwKy2D6RIEZumBDeHI/Bk/OrKNzwN8Rr3wf&#x2B;yXrGsLeXE2sXOpTWNlJcSM8iyyFcHeWJ&#x2B;WPzCDnGeO4qXS/2S7PxB8IdAvbS&#x2B;a28Y3ot9Rl1S5ld1EchWRlKL/EqMpDA8tu7VxE1jc3P7HttPHGWjs/FDXEvljkLtKD/AMfYD8fTmvoCP4yaH4J&#x2B;AHhnxYf&#x2B;JpENPsrRLO2lUSzSjy4pUXJ6qyOP&#x2B;A0EnB/H7RZb7Vzptxe2Y1sJFdtqeoNFbi8t0sL2FljZ2H7w3DEYBODcqxwASPdfh9&#x2B;88KxXX2V7RL26u76OCRdrCOa5lljYjAwWR1bkA/NyM1dtYbLxVpelXmo6TBIGWO7W31OGORoJGQHAyMKegLD0HFaysZDliSzHJ3Nk&#x2B;tQUJS7SaQEMAQcg804GgBNppelGRS0AFNbrTqTaTQA2q98cWrZ/vVY6VW1Di1Y/7QrNgZ24il3Uw4o4rAokozUeaM0Ej8ijIptFADsijIptFADsijIptFAFX6Uuah3mnq3FAElFRl6TzKAJad0qFc9afx3oAlDD1pdw9ah4pcnt/OqjuA9mOajb71LTW61sAUYNFHFAChfeuS&#x2B;I1p4hntdFk0Jbi4hS/wDJ1K3twnz20kMikncR0bHHXmutx71yfxA0nR9Wm8LjVLm&#x2B;iurfWYJdOWwcK0lxtfKScZMYRWcjn7vuAQDwz9nX4X/DX4l/CfTrLVPD099rMdpuv7udLqBGzMygpJkI5AVQQvQg5r6hs7OLTrWC0gi8mCCNYkjwRhVGB1Jz069&#x2B;tedfAfwf4u&#x2B;HHgu08KeIotFbT9Li22l3pl1O8tw7SuxLI6BeN&#x2B;PlPavSlAUBQfu8fl6&#x2B;9BRPDkutX9pqjB/rErQwaBny5&#x2B;0IzTftKfDGAcMsmnEHr1v2/wAKd4o1Kb4WftZeJNWgQRRav4fu7&#x2B;HH3OLZ5cEf9drNhz/z0q58aPDOt6x&#x2B;018P7uw0fUL2xtDp0txdwWkjwwql7I7l5ANq4XB5Irf/AGnPgv4i&#x2B;KGqeGrzw0lu81rDc2d1JNceXsjcDZ35XLSZAyfmNaGT3PNNA0VtN/YZ1a4cAHUtVS9DMPmbbcxQA884/du/41q&#x2B;ONGutY/Y38F6hagudIuI7qRVAY7MzRFsdSFJXp0617TrXwlk174HWfw/N/Dp06WNnbyXccJmiEkTxu7bSVPLB2rovh/4Ht/A3gHTfC8ky6zbWsEsMkk0IRblZJHchkLNgDfjr2p6lHkvh39pjwtpXwLsr6a8jg17TdMXTxpOSZvPijCK4wPuMAGLdOetcp8K/Bk/hX9knx9qF1b&#x2B;Tca1Y3MsaMP3jwxwtHGR7MxYjuRgjI5r1Wz/AGXPhrY6zHqC6HJIY5PNS2nunaBDnoEGMr/s9K9W2qilY1WFAuwRxjYqrtI24BOAPlH4UagfFHw7&#x2B;JHxH8A/D/8AsTSfC89/p2sxyy6ZfJbyO8G9ij4Kg7csh&#x2B;9gjOele5fCz4Naj4L&#x2B;AGteFrlYIvEOt2d29wrFlSOWaBoo0LDk7QVz7sccV7U80jMzb2Zi2chif84qLG339/X3/GjUDyn4V/Bx/Dfwf1HwT4oe2vk1CSZpjZM&#x2B;wBtpVgWAO5Sgb8a5fwn&#x2B;xz4b8PeJLbU9R1q6122t5hNFYNAsSFgcqXYMckH0Uf1r3xutAX0P3j09enH8qnmAzrrxRZR&#x2B;KrTw9vnm1W7s5r/bGgZYIEZE3t9XIUAcnnA61j/Erx8fhvodprU1is&#x2B;nf2nbW168jsFtoZHZDNwMkAlRtHP0Fcp8O73/AIST9oD4o38gzBpNtpmk22ByAySSzA46gSJ2/vc8Cuc1r4kQ/GL4M/FfTdR0c6Ld6PaMZrVpRIxTBkgk3KSC3yMDg5G3k/MMgHvcieWxQNvC/Lu3Bgce460i8nHbjr7/AP6qxPA91LqHgjw1cTtuluNLtJXOMZLQqaqfEjxVJ4L8Aa7rlu6x3VpaPJA0ylgJGXy422jkqGccY5OfQ4AN6HUbSa&#x2B;urFZla8too554erRq&#x2B;7YSPfy2/L3FWu5&#x2B;teC/C/Qnv/jtN4nj8RDWbO48H2Nyk6B4xdMzLbh9jAY2vbythgCPNxgdK94jdHeSJCrNCyxOFOdrbVYBvQlXVvfdx0OAB3&#x2B;OKTcBu5AC&#x2B;/TkD&#x2B;oqn4f1iz8UaTp&#x2B;qaXcLeadfRedbTqDh1YqFIz04zwea4z4UfGTT/i5qviWz0&#x2B;yltY9Gu0himkm3rdxMXCy7cccxk/hQB33BwQRyAevtVPVGP2Q/wC9ivNPA/xmvfGXxi8R&#x2B;GpLP7N4fhs3m0q6kjKvd&#x2B;VKY5WDYAILK2PbFem6sM2xPQGYL&#x2B;f/AOqs5bAZW71oyKZuoyKwKH7h60bh61GaUGgkfupeDzUeRRuNAEvFHFMVuOTRuHrQA/ijim7h60ZFAGfupwkqDmjJoAsbs80ZFQBjS5NAE4Y09W4qBWAXnrTvM9KAJtw9aUN71DuzzShjVxAmyO5pNp7U1W4zUnXnNagN2mjaadt96NvvQAgX3rkPib4Z1XXtP0W/8PlZPEHh/U49VsrSVgkd2QrRvCxZto3JIcE4AK8nnnsNvvUtiyx3kMjEERyKdmeTjnjv6/lQB4j&#x2B;zT8TPGvxGsbu68Q6ZI2lSWslxa6vJbrCplE7p9lUD/WqqADdgYYEc4zXuH8R5yO2BjjtXgv7KOqeIYdJ1fw5q2h6jYaRpssl1aXF5YtbrG73EhMKs3Lggh8hcfNjNe9KNvbH4YoKJ4f9YK0se9ZsP&#x2B;sFaWPegY9ZGjGFds5yAASpx0BGR3JPSmplVGTk49c/rikooIF204UgNGRQAtFJkUtUAUUUUwGt1oX74OcdMfgcn8&#x2B;KG60h5U9veoA&#x2B;eZPt/hfxX&#x2B;0ZZWby211JpdvrFpNGCHKm2k85l9SpYrx3Hsa0/G/wz0D4P/BHxNp3hG1uJdY8Q/ZNKE11dPLLeTSTBApy23O2RzwO1eoXngOzvPHC&#x2B;J/Ok8&#x2B;bR5dFvLUcx3MDSB0Bz0IO8cf3q19T0HTdYXTxd2iTf2bdLeWW5mCwzKrLG&#x2B;B1K7s/hVAT6bpcej6fY6ZEd0dnBHarJn&#x2B;FFC5/EV5/r0mv/Ebw14p0nTdH0nU7STV5tK26hO8cNrFCsYaRwgJkkEyylR0AxXo/mBW3gcLghPUDop/SvlHx1&#x2B;zn8R9S8feJLnQr&#x2B;KLRdW1CW/Vv7SeCI&#x2B;axZhJGAScZxwO1BJ6Y1vo3wV&#x2B;Jnguyv9VttO0uHwfNpD3N7KsUbSxXEDq7FsfeLTtXMaF8evCPgfx38RJrjXbnxHpeq3drf2A0uBpWZjB5cw3Y2gLtjUZ7YxXMW/7Gv9n6RJqfi3xpp&#x2B;mxxIstwYLUSxqAeB50pGMnafuj8etZN34b&#x2B;EPhX4d614obTNa8Xmw1w6Eov79VhuHUli8TR/w7MH5gB2zxT0A96&#x2B;BMJP7P&#x2B;ix6RJIgW21COykmwHQC5uFiDAHG5VCgc5Oa&#x2B;ZvB&#x2B;ufE&#x2B;PVrzRfCnh99H1iWxtNIvha6eysqRb1WSRmwFLK2C/GQOM9a&#x2B;iPGPxA1X4C6PaWuk/Dp73wysKtpg0&#x2B;4kb7JKw3vFPGAf&#x2B;WjOQwyMEd8itL4BeE9b0rw9q3iTxU8q&#x2B;K/FdyLy6E0jZit1H7iE9OB97GBgPg0/MDhfg7&#x2B;zt4u&#x2B;GvxK03VtR1ez1LRbG0uLeJY55S6BzkKqMMDLFjwec5r3zWMx2KnAH75WwPbP&#x2B;NXFQqoGCqAYGew9KzNcuoWtjCs0byqwJRXG4D3HWueVSLdrmkYO12jK3beCaXg96YT/jShhjrWYx&#x2B;Pel2&#x2B;9RF6PMoAl6d6Mio9w9aNw9aCCTIoyKj3D1pdw9aAH5Pak3UwvRuHrQBn7qTfUfmbeKXdnmgolElOElQZFOXpQMm3Z5pQwx1qMGjIoAnVhjrS7qr&#x2B;ZinBs0ATs3y1ajBKDis/ceMVpW5Pkp6H/GtokCbT6U9V4oPWlXpVAJtFOXPAXIKsGXOCNwPH86MGpLVR9qTcMjKjOemT2/IVnKapptq9tTSEW5JLqEy7VAztGBjzDnI6jGTRtZuec9Tk14nY&#x2B;MPEFjAgTVJsKv3XQOD7YNdd4V&#x2B;IN/q2sWWn3tva4lLDzowUckKWyR06A/lXhYfPMPXq&#x2B;yd0z16uV1qcPaPY9Ch&#x2B;&#x2B;K0h0FZ6KwZc9fYYrQX7or6E8cKKKKCdQooooELil6UL0oIoAWik4Xrx9aNwPAoARutJTmU56UMpWMuwwg6seg&#x2B;pNRKcY/EyoxlLZBwFFIQdx45rLufFei2KlptRh9hATKT/AN8g4rGvvihpscTC3tLi5btu&#x2B;VPzJP8AKvOq5lhqOjmjsp4GvU2gdeY2X&#x2B;Ej6ilQO3CqxHoBnFeZ3XxO1OSPbbWtrbZ/iYGQj&#x2B;Q/SsW68UazeRss2pSlW6rENmf&#x2B;AgfyryKvEOHp/AnL8D0qWTV5fE0j0D4leD9D8eeD7/w/4hujbaXeBfN23AjLFWDKTuxxkYqlPe&#x2B;BdP0KXRo7Szm0wvu&#x2B;xQWvmI0gGN&#x2B;SAu76GvNLmSWG3lnjj8&#x2B;RELqMliSASOeccjFVvDt/J4g8P6bqJtzA91bR3DRbt23coPXA9a8urxBiJQvSjZHp08mpRf7yV2epz/FiNd32LTZN8n/PZwgHT&#x2B;Fc55buf0BrEuviRrlzgrLFZ7&#x2B;T9nhBPPuxJH51wPiLVLjSZNEeBPMt5tThtLnttjlV4wc/77p9OvrhPCLXV3oqXVyTJLePJeKApO2KWVnjX2wjKPwrzKmYYyrDnlN6ndTwOGhLkUdTpbrVr/Ucm4vriYNzsadip4Pbp2PatXwVEsVxe7QuPlUjHqf/AK1eE3F0mtfHCBLaTUILzT38ho1QfZvsxgDEvzlmMjHHHH0r3fwhIN18SNpJTjr3NduAjNYqnzTvdXObF8rw07K1jp2YZPbvSc9ulVWvF9M&#x2B;9H25f7tffanxRa&#x2B;vWjHvVb7cuPu0n25f7tFmBboqk18uelH270HFVygXNwpdx7VT&#x2B;3e1J9uPpRykF2iqX24&#x2B;lIb6TsvH1p8rAofbk6YyaT&#x2B;0EXgiszIA9TQGp8hZp/2knpR/aK9lyKzNw9aerDFHIBpLqHy8Cl/tA&#x2B;lZqsegp24dzijkA0P7QPpTl1BscCs7g96erYHFOwGgt8eTW9pzGaxt3x13f&#x2B;hGuTVs11Ohndo9t6/N/wChGqBltV4560u0Uu00bTQQJtPbpUltlbhCf76/of8A69IKfEp86P8A3h/OuWt8MjWn8aPl/wARahrWh/Zb7TtO/tTT4w4voImxcKABtePJwcenX2NaXwl8ZQeJ/itZR2F55&#x2B;mLbrIseza0UjCdX3hgGz93qPpxVW&#x2B;kgj8U6FnUbi3ucXISzhGY5gVUO0n&#x2B;6MY9zW58Kv8AhH9S8dWmr6G9jPc3BYXElu6sz4jYqZFXo1fneFdONaN43d9/mfeYnndKVpaW/Q&#x2B;gEGGUHr3q9VCM7pFA6s2B&#x2B;Y/qRWgFOBX6XzJK7Z8HZt2QlOAPUDIqje6zYaa2y6vreB/7rSKG/Lr&#x2B;lYd/8RtFsWUo890x4xDDtH5vgH8K5auOw9Je/NG8MLWm7RizqV&#x2B;Zcjn6Chht68Z6ZrzLxF8ctO0GNGkFpp4cEpLqFyke/H&#x2B;znn8Ca5ex&#x2B;Pi&#x2B;MNSmstF1qB5oU3TrY274AzgfM4/lXl1M5oU480U5L0O6GWVZy5ZWR7vtZc56DrnHFUb7X9L0yPfc6hAh7qH3EfgOf0rxe91K/wBWAF3eT3YU/dklLKPw4C/lWBqHirQdL0&#x2B;a8utVsobWCQROyTCQK56ABV3Z&#x2B;grxpcQ1an8Cnc9SOT04/wAWZ7XefEzRrePNt598x/54psH4luaxrz4p3BUiy02KJiceZPIX/TpXlEnjrQV8KzeJYr5brSolIDoCCXBA27SAwOSO1clp/wAUNd1TxnpWi/8ACNR6TFd7Zib18StBhy0gxwfu5x146VxSx2ZYmMmvdSOpYHBUWovVs9pvPHmvXiGM35hX0t0WP9QN361iXE018266nkuT1zcO0jfmSKRlCsQBgCkr5qeJr1fjm38z2oYejT&#x2B;GKBlHDAkN34FP4plFc17vU35ew/gfTGetYreMtJj8QXOiLcx/2vHbmYxSkIh&#x2B;UFVLk8HkH6HHWtqMjcOx3fxZIxkA15vdfCm08datfanr2r3Mlu15cQw2dqFjWFElMeNxBJJ2Z4x1r0cLClKT9q7I5MTKcY2pq5F4f&#x2B;MEWkahqGneNbi0t7iCTfFdWOZ4mQggoxTPY9wK51/HF7r&#x2B;neG7Hw7puqyR6RJbia5t428vcroq5xyVCbj&#x2B;Ndn4R&#x2B;G&#x2B;g28d8194Vs7R0u5Etzcv9peSLja5y3XOa79GW3j8qMCJFAQIg2oFHQ4GAPzNelWxGGhJ&#x2B;xhf5nFClXqRXtJWM7xNpsmteH9SsLdlgluoZFibtDIVJXH&#x2B;62Kj1PSJZ4dHtbO5ns0s72CaRoWGXhRSNjD&#x2B;6eK0kl85wseZZCfuxAuc/lWvY&#x2B;E9bv5AsWnzY7tJiMD/AL6IzXn0o4iq7Qg/uOyVSlT1nJIyo1SGZ5VVI5nGHdEGXHTk1ueHR8tyUPdB1z3NbNn8L7qTH2rUYok7rCpJqbVvDdr4VgtxaSySNcM5dpv9kLjA7csK&#x2B;myrLsTDExrVVZHhZhjqE6MqcGVVJx1o3DuaiMh78HHrmm&#x2B;ZX3h8kTFqTdUPmbjjvQX28ZoAn3D1pN1QeZ70eZ70EE/NHNQbv9qk8wjvQBY3Gl8zHeq/me9Hme9AGV5nvR5nvVbzPelEwHFBZZEv404SZqp5ue9OWQetAFtXx1NO8wetVfMzRvoAtiT3pyyVVWTjrTlfvQBbWTaa63w&#x2B;C2i2592/9CNcV5nNdt4ZOdBtv&#x2B;Bf&#x2B;hmgHsaO00bTTsGjaaCBu0&#x2B;lPjO2RSfUfoc/40BfejB/X&#x2B;hrCp8LNqb99fI&#x2B;YfFWnavHqFlq&#x2B;jQQ31/p/nQGxmk8tZo5Fwct7FR3o&#x2B;BvhKbwr8RNKSSziti2lIbhrdf3bTBpS4LDqQpUfhVvxdJ4mt5IZPDtlZ6kfNcTWt1IYncZ6Rt09K3PhHrk/iPU7C4udPbSryO6ltJraSbzCrohDc/U1&#x2B;c4aVWMo6Kzf6n3NdQlCXe36HrvjDVLrSfD91c2UnlXCNHiTAJGZUU8dO4rzK71i&#x2B;1BiZ726lBP3WmIX/vkcD8q9E&#x2B;IGT4Wv/8AfiP/AJHjrzAdBRn1arDEKMZNK21zPKKcHRbcU2cT4wHj&#x2B;bVtnhyOxtdM8vH2ufy2YtxnhgSOvXbj3rP&#x2B;E95r2oa94lOtaw2pPYSLY7Y2xFvBO/aNg6dOnUHr1rvdU1aLQ9Lu9SnGYrKCWdueoVCcfjn9K434K2osPAEeoSgQzahcTXUpkYDB3bFyTx/DXHCt7TByvFX2Xc7fZ8mJT5nbdnOfGO80iPxt4Wi16Oa502K3meWJSd7gnA24wWyRiuv&#x2B;HHiHwjrUd1D4c09dJnhG6SGS3VZCpbAO4MScE9Cc1t39v4bXxNZyX72S63FCxt2uJQrLGGOSAxx1&#x2B;lcJ4HVNZ&#x2B;MfivW7AiTTEiSITIMK8m2IEDgZwVaujmjVwnK01yrcxUZUq97pqT/QsfFi1m1fxN4K0tLyazgvp5oJnhkKsQTGGPHse/rWX4P8DaFY/GbWNNFgs1lY2sdzDBcfMqyskRLEdCfnc810njzSr288c&#x2B;BZbW1luIbW5laaSKIlUTMeCTjj7pP4VoaP4Zv7b4sa7r0gQabdWkcMfzBi5EcaklRyMFW69cVpQxEaVCMebXl/Uzq0XUqt8ul/0PKNNsYJvgr4viaVLVYtdEke/Plu4FuqqfTJK/nXe&#x2B;ETca949ttd8RahpNvqFnaC0sNOs72OSTJ3bnYbj1DHisbxV4T/AOEA&#x2B;Geo2k8y6pBqWtRz3Pk2xDwxELuC/NgkGNe1QeHPD/h/XPGHh6Xwhpl5DpulytPe6tceYu87flUbjyc9cDrXdOcK9CfK979Dn5XGtFNdj2zYFAAIAx0GaVR2HJpYIZb2UJDFNNI3O1ELnJ&#x2B;grdtfAOuXUkaNZG1jb7z3DKMf8BzuH5V8tTwdetL93B2PbliKVNe/JGDtI6jFG0&#x2B;ld7ZfC12Yfb9RXYP&#x2B;WdvGw/Vj/St2y8B6HYMXFoblvW4befy4X9K9qjkGKq/EkjzKubYeHw6nlEMTzvsijeWTPKxoWPr2H0rT0b4f6zJDKbeyaISStK73EgjClmLH5Tz1J7V7BaW8FlD5dtBFbRjokUaqPXoKmZyy8jK/3e9e5R4dhBfvZX9DyKmdSl/DjY89s/hXcMn&#x2B;m6kieq26E/q3&#x2B;Fbtn8PNEsgu&#x2B;CS8k9biVio/AAfyrpFPHJ5pdpPNe7RyvCUdoXPKq5jiam8mRWtpbWaAW9vBBjj93Eq4&#x2B;hFTMzHnczg&#x2B;rEn8e1N2ml6V6kacYq0VY4HOUvidwrlPiBIFbSQTwfOP5GP/ABrrK4z4jsFOkH/r5/lFTIOcZ/mIz04pN9VDM2TR5xoKLLSYoEhxyar&#x2B;ZR5o9aBlnfRuqr53vSGQ&#x2B;tAFrfS7qp&#x2B;d707zTtzniggtbqTfVTzvel8w&#x2B;v61QGR5ppfMrO&#x2B;0988Un2wetZXRZped70efWb9s9KDeY64ouBrLN8o5pfO96yBfj/Z/76FO/tNV4LKPxoA1vP8AenrcfLWK2pR9TKo/Gmf2tF2mWgDfE&#x2B;c816B4RYPoFsc9CwP13GvIBrECsczc/Q/4V6r4AuEuvCtvLGd48yTJx6E0R3EzotvvRt96B/LiirJDb70d8d&#x2B;o/DP&#x2B;NFGM9PvYIH5VlU&#x2B;CXoXH4kfKPxZXQUW0bXbzUtNUXEwiv9LLK0RyM7iueOM8/Stv9nSS1muITa3k2pI2qzj7dLndcKUG1uQDnGBz6VxHj/xFqui&#x2B;PNZGl6ti4e5MR026RHh&#x2B;ziKNt&#x2B;08jLs/zDjivTfgzfTahqNikos2uLTUJbZpdPx5MoC7w4x/ssM&#x2B;&#x2B;a&#x2B;BjGUOTzf6n2spKXP6foet&#x2B;Psf8InqJ7ZiP/kaM/0NeX9cY9K9T&#x2B;IG3/hFNRO5f&#x2B;WZ6/8ATVa8sBGQA3J6Y5zXFxBGUsXFJdDbJ5KOHbfc5f4labq2teDrvTNItlubq8eONm3qnlxhtzH5iM52449aj8UeAZPEHgXTvDltdixW1&#x2B;zqZtpKyLGuGB6deTx3rvbHw7q2pPi0sLhx/eZdin8TgGt&#x2B;x&#x2B;F&#x2B;rXDbrqS3sR6Ft7/iF4/8erlw1HGzhGFKGiOqtWwsZynUkrnk2sfCvw54ggsF1G2a4ksrdLZLgSeWzIoA&#x2B;br1I9a6DR9J03w5p6Wmm28VjbD/AJZqxbJznqfevWLH4X2EK7ry7uLt&#x2B;6r&#x2B;7X8Op/Wt7T/C2k6YrC106Af7c2XcfietexTyXG14clWdkeXPNMLRfNCN2ePWNnd3/wA1nbTT88mON2GenJFb1h8O9dul&#x2B;eKG0X&#x2B;Frkjdj6ITXrCyNGgRMBO6g7f0H&#x2B;NIM9M8fTFerR4doR1nJyOCrnVSXwKxxNp8K7ddpu9SmlbusMaqB&#x2B;JGf0rdtfBWhWgTGnpPt6Ncgy59yuQv5CtrpRXt0Mvw9FWhBHj1cbXqPmlJhGFgQRxKEUcBQAB&#x2B;AHH6U7djgcCm0V6EIxgrJHI5Se7H0UgNLVEhRRRQAU4Gm5pMigCSimq3H/1qX738uaADNcL8UJNsmjc/8/H/ALR/xFdztJrx/wDaAsdWvJvDh0y6a2Mf2reQAevkEfyNAFH7QOx4&#x2B;hpDdD/INeb/ANk&#x2B;LDydWfP&#x2B;4KP7C8UvydVbP0xQP5Ho/wBq7j&#x2B;VJ9qJ/wD1V5w3h3xM3XVJCfakXwx4jPXVJc/Wgdz0Y3X1/I0fav8AOK88HhnxEP8AmJTGnL4X108nUZc/UUEnoX2j3/Sjzu&#x2B;CTXBL4V1phzqE2f8Aep48J6x3vpSf981IHdfavXIPpg0n2oZ71xC&#x2B;E9VHW8lz/v1KvhPVO91J/wB9mqA2v7LYnlqeuk8ferS8tm5CnFPWF8fdqOUq5lf2Sm7JZs&#x2B;xpf7JjJ53GtTyG/u/pSi3b&#x2B;7Ryhczho9v3X86VdGtt2TGDWotm7KOKeli3pT1C5mLo1uP&#x2B;WSke9P/ALJt/wDn3j/KtUWT&#x2B;lTLp77aQXMhNKgwMRIPbFejeBbcW/htUUBf30gwPoK5RdNb&#x2B;7muz8Kx&#x2B;TorIeP3zfqopok1eBwOlFKepPqc0lUAU5f502nL94H05P8An8axqfCy4/EjwLVtEsL7W7u6msop7kGa2MzJlvLZjuQn0NWfhj4dsPCuvWdrYQtbwTXnmeWGyqFgFIHtnFcn8Vrq78PWmqa5YzXQurK&#x2B;RTEs7&#x2B;U6m5VCpTOOrDt3rtvAstxNrHh&#x2B;a8txaXMjwvLCOiMdpI/A1&#x2B;YQVSNWEubTmP0Cpyexkra8p7Pd2cOoW72t3Es0Em3fG3IOGU9PwPenabpVhpPzWllb2zEctDEqP&#x2B;J5J/OpD941KtfpzpU377ir&#x2B;h8D7SavFSdh7SFm&#x2B;ZmYdtw/pupdxboPwUYFJ5b7chHbqQFBJOO4HcDv6fSnJbtJkFWkTJztzzyFOD/d71slZWRm3fUM/LuIIGducdOM0oyzKo5LYxj3rzHwb8btD1q/v7HXNS0nR9VXXLrSbGzE2GmSJ1UE&#x2B;hJPU8c4rCsPiZdeF9S&#x2B;Jk189xrEieIbfTNI0&#x2B;4uSqedKiqiBiNsaDDMTkDqSeRTEe1cldxBwO/bnoPqecfQ05VLKHByhIAYdDnoR&#x2B;tfLnxH&#x2B;Ieu/EnRNI0zNn4e1HSPG&#x2B;m2F29i/wBrBeQj7LPFJkIQMuWRuPXPBrd8RJqvhn43aHP46sdc13QZZtMsdD12yuzBbRXJVVkaeBBjLyljtb&#x2B;9QB9CYzgg8dqWg5YklsnvwB/Kjb70AFFFFABTl6U2jmgB&#x2B;aTIptKqlgSo3YPJHbp/iKAF5bOKaeO/OM49vWuF&#x2B;IHja98M2upIZl05A1pFDqUMDXD2UMzSI9yyYONpjcDsOvrjoo/EemaM0Fhc6lJHFDZ21xFq1048uZZGaNHEp&#x2B;Vn&#x2B;Qk4JHzjnBBNAW7rXLKz1bT9KkkaTUb4M8NvGpZ/LUZZyB91P9o4BOQDkEVFdatcWfinTrJYoTazWl1dSSSMd&#x2B;Ymh27R3B8w8j0rzTQfirpGvfETTL7w3qza5aaxCtheaNZ2jT/YI1LtHK1wikRnJG6MkZJxVbxjeeObjVvEkcsWhwaJp9/cWsF5cs85aGa2RFiW2jTLk5V2LuoVlIzxTA9n&#x2B;1Q/aprRbiOS5gVWkiV1LoCSFYgdMkVyvxCs/tUmlYABBm7e8dJ4Q&#x2B;Hj&#x2B;GfEGqa9qGv6hr&#x2B;t6lEkdzJcrHHANv3NkYDFQBgYLnpW5rVj9r&#x2B;yEL90yAcY67P8GqZAedropwPm59qd/Yp6bvzFdj/Y43ZxinLpIz92kBxn9hf7RP0pV0P3/Ou0/skf3RThpYx92gDizoppRoYxyOa7VdK46Yp39lr3XNArs4ldDPYVIuhjqRXZjSx/dp66WMfdoEcZ/Yi&#x2B;n6Uv9ir/AHf0rs/7LH0pw03igRxa6Fx0qVdDG0ZTNdmumfKMDFPXTeOtAHFjRV6eXUiaJzwgArs104L2zUn9mo3OOaAON/sH5s7OPwpy6H833K7NdNGOV5pRpoz92gDkV0MdStSrooHautGmjHSnrpq4p8oHKLo4x0q7bW/2WFUHdifxxW/9gUdqo6lD5LRqBjPIpAUew&#x2B;lFFFBYU5ev1AH603HvSrxj1zn8iP8AGs5/Cxx3R8r/ABytpf7H1e7jmmLWt9lbZCNkhN5Gfm78bc12XwwtdStbrw/Fq8nm6m0/mz4/hZpt23/gIIX8K5r40WxuPDPiwGYQ&#x2B;VcvLvGNyhblWJGQewPWt74d2s58S6Vff23catYXUseyO5iiTDNIOQUQE4PHPpX5xD3pRvb4z7yVuWXofQJ4Y5BB96kVh&#x2B;FQqp9/xNSKvHWv0pbHwZ4Z42j8UX/7UXg610/U7LTLT&#x2B;zpZYWkhaYtGpJnDKSFDEZAPYAZxXL&#x2B;IvEV9afEjw1q2l&#x2B;J/EeuO3jGHTLrUeLfR0iaRl&#x2B;xxQ9XKoqhnTKbw3Nen&#x2B;Pfh34o1b4oeGPFXhjUNMsXs7Sewun1BHdkjkIy8YAILbS456VV0P8AZv0nSrjTjeeIdb1S10jVP7V0myMixw2spdn5QcHJZjz61YjyHVrfw5ffDn4haVbx6XN44v8AxzLbabAFja9z9rjYbeQyoEVstwuB1rofFXw/1fxVe&#x2B;PnsNE/ttdN8Z2WpNp8xEa38KRKsiRtJhcDOf8A6&#x2B;a91034b&#x2B;E9D12XW7Dw7YQaxJLLN/aHlhrjc7Fz&#x2B;868szd&#x2B;OldKZGPVt20lhkkN6Z56jHemB4lJ8KNZ8XeAVgttI0X4a38WuWuq6ZZWNus/2ZYOFM7KSrsx3uMZxvAPINdbb/B62n13T9Y1vxJ4g164tZLe6NhNd&#x2B;VpzXcSKqyiBRgfcB685z3rvt27aOvTG3nPuPXpn6c05eSBlSxGeuc/T1z&#x2B;tAC53ck89zjGfejihlKltwI243A8bc5xn06GkqAF4ox70lHFADtvvRt96THvS7fegA2&#x2B;9Z/iDUH0rRb27iga8uIYGMMMe1ZGkPCKpf5VJYj5jxxz0FaG33qlrGmDWNLvLF5DEtzC0RkX7yZBG5fcbs59qAOG0nwh4&#x2B;uLW1fUvGY0m6kt2t9QW1so7maSMTStCnmuAg2pMUP7tvu9e9VPC/wR0Ox1G7/tjSBr9jZpHBpreILo377Rkuwjb91EpwiqFXI25xzXqbyeYxc5y3Pzdfx96bVEjHt4/sP2JF8mHy/L/cu0e0ezJtZT7A9ah0bSrPQtPisrC3&#x2B;z2kZYhGO45Y5Z2JyxbJyST1NWacDTEOZizMWJZickk5yanS3E0Ck8lW4qv2z2rZ0eFJrRi3Tfj&#x2B;tAGebD2xSizGOlbjWoZiQODSfYx6UCMX7CPSnLYHHHStr7GB2pfsnt&#x2B;tArmL9h9RzR9jxW2LMU77IPSgLmIthuGduaeLEelbH2X/Zpy2vHSgLmL9hHpTv7P9q2ltV9KVrXngcUDMZbEbR8uactiPStpbUY6U4Wox0oEY/2EelAseelbYtv9mk&#x2B;y&#x2B;1AGQLPHapPsO7nFaot&#x2B;KetuNvSgDJWzCjGKX7H7Vr/AGUelL9l9qAMj7CPSuf8UQ&#x2B;RPbY4&#x2B;U/zrt/s3tXK&#x2B;NoTHPYEdSHx&#x2B;BH&#x2B;IoewR3OXooGMDHTFFQWFH8Q/H&#x2B;a0UvHGfr&#x2B;orOWzLh8S&#x2B;R4dr1nb6lq2r2d3bx3cEl5cK0MyBlYGQ8c59qn8I2cGn69otpaQQ28UV3EPs9uoRUJkBI2gDHJNQeJrdLjVNYt5J2g8y7mVZI5NjJl25ByPmrJ&#x2B;Gnh0eH/F9ssthvnlvbfOpSSM73K71AVwzFlI4H4V&#x2B;XU/94u5dT9Cn/Adl0Po3&#x2B;I&#x2B;lOpjcsSPU0oHvX6otj89luPU54HTIXOccnt9f5fjS4KrkjPGfyxkfUAgkdq818TeNtS0X41eFdIE3/FO3Vk8eoRsoKxvK0gimY&#x2B;m6JVHua4bw14j1lfDtzpkE19Dqut69NeXV7HcQo1tHJpsN4ELy4VArzBSM5KqAATViPeP7WtANQLXMcaafKsNzJIdiRuVRgCW4I2yoQQedx7g1Rl8b6Hb39paJfJfXE8sCRWthieSTzVkZHUg7SpWIkHO35DkjcAfMI7jV7uTS9Q1OCbX7O31qzvNb/sqF50mkbR0VJgqruZBceWdu3HT0NXfCfw/1y117w1rsVnBoTaOrpHYTFWza3M9xNLbkoTtaCOSFIyTw6ydiMsDpfDvj2&#x2B;1iHTVt7eG6WLSrO&#x2B;1XUdQl&#x2B;z7DPEzEqkakMBt3kEgEMBnJxXDr4k1nxdJoOk6lrN39hvvECQzT2cP9mSS2r6VLchAqMXRWkVSN2GxjODXbaf8J7CzuLKSa/upYk0&#x2B;2sL2xjAS0v2gjZUlcAB1GT90NjG3pjFdB4d8I6L4UtUi0nT47Ta6yCWUmaUOFKby7ksSEcqOeAABwKAOU&#x2B;C/h3&#x2B;x9Js777LOtzeeHtKlurm4cvJPc5uGlLSNuZmBdAMngYHavRFbKrlt3AGfwpC5baefl2kKzN2HHX0oGMcdP5&#x2B;9QA&#x2B;ikBoyKAHAe9Lt96aMUvFBIu33o2&#x2B;9JxSbgO9UIdt96Kbwe9LxTAWikx70e2eaAJNw2V0XhVFmsZ/RZcfjtB/rXNN92ur8C2&#x2B;7Tr4jktdZ&#x2B;mI1FApGp9l28Y6cUC3GelaZg5NH2egkzvswPaj7N7Vo/Zz6UotzjpQMzfs9OW34rR&#x2B;ze1L9nHpQBn/Zfal&#x2B;z&#x2B;1aPkUeTQBnfZx6UotxjpWh5NHk0AUxb8U4W49KveT6Cl&#x2B;z0AUhbjHSl&#x2B;zj0q59npwhoApfZR6Uv2Yf5NXVjHTvTvs2eaAKPke1OEHtVz7PinCH2oAo/Zx6VxvxGjEMmlsP7sn6Mn&#x2B;Nd/8AZx64rhvicvltpI/67fzjpMI7nD&#x2B;wpKKKksKFwWwfp&#x2B;ZH&#x2B;FGPehfvD6g/qKiWxpHdHh/ji1tZ9U1sX8YktVuZZWHfhiwI55HWq/gHxFZ&#x2B;ItS0a5styRLd2u6GRSjoDIhXIPOCvI9iK0PEw8zxFqqkKw&#x2B;0yLtbJBBJBB9MgmsTwJ4R03wpr0ElgsoNze2x/eybtqqyqoHsAAB7V&#x2B;WL2f1l82/MfoD5vYK21j6JOQSD1zRxScLx0xS1&#x2B;qR2R&#x2B;ePc4zxh8L7bxpfaxNdX81tBqGlQaYVgUCSMx3DzrKrdeCQD9a2rjwJ4euvtcc&#x2B;kwXUN1dJfSLdr5wEyQpCrjdwP3caDAwDitnil4qhjl2wqgVFUDGFjBUJgYGMEdvc0u48855zzxTMe9LQAtJRRQAU4Gm0UEj6KQGjIoEPBoyKZkUZFUA/IpDTcijIpgPBpaZTgaAF4pR96ko4oAc3Su3&#x2B;HyFtJvDj/l4I/wDHFrhm5HFd58Ov&#x2B;QLeY/5&#x2B;j/6LWgUjp/JpRCKkwaKCSPyRSeXUmaMigZH5dHl1JkUZFADRHR5dOyKWgBnl0eXTs0tADdoo2&#x2B;lLkUZFACbTTlXikyKNw9aAF2c5706kDDHWloIFxRtNKvSloATafSuB&#x2B;KnytpH/AG1/nHXoINef/Fj72kf9tv5x0DW5wVGPeikOKg0F2&#x2B;9Hv3BH8xSY96X&#x2B;Ej/PJH&#x2B;FRLY1p/EjxzxUgXxPqoHTzyaq6YSurae3927hP5OD/jV3xXn/AISjVM/89c/oKo2LBNQtGbgCePP0zX5L/wAxn/b36n6Kv91Xoe5NwzDvk0q9KJDmRznILEj86Aa/XI7I/N5bsWikyKMimSLxS8U3IoyKCx3FGPeko4oAdt96KTijigkWik4o4oELRScUcUALRSY96WqAcDRkU2imBIpGKXIpgNLQA/8Ahrvfhv8A8gS8/wCvoj/yGtcD1Wu/&#x2B;HLBdFuuf&#x2B;Xtj/5CWgUjq&#x2B;KSm7h60xpMN1oJHt1pu4etRtJz1pjOd1AyVm5pN1RbjRuNAE6sMUeZjvUG40bjQBYB3DNO3Dpmq6yfnT1NABupdx9KZkUm49hQBJuNGTSKMr1xRx60AODGnCQ4pgo/z0oAl3mnBqiHSnK3Hf8AKggfurg/it8w0j/tsP1jrus/5xXC/FMZj0pj0VpQfx2f0BoGjhOvejn60gBPOaXb71BoGPfFAxke2Cfzo2&#x2B;9CgjJ7cVMloXD4keP&#x2B;MPl8UakD18xf/QRWbbti6tz/wBNoz&#x2B;TVpeMvm8Valj&#x2B;&#x2B;n/oC1lQsPtEX/XRT/48K/I5f74/8R&#x2B;kw/3Veh7w3ysRSZFLN/rCe1Mr9cj8KPzWW7HZFGRTaKokfRSA0ZFADwaMimZFGRQA/IoyKZkUZFAD8ijIpmRRkUAPyKWo8ijntVAScUvFMU8c0u4etMB3FHFM3D1paAH04GmbguMnGfWlGW6UAPDHBxXe/Dsj&#x2B;wrk9/tbD/yGtcF0yM4IGcfXiu&#x2B;8AALoMw9blvzCgUCZ0Rk5NNZiTQ33j9aTHvQITmlwfWjb70bfegA2&#x2B;9Jx6/rS7fek/wC&#x2B;T9aAFFLim8euPpT1x2oAQfL1qT73IPFHl57Uu0igAwKcFFJsNLtP&#x2B;TQAbfek&#x2B;77inbT6/qKPLPfH5igBFbjpS7vr&#x2B;dG3HAx&#x2B;dG36fnQAdaXb7t&#x2B;BpV6dR&#x2B;dG0fX8aAD8T&#x2B;dcR8UlJtdM9C8g/Egf4V2&#x2B;0en61xfxQA&#x2B;waa38Kztn/vkn&#x2B;hoJR5&#x2B;ORnNLt96QKfWjj1qDQXb70nO4AeuaMe9IPlas5bMuHxI8j8bLs8WakD/ejP8A5DWsZT5bq5&#x2B;6GBP4HP8AjW14648Xaj/2z/8ARa1gzZ2n06/pX5RV/wB9f&#x2B;L9T9Ih/ui9D32bhiPTiotwHepJDliahJ5r9Yh8KPzeXxMduHrS8HvUeRRuNakEm4DvRwe9R7qNxpgSbgO9KGGOtR0oYetAElGaj3UbvegCTIopm4etG4etAD6cDUXmfjSjDc0ASZFIabxSbsZoAdS7ioPfALfkM/40wsF&#x2B;8doxuJPAxg5PPH8J71zOkaxHqvjHUZLS&#x2B;hvNNm0y1MTxybohIs92sjBhxwQqn3GO1AFnXfFKWurW&#x2B;lW07Q3S3VrHeS&#x2B;QGSNJZVVYyx6O2RjB6EVdvNWu7PxPoVqbZW0zUI54pX6PFOqq8YPsVWTPuv8AtAHznztZ8XfFi8SAywWVmkcU1v5MqxB4NQRgxZiEcmNWb5ckY29eD6rNAt00L4K&#x2B;VJ5qLnPzFHXr9HpgQaRrQ1TUNWsxa3EDadPFC0si/u5t8SSHYT6F9v4V6j4BX/iQyEBsfaG6nP8ACK4Fm3L8rfKCSoI49AT&#x2B;GK9B8BYHh9sbsec36KKQG&#x2B;eppNpPrTufRvypR/wKgkZt96NvvTjn0b8qTafSgBv50bWPQ1KvTpRtPpQBGFP1p6oR24o28/xfnUqjj/GgACnHpS7T6Zp6qcUbW/yaAGD6Z/Gj8P1FG3/Yx&#x2B;NLt/2R&#x2B;dACfgv4mjaf7q/mKXb/ALK0v/AU/OgAVeOi/nS49l/OlG3HIUH60u0H&#x2B;FcfWgBu0f3V/Ol/BRTwnoEApdh/2KAGf981xfxSU/2TYn&#x2B;H7SRx6mNv8K7bYf8AZrjfijGf7DsicY&#x2B;2KOPeN6p7Ex3POcZ5zTTSr8yg560hrI0Dijvn0opD901MtmVHdHk/jo48X3/H/PP/ANFrWBIcxt/nsa6Dx5/yNmof9s//AEWtc/L8sZ&#x2B;n9DX5NX/31/4v1P0Wj/uy9D3uRhuIz3qBvvGp2UNkkd6rSMvmHBwK/Wafwo/O5/ExDik3Ad6YxOeOaTPrWpBJvX1pPM9KiYjNGRQBLvo31D5mOKN2aAJt9ODcVCrDFLu9KAJd1OVhjrVfzPenKw65oAn8wCjeai3D1o8zHegCXcaZPceVGueAXRfxdwgwO5JIH403fVHWtLttc0u5sLoSm3uNpcwzvC4KEMhBXngj1oA5PxxpfiHxlquoaLomsWFlpPkQR6obiJ53SRWdjEsQIViVMZJc9OK1/Dvgt/AXh02Ph5oJtRYPvurw&#x2B;VGGeSSQsEiXbgNM&#x2B;F6AKuSTydXw/oOn&#x2B;GdNGn6Za/ZrbzDI2WZizkkmRmZmYsc9z9OOK1EOef6UwIdF03&#x2B;w9HtrBLiW78oEyXExw00jEtI5HqzFm/4FV5fb9KZj3pVJBxSAmHC16F4Dz/wj5&#x2B;9/rn6f7orzxSMZNei&#x2B;Ax/xTIYbuZn6fSgDf/77pMD0b86ftP8AtUbT6Ggkb9Cw/Gl2jvu/Ol2n0pVU0ACrgdD&#x2B;dSKp29KAvHTNSL93pigBuz8KXaaXA/yaXb6D9aAE2&#x2B;360m32/Wnbfb9aaynP3f1FBBHu/wBmnBSwzsX8SKb5Y/55P&#x2B;dOCf7BH1oLDYf7n5EUu0/3V/Gjaf7v6inBTj7tBA3af7i/nTlj77PyYUbB3Tn60oHbyz&#x2B;dAC7T/dH50v8AwBaUBe6HNLtHZeKAEw3YIB9a5H4oK3/CO2vTP25Dx/uPXXbT/cFcp8TVI8NQkjGLyM/kj0DR5euNoopMijIqDQWmt3pcim/xUpbMpdDynx0c&#x2B;LL0j/pn/wCi1rAmb9030/oa3vHGP&#x2B;Eovc/7H/oC1z03ETfQn9DX5NiP99f&#x2B;L9T9Fof7rH0PffX61TkPzGrQzx9KoyMPMOTX6zT&#x2B;BH55U&#x2B;Jisx7UwsO5pGb5aZk4J64ycY5OOwHc81qZj89&#x2B;tG4cAnGSB&#x2B;f/AOqmE7mMa8npgdf88VVj1O0bUDp5mxemL7SY9p/1e7b97GM5/hzn2pgW9248DJxk45xShl253Lj1zgfnXH6p8TtM0i0u5L60uD9muJoWt7UBn&#x2B;zwOiyTtnhVXevHUk4AJBA5nUfHXii20zVNWuBO2kWmvXFpdXGjwwyXVvZxb8ErLgOdxXKgZweBwaAPVz8vByp9CMU3fTMq3KY2t8w2qF689AAAfYCjNAEoakL1F5mOKXdnmgCUSUeZUVG4etAE4ko35qv5mKVZO9AFpX7VKj4qmJBnOaf5p7VIF7zN1OWqccvqcVOkg9aALe4YFekeA/8AkVYyd2DNJ3968zVhxXpnw9b/AIpeIHp50mKAOhb7x&#x2B;/1ox676cG7EsPoKdHGXbJZtvagkRYcjJVz&#x2B;NSLGoXlXqQY6ZYn1p20erUAR7V9HpCB/depfxb8qOP9v8qCCLYDz5bH605VGPuGn/8AfdL/AN9UAM2/7NNKn&#x2B;7Uv&#x2B;eaQgejH6UAQbfd6X/vugbcf6w0v0ZiKAEwPSSl&#x2B;X0enLnHVqN3&#x2B;01ABtX&#x2B;45o2Ddna4pd5/vN&#x2B;VLuP95vyoAXYv91/zo4HGGo47s2aX/vo0AG1e6ufxrlfidGW8KgKCP8ASU6/7rD&#x2B;orq9w9WrlviT83hWT0E8ZP5mgaPJ9wyfrSZFIetJUGg7IoU/NTaQ5zxUvZlR3PK/HTBfFV79EP8A44tc9N88ZA9D&#x2B;oNb/j5v&#x2B;KqvCf7kf/oIrAdtoYn/ADw1fk&#x2B;K/wB9n/iP0Oh/usfQ97U5hB9s1nzEeY1XY2/cr/uj&#x2B;VUJv9Y1fq1P4Efn1T4mVb7U7PS0he9uo7VJp47aMyNjdJIwVFA7ksQPxrm9U&#x2B;IEGn&#x2B;IotMbTbh9O/tCLSrnUg6gRXc0QeKLYT8ynzIct2LH0JEXxRvtO03wzDd6i8CLb6np08bSAMVKXkLMyr1LbQ5wAeF9SAciTw7qureJ76wuNOYaDN4ih19dXjuIykiR28eyEIG3h/OQ5JXGOM1sZlrVPGmsQeKvF&#x2B;nItna6fplpYPbTmJ7mUy3ErR5WIDDEkMBuIxgE8c15n4i/4rKxQa1FNqOvz6Df2WmsIyhF4l6yQsxiOxGAi5Jbbz15Feu638P9M8Tapql5qE93JDqkNvFcWUc3kx74JDJFIHjVZFKszcB8YNdBZ2drpduttYW0dnbRgqkMKhAgJLHGB3YkknkkknJOaoDz28&#x2B;F&#x2B;p3uuRX0kmms8N7fktqUBn2rO0LC4iGQBKDBj5uAH6ZzXUR/Dvw&#x2B;bu5mureTUlk1B9RSK&#x2B;cyRxSsQGKICBz8zHPcmt5pH3HcevOc5oTLsFTLHOB7H1&#x2B;lMCR5SzEsxZu7Hue/4Ubhxk7e&#x2B;Txn8aijIby2XlJAGQg5BFYGu&#x2B;OrDwpbzy6yTbQ/avsloluGuJLtvs4mx5ag7SPnGDjOM9xQB0nLM2ATjrtGcfWkaSOFFZ5EQM6xqWcAMzHCgZ75ry3xF8XrpmSbw7ax3NvBZNqMv2yJzKUaza4QouflXd5Knqcs3o2KWh282ueKvBFxqs667Eo1C7jmjBuoLYtFCUVpNigkHcVzwuQO1AHsBJ9MUlNbduOevfn/ADzTcmgB&#x2B;4etJ5mO9R5o3D1o1Ak3ml83HGag301pMdeKALaze/FTJcDGS2B9aoLudgq9T29aztW8Rafoa/6VdKJCcCGMb3J9Nq5I/GpA6qO4TywzOoHua9T&#x2B;Gd4k3hllV8tHO4wQR1UHr3614Ppcmv8AiFVaw0r7HZk5N1fvtJHsor2XwvrDaHZw2bQxCJepjJJO7OTzQLU9DVd3Jfb7EVJu28CQY&#x2B;lZFj4iiulXDR7schjzWkl4r4w0f0oMyZW7&#x2B;YPypcg/xg0zzmPO6Ol3HuyUAOyP7/5Ubh/fNN3H1X8qTzB3ZBQArNz95qbvH95vyNBb3z9Kbu/2wPwoAUsufvNSqwx1amH/AHwabn/ppigBACByVp3/AAIfhUXH/PNjRn/pm350ATK3bev5075u0iVXGc58n86erY/5ZUATc/8APRaUN28xc1H5n&#x2B;wB&#x2B;FO3HGRGpoAk5/56LS72HHnKKjDHvGM0Z/6ZigCTzD3lBPsDXLfEsk&#x2B;EZz5mR50Zxj0z/jXTbmA4TH41zHxIYt4Pu&#x2B;gO9D1/2gP6igaPIhwAPTil4701mBYnPejcPWoNBdwHegEHvzTCwzTQx3cdKiXUqO55d4&#x2B;XHiq4B6FI&#x2B;fwH&#x2B;Fc9N86MQc9/0P8AiK6L4gf8jRJ6mND&#x2B;Fc4zAR8nt/PH&#x2B;FflOM/32fqfoeG/3WPoe9QcwxEdPLU/pVGdhvardqwe1gI6NEp/8dFULpj5zV&#x2B;q0/gR&#x2B;f1fjY0S7cAKGOdwznA4698t&#x2B;ApGkZsdST6nJqPPTJxn8&#x2B;hPHqcK31xXM&#x2B;IvG66Ve3Om6Zpr69rFtF51zbrIsNtZL/euZn&#x2B;WL/cHzYxgGtjI6ZuAcDjrmop7qCzt5Lm5mjtbeJS8k07rHGi45LMcAAY6k1xN94q8c&#x2B;HU/tDW/DGl3WmJ&#x2B;8ml0LUpJ7mKPGTIqSQoHAHOBk4rd1TUrbVPBuo3dlPFPa3WmzzwyKNoZWiOMgHuP4emc9KYD9P8baBrEV6bbVYXFjHFNcSOWjREkGY33MAGVh0ZSQazbz4naDb32iWcEraourmILPayxtHFHIzLGx5BO4pIDtzt2c44NeSaPp&#x2B;rSRxwQW0euwR23hm&#x2B;vvsMBimWFGANocyENhQkjD0fPTgd/wCFfhrqei61Hq/9ow6bLc20i3dp9mSSa3kNxc3CrDJuYIFMxTgEfLVAcPoetapa/CO20&#x2B;91NdJtY4dAkim0&#x2B;V7ZxDc3kkUod92XBSPPQYziuzl8I38muXtto2m/ZLa38QteR3F45VXjOlpbHGcs5MhflRgkccYqWGbwn8M1mtrO0mubyyk0yymuLjDtGJZWjgYvIAm1WLt8ueWPeuk1Dx1pFlfaVZrMb59SMaQm1lV02O5RNzE52ltw/dglSSTgA0agcd4P&#x2B;Fus6Hr1tJqep3Mlhp8FtYwwpeMsF5bw2axFHtwAMFzITuPPXHOK9NsbS30mxis7K2itLWFQqQ26LEgAPQKoA5zzkdc9eteIWfie81LSPDdtZ38nh7RrjStMuhp1o/zsbi&#x2B;ETgyt87Dy89D2r0b4S28un/D&#x2B;wtpo7mIpLc7Fuwwk8s3EhjJ3c4KFSM9iKAOvzjI644ye9G73poYetJncTjoOpxx&#x2B;NSA8&#x2B;vaoywyCTj60l1PBY25muriK3hxndLIFz9Mnn8K5CT4hHVJzb&#x2B;F9NuNZmztMzKY4FPrjGW/ECizC52O07S3RR1Y9B9c1zOo/ELR7GcW9oJdZ1Atj7NYoWA7ZZ8bav2Hwl17xVsm8Waz5MH/QP08GNfxx1r0jw74N0TwrbLHptnBb8/NJs&#x2B;dvqaepNzzPT/C3jXxlse7nj8Macx3eXCC8zr6ZPSu18NfDPw74RYywWLXd91N1eN5jk9c110jlmOZfxxUTEHgSMfcUhjWIk&#x2B;8nHpkj9KlUbexP1NQ9cYf86eWz3zQImXAbdtwfrV&#x2B;31mWHHyjHpmsnd70nmL/eoA6&#x2B;08RFlGUWtW31fzAP3a154txtbhzj6GrMOobW5kagD0Zb7d/CB7A1MtySv3FPua4W31heAHc1oQ6suB8zZoA6wTN/dApd5Paufh1FWAyzZqyt4p/iagg19zf3V/Gjce4WqC3i7RzmnLcKegoAn3D/AJ6NSeZ/00ambz3TJ&#x2B;tNMvP&#x2B;rNAEnmD/AJ6tRvH/AD2P51XZyWzsNG8/88/zFAFoSgf8tTS&#x2B;aneU5&#x2B;tUmmIP&#x2B;rWlEzf881/OgC75if8APRj&#x2B;NNaRc/ff86q&#x2B;a391RThI2PuflQBOXQjl2rm/iBsPhK9wdxDRn/yItbbTOG&#x2B;4v41gePJGbwjqB24C&#x2B;WTj/roP6A0DR5XuGT25pM0hyM55NN3D1qDQduHc0isd3FNpNxDVL2ZUdzzX4g5/4Sg&#x2B;pt0I/M1zb/NGT2xXR/EXP/CSof71oh/8ff8A&#x2B;JNcyx3KQD6n8xX5Njv99n6n6Lhf91j6HvGm86fZf9e8f/oIqldf6xqsaS5bSrA&#x2B;ttEf/HBVW6I81s1&#x2B;s0v4cfQ/PavxyMDxbrl3oOjbtMMP9t3sy2GmrMpZPtEmNruP7qAM5x/CrjqRnivGmmaJ4Q8P6fpt4Wu/D8cd5qd9Zspa51eeCLzdssnA28Fjk98DpXVartufiD4Xt3TcLez1DUYueBKrW1uD9dt05/4DXEfHdk&#x2B;wW0IlRpE03Vwy7gdubB8AjtWsdzI6j4WjT7Lw3e22l2Uun2Fnql9arby3T3CgRzPGQpb5gpAb5fRsdqreGfsOm&#x2B;EfEWk3sf2fRNJ1G&#x2B;tdqhii2&#x2B;TNt2jJYL5jIABnC9K5Dwn8TI/Cs&#x2B;pae9tEIV1q6uZ7uVvlWGXVJY8DH8Q2H67uM4OOsjM0Hwn1e6vYRaXF3Z3&#x2B;pSxMclGnZ5Ame5VXC/8AAasDoNJ1Tw5oek6Nb6ZNYaPpl95f2C1UrbeaJfugKSG&#x2B;YY5OMEEccCuWvviubm5vNP03TJw2&#x2B;1htrxwrpcNLO0O7y17YjcjeysBjI5FcZpPhe91fWNLvLDR5JljsvDs8l60W1PLgDvLtYj5ztKDC&#x2B;uOoONT4X&#x2B;BbzXNLuG8Q&#x2B;dNpV2IroafPafY5ILsSMx2OpMmF3EfN16jgikBFfNqHia6e31OzS51Jm8OC9t7Yeaq&#x2B;XPLLIp25AABBPOOeO1bPgf4aanpGraZrlwLbSWXTBZ3Fi1urXMOyeeRBFKGIQ4mGcA/dxXpVvHDZwiK1hWBAgTEf3ivypyepO0YGT2NSruk3MTwoyzcY&#x2B;tK4GJ4b8F6P4VsrC1sbRWksbcWsVzP&#x2B;&#x2B;kVAeBk8qAzFuB2rebc7At8pbp82c44wPXHSuV1v4haLpEggidtUu2&#x2B;5b2Sbzn3fGB&#x2B;tQ2Ol&#x2B;PfHsY8ryvDWmv8AfYud7r0&#x2B;ZiM5&#x2B;gFMDb1jxRpXhzB1O/jtm/hRQXkJ9Nq5IrCg8SeKfGEyReGdEa0t84N7qHzNj1Rfuj8zXd&#x2B;EPgXoXh11urpf7VvevnXHIB9s16JFElrD5cISFP7iqVH6UCueTaP8Bbe6mW78V6hc67dZ3BWkOxD6YIr0/TdGsdHgEVlaQ20eMfu1wf0q7u9GAHpUckn&#x2B;2KVzMGKquAnH1J/nUTMMfcpGm/2/0qJpPRqRQrMMfcNRhgufkpGZv74H4U0njl&#x2B;aBhvH92l80gcLxUX/AAOlz8v36AFMpJ6Um4&#x2B;n60zn&#x2B;9TWbnrQBJ83p&#x2B;oo3svbn61Dkf3qXcPX9KAJ47h15xVuG&#x2B;as3cPX9KVZMfxYoA3odQfj/GrsOpvxkcfWuXWfHcmp47occmgDr49QyByBVmO&#x2B;LdP51ycN4u0cmrcN4OuTQB2nmf8ATT86jaT5j&#x2B;8P4VW84jjywfqKXzh3TFBBNuz/AMtGpjMN3&#x2B;tYVE0wz92mNIM/dNAE&#x2B;5f7&#x2B;frTGcbuHqEyf7FHmL3TmgCTzP8AbpDKB/y0YVEzjP3TSFiRwKCib7SF/izVTWLddY0u5shKsfnKBubpkHihmbpiomYqQdiseo3DigZ5xrejyaGwF3NAEZtiSeaqhjjPAzmstuxyDnmm/Fa31rVofJuIkNqh3I9unzg&#x2B;5P8ASvIE8S&#x2B;IfCtxlHN7aZx5VwvIHsayb1LsewFtp/p3pOK4nQ/irpeoFYrzzdMujwBNjYf&#x2B;Bf4110dwkigxuGU8hgcipexS3OA&#x2B;I3y&#x2B;IoD2&#x2B;xoP/H5P8RXLt9w47Z/9BrqPiN/yGLVsHm3APHo7EfzrlEcqnPXBJ/Kvy3HK2Mm/M/QsL/u0fQ900UltE04nr9kh/wDRYqveY81qk0OTdoum4/59If8A0AVBdZ81s9a/UqH8OPofn9X45HD/ABAvJPDOoeH/ABX5ck2n6XLLb6mkSlnWznUb5FA5JV4ojgAk54Bwa8Dtbia60W4lnmkuLh9FJd5CWYsdCUk49Tgn6n3r6s3FcnCkdCCu4MMj5SD14zWSPD2jpctcppdk1wy7GkaEZxsEfzc/3Bt6dK6DI8u8H/DI614k1a&#x2B;1q2KaO15M0du5AMskep3cq7gOdoBjPPXNexyiO6VxcJG8cqkNGyjYB3BX9B6UjM0jFiSxY5DEct7iqGsa/pXhyNJNSvorMP8AdVzukf2VOp/AU9QNKPiJI4lKwrtwsZ&#x2B;VcD5RweOKS5uY7e3M93cww28f/LSWQIvA7sxx&#x2B;tcB/wAJ7rPiWY23hbQJi4yq3d9Hkjnqq5GPxrotH&#x2B;Ad94gnhv8AxpqM19cKPlhJDmMHsAflUfnRqK6Mu7&#x2B;KdlPKbXQLS4124ZvmZQYoAenJxub8ODVyz&#x2B;GPivx0ySeIdUbSrDO5LOyAj49Djk/jXsGg&#x2B;EdL8NQrHpunQ2qqMbsAsffNba7&#x2B;uAf97rRqTc5Dwn8L/DvhGMNZ2CtOxw1w4G7612MaxKcBGIXjB6fl0pCz57D6UySSbb8hUfiKNRkzEL1yajaRc9KY00g4JGaiaST8akCR5AexqCRk/uk03zJKYzN3NBAb1H8HFNMg7LSNu7GmbZPWgBxcf3ajZ13Hiht69SKbvf2oKDzB/cJo8wf3aTc/t&#x2B;dNy3dgKBjuDzimlvak3HOA1Id/rQAu9e680oORkDim7j3PNGGbkNgUAP8AwpNzdlpuG/v0nzf36AH7j3FOVyO1R/N/epfqaALKTH0qdLl14C8fWs8detSqx9aAPQmkkzSb39M/iKhKg/xUm0f3qBEjSSZ7D8abmQ81G3B&#x2B;9R&#x2B;NAyT5/Wjc/wDeqPYDzvxS7QP4qAH7n/vUbn/vUzaP71G0etADvmPOaDnGKZ5Y/v4pdoH8VAFe8s/tUe1gGBHTiuB8R/D23vlfCKrHvxXouBu5fiq9xbo0eC2T9KNBnzN4o&#x2B;FNzGsmII54wc445/OuNgt9f8JzZ0&#x2B;7miXP/HvLIWjPtyOPwr6yvNLWRThgB7iuR1zwXaXzN5gBb&#x2B;8orOUS4yPnfxB4zkvmtpNStWsp4gUaSJ98bZ6Y4yPxxVaO8SeENG6yAqclCD29RXoviX4VvIkhtpVZD1jkGQa8uvvAd3o8zyW3m6c3cRHfG3Xt2/Cvkcdlntajqx3Z9Vg8eoU1TnsfQPhy5VtD0v5lJ&#x2B;yxdx/cFNvGJmb068VwHgLx8NPsbbTNWZLR4Ywguoi3lP8A7ykcenBrY1vx9ptnhLMHVLx2wLW1O4fUkDA9eK&#x2B;po3UIp9j5io05to6FVZmK7Wz1xjNc9r3jjRvDsyx3NwLi66La2uJpM&#x2B;hzwn4kVn2ngzxz8Q5ALy4/sHSmOfJhBQFc9Gb7x/IV3XhP4J&#x2B;GvCzK7A3845LTYWPOeuBn9a6TE83tdQ8deO2aLQtPTQrVjhpnwZWX3dsAf8BzXX&#x2B;Ev2f7CxkF3rVy2qXzHc25yQD/ALxGfyxXqixRwx7Yz8i8BY1AA/Kn7hgEce1BNyOx0m30y3EVrFHbIvAWFQP1q4uR/Eo&#x2B;hzVbcD1PNG5PWgktMxH8dRtNg/fqBpIx2Yn2NM8xPQ/jQBa8wNyXqN8bifMqvuQ80FkxjFAEuR/fpjHn79R7l9KaWHpQA9sbvv0xhz96o2Zdx4NG5aCh3H9&#x2B;k3D&#x2B;/TCy&#x2B;lNZhmgkeyhud9RcLxuzQzD0pnH92oKH7lo3J61EVHpShUxytUMe0ijoaAxbnNJ8v92j5fSmAHHc0mV96RmAP3c0n4YoAXK0vy&#x2B;9N&#x2B;XuuTTl6cDAoAcGAGM04MPWmgn&#x2B;7S8/3aAHhhinqwxTFz/dp6q39w/lQB3fH09qTcv96k3D0zRuTutAC/Ke/wClJx60bx2HFG/2oAX5e65pfl9KA3tRuH93NACZX0peO2cUox6UbwvGKAG8dwTRlf7pp&#x2B;4Yz2&#x2B;lG8HoKAG/J9KawVvp9KlH0/SnLHu/hzQBQmiQkjHFULi2QsRt4&#x2B;ldALMuc7eKeNNGeUqB/M4W809GLYTP4VlzeE0vhtMG9T/CQMCvUP7NjXny8/hTltlUZWPHtip5Ex87R5BL8FdMv23TIFB6rgYrU0f4c6P4W/48tPhWQ9ZdgDV6S0fzElf0qGVAcgx5q0uUyuzjpk6llc&#x2B;wJ/kKZu/2BXTz26c/u/0rOuLUbiQlUBkeYvdKPMUj7tWZonXP7viq7KV6rigBm8f3ab5i&#x2B;lOZ/l5FM8zb/DQAeYO1IXyOlNZtxzim&#x2B;YV4AoAeJMcYpDIPSk3Z6ikLN26UALuprSbe1Lub0zTHY9xQUIZN3OKTOaVWOOlIWP8AdoGNZgtN849hmnMzfQ0z56gBfMJ/hqNmO4/LTiz&#x2B;lNLNQAm4&#x2B;lL5ntSbnpy7zQAvmH0o3n0pjb9xpRv9aoBS3tSbvalw3cZNGxj2/WmAZY9OlOAk9aVYyO361II2J4/nQBGokzUoV2FPWGTNTLDJ60ARRxvU6xyerfnTlgfPWp44H9aAOo3H0oyfSnc&#x2B;lG0&#x2B;9ADcn&#x2B;7Sbvan7T709VP93NAEY&#x2B;lHPpVgRt/dpyRH&#x2B;7QBAu7ptNLtP90/lV5YW9KlWN/7tAFGOMsB8vFSrBj&#x2B;H9KvrG3pUyq3TH6UAUo4eB8lWY7f/Yq1HuHGKnUHqcUAV44to&#x2B;7gfSpNv&#x2B;xmpufal/edsYoIK7N224/CoJM&#x2B;n6VbbfuNRPv59aAKEm7nioH3/wB2r8iyelQPv9KAM&#x2B;VWI6VVkjOOn6VoyRyNzVeSORe1BJkzRtyNtUprYtnj9K3GRz2qtJDJzxQUc9PbsvRCRVaRZPSuikhkx1xVSS1ZuvWgDC/eelMYyA5xWlNaurEAcVWktJm5H86AKu5xRub&#x2B;7n8aka1lz1/WmtA469aAGbn&#x2B;lMZn3VIY5PTIphVvT9aAGbn9aX5z3pdpo8lj/wDroKGlZPWk2t360MrKcUbTQMa24Hg0wqTyakMZo8k1AEe1&#x2B;x4pVR&#x2B;uM/jT/JNPWM7etUBH5b/SnLG2Omak8ljT1hfb97FMCHy29KVYGJz/AFqbyX/vU5YW&#x2B;v40AR&#x2B;S3&#x2B;TT0t36j&#x2B;dT&#x2B;Qx/ixT44fVuaAI1hcdev1qVYjUn2Yt0bIqaK2wBk80AMjtyasR25p6Q&#x2B;9TpGPWgVzYbrTl7UUUDHrU0dFFAEv8ADT46KKALK9KkjoooIJl&#x2B;9Tx96iigCVfvUN940UUAC9KWiigCNvvGkoooAa33arS9TRRQBXeon/1dFFAFVqrS96KKAIG&#x2B;7VSb7xoooArvVWb7xoooArSdahb7tFFADP4RULfeNFFADG603&#x2B;KiigBjfeNKvSiigBrdaKKKAJF&#x2B;6KevSiigoWnj7ooooGKvSnLRRQBIPvVMnSiigCxH2qT&#x2B;KiigglWp17UUUAf/2Q==" />
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>